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Abstract 
Obesity is becoming the healthcare epidemic of this century.  Weight loss surgery is 
the only effective treatment for morbid obesity.  Furthermore glycaemic control in 
type 2 diabetic patients is improved after metabolic surgery. 
 
Here I observed that with gastric bypass, type 2 diabetes can be improved and even 
rapidly put into a state of remission irrespective of weight loss.  This is achieved via 
an improvement of both insulin resistance and insulin production.  Reduced insulin 
resistance within the first week after surgery remains unexplained, but increased 
insulin production in the first week after surgery may be explained by the enhanced 
postprandial GLP-1 response.   
 
In addition, I demonstrate that bile flow changes lead to increased gut hormone 
response in animal models.  Roux-en-Y gastric bypass in humans causes changes 
in bile flow leading to increased plasma bile acid concentrations.  This phenomenon 
may explain the improved glycaemic control following gastric bypass. 
 
In conclusion I investigated the mechanism of diabetes remission after metabolic 
surgery and explored the role of gut hormones and bile acids in the changes in 
glucose homeostasis following metabolic surgery. 
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1. Introduction 
1.1 Metabolic surgery  
Introduction 
Weight loss surgery is now recognised as the most effective long term treatment for 
morbid obesity (Sjostrom et al 2007).  The effect of these procedures is not restricted 
to sustained weight loss.  Improvement in obesity related comorbidity may represent 
a more important effect than weight loss itself.  The Diabetes Surgery Summit in 
Rome in 2007 suggested the use of the term “metabolic surgery” to reflect profound 
effect of weight loss procedures on the metabolic syndrome.  This concept is gaining 
acceptance as evidenced by the number of scientific societies worldwide which 
include the word metabolic in their title.  Of note is that the British Obesity and 
Metabolic Surgery Society, the American Society for Metabolic and Bariatric Surgery 
and the International Federation for the Surgery of Obesity and Metabolic Disorders   
have also changed its name to reflect this.   
 
Obesity Staging, the Edmonton obesity staging system (EOSS) 
Body Mass Index (BMI) is used as the main criterion for qualifying for weight loss 
surgery.  The National Institute for Health and Clinical Excellence in the UK, as well 
as the National Institute of Health in the United Sates of America, recommend weight 
loss surgery in adults with BMI of 40 kg/m2 and above or BMI between 35 kg/m2 and 
40 kg/m2 with obesity related co-morbidity (The National Institute of Clinical 
Excellence, 2006; Gastrointestinal Surgery for Severe Obesity. NIH Consensus 
Statement Online 1991 Mar 25-27).  However it is recognised that BMI is associated 
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with a number of limitations (Hu 2007).  Sharma et al proposed a novel clinical 
staging system, the Edmonton obesity staging system which scores obese 
individuals on a 5-point ordinal scale and takes into account severity of co-
morbidities and functional status (Sharma and Kushner 2009).  The objective was to 
provide a simple framework to aid decision making in clinical practice (Sharma and 
Kushner 2009).   
 
The ability of the Edmonton obesity staging system to predict mortality was 
examined in a nationally representative US sample by Padwal et al (Padwal, 
Pajewski, Allison and Sharma 2011).  Data from the National Health and Human 
Nutrition Examination Surveys (NHANES) III 1988–1994 and the NHANES 1999–
2004, with mortality data up to the end of 2006 were used (Padwal, Pajewski, Allison 
and Sharma 2011).  Overweight or obese individuals aged 20 or older who had been 
randomized to the morning session at the mobile examination centre were scored 
according to the Edmonton obesity staging system (Padwal, Pajewski, Allison and 
Sharma 2011).  The analysis was retrospective. Individuals with class III obesity 
following adjustment for metabolic syndrome or hypertriglyceridemic waist (this was 
defined as waist circumference ≥ 90 cm and a triglyceride levels ≥ 2 mmol/L for men; 
waist circumference ≥ 85 cm and triglyceride levels ≥ 1.5 mmol/L for women) had 
similar mortality risk compared to class II obese individuals (Padwal, Pajewski, 
Allison and Sharma 2011).  In contrast individuals with Edmonton obesity staging 
system score of 2 or 3 had a 4 to 12-fold greater hazard ratio compared to 
individuals with Edmonton obesity staging system score of 0 or 1 (Padwal, Pajewski, 
Allison and Sharma 2011). 
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It has been suggested that the Edmonton obesity staging system may have a role in 
patient selection for weight loss surgery (Gill, Karmali and Sharma 2011).  However 
it is important to note that this score has not been prospectively validated yet for use 
in this population.  
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Table 1. The Edmonton obesity staging system (Sharma and Kushner 2009).  
Stage Description Management 
0 No apparent obesity-related risk 
factors (e.g., blood pressure, serum 
lipids, fasting glucose, etc. within 
normal range), no physical symptoms, 
no psychopathology, no functional 
limitations and/or impairment of well 
being 
Identification of factors 
contributing to increased body 
weight. Counselling to prevent 
further weight gain through 
lifestyle measures including 
healthy eating and increased 
physical activity. 
1 Presence of obesity-related subclinical 
risk factors (e.g., borderline 
hypertension, impaired fasting glucose, 
elevated liver enzymes, etc.), mild 
physical symptoms (e.g., dyspnoea on 
moderate exertion, occasional aches 
and pains, fatigue, etc.), mild 
psychopathology, mild functional 
limitations and/or mild impairment of 
well being 
Investigation for other (non-weight 
related) contributors to risk 
factors. More intense lifestyle 
interventions, including diet and 
exercise to prevent further weight 
gain. Monitoring of risk factors and 
health status. 
2 Presence of established obesity-
related chronic disease (e.g., 
hypertension, type 2 diabetes, sleep 
apnoea, osteoarthritis, reflux disease, 
Initiation of obesity treatments 
including considerations of all 
behavioural, pharmacological and 
surgical treatment options. Close 
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polycystic ovary syndrome, anxiety 
disorder, etc.), moderate limitations in 
activities of daily living and/or well 
being 
monitoring and management of 
comorbidities as indicated. 
3 Established end-organ damage such 
as myocardial infarction, heart failure, 
diabetic complications, incapacitating 
osteoarthritis, significant 
psychopathology, significant functional 
limitations and/or impairment of well 
being 
More intensive obesity treatment 
including consideration of all 
behavioural, pharmacological and 
surgical treatment options. 
Aggressive management of 
comorbidities as indicated. 
4 Severe (potentially end-stage) 
disabilities from obesity-related chronic 
diseases, severe disabling 
psychopathology, severe functional 
limitations and/or severe impairment of 
well being 
Aggressive obesity management 
as deemed feasible. Palliative 
measures including pain 
management, occupational 
therapy and psychosocial support. 
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The King’s College criteria  
Aylwin et al have proposed a score with the objective to stratify obesity in a weight-
independent manner but focusing on the disease burden, in other words moving 
away from morbid obesity and focusing on obese morbidity (Aylwin and Al-Zaman 
2008).  The criteria can be seen on table 2. 
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Table 2. The King’s criteria (Aylwin and Al-Zaman 2008) are summarised 
below: 
 Stage 0 Stage 1 Stage 2 Stage 3 
Airway Normal snoring Require CPAP Cor pulmonale 
BMI <35 35-40 40-50 >50 
Cardiovascular <10% risk 10-20% risk Heart disease Heart failure 
Diabetes Normal Impaired 
fasting 
glycaemia 
Type 2 
diabetes 
Uncontrolled 
type 2 diabetes 
Economic Normal Suffered 
discrimination 
Unemployed 
due to obesity 
Requires 
financial 
support 
Functional Can manage 3 
flights of stairs 
Manage 1 or 2 
flights of stairs 
Requires 
walking aids or 
wheel chair 
House bound 
Gonadal Normal PCOS Infertility Sexual 
dysfunction 
Health status Normal Low mood or 
QoL 
Depression or 
poor QoL 
Severe 
depression 
Image Normal Does not like Body image Eating disorder 
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body dysphoria 
Junction 
gastro-
oesophagus 
Normal Heart burn Oesophagitis Barrett’s 
Oesophagus 
Kidney Normal proteinuria GFR<60ml/min GFR<30ml/min 
Liver Normal Raised GGT NASH Liver failure 
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The criteria were modified and the score was used on patients undergoing weight 
loss surgery in a study by Aasheim et al (Aasheim, Aylwin, Radhakrishnan, Sood, 
Jovanovic, Olbers and le Roux 2011).  Inter-observer reliability was assessed with 
eleven clinicians (six physicians, two surgeons, two medical students and one nurse 
specialist; of these, four physicians, one surgeon, one student and one nurse had 
previous experience with the modified King’s Criteria) scored the same 12 individuals 
(Aasheim, Aylwin, Radhakrishnan, Sood, Jovanovic, Olbers and le Roux 2011).  
Different assessors assigned mostly similar scores for the same individual (Aasheim, 
Aylwin, Radhakrishnan, Sood, Jovanovic, Olbers and le Roux 2011).  However there 
was high variability between assessors for some domains with Body Image being the 
one with the worst observer consistency (Aasheim, Aylwin, Radhakrishnan, Sood, 
Jovanovic, Olbers and le Roux 2011). 
 
Aasheim et al demonstrated that according to the modified King’s Criteria patients 
undergoing weight loss and metabolic surgery experienced improvement in their 
health postoperatively (Aasheim, Aylwin, Radhakrishnan, Sood, Jovanovic, Olbers 
and le Roux 2011).  The authors suggested that in the clinical setting the modified 
King’s Criteria added structure to a patient-centred clinical interaction.  More 
importantly this work highlighted the need to focus on outcomes of metabolic surgery 
other than weight loss itself (Aasheim, Aylwin, Radhakrishnan, Sood, Jovanovic, 
Olbers and le Roux 2011). 
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The King’s criteria are a useful tool for the risk stratification of patients preoperatively 
but also postoperatively with the comprehensive documentation of risk and the 
potential increase or decrease following surgery (le Roux and Pournaras 2010a). 
They will be used in this thesis as a roadmap presenting the benefit of surgery for 
patients, focusing on co-morbidity and functional improvement rather than weight 
loss (le Roux and Pournaras 2010). 
 
Airway 
Obstructive Sleep Apnoea is common in the obese population and in patient 
undergoing weight loss surgery in particular.  In the Longitudinal Assessment of 
Bariatric Surgery study obstructive sleep apnoea was detected in 48.9% of the 
population consisting of 4776 consecutive individuals undergoing primary weight loss 
surgery (Flum et al 2009).  Furthermore obstructive sleep apnoea was associated 
with a significantly higher incidence of adverse effects perioperatively (Flum et al 
2009). 
 
In a 2004 meta-analysis, 85.7% of patients achieved resolution of obstructive sleep 
apnoea (Buchwald, Avidor, Braunwald, Jensen, Pories, Fahrbach and Schoelles 
2004).  A more recent meta-analysis confirmed that weight loss surgery significantly 
reduced the apnoea-hypopnoea index (Greenburg, Lettieri and Eliasson 2009).  In 
the same study the levels of the index recorded suggested moderately severe 
obstructive sleep apnoea postoperatively (Greenburg, Lettieri and Eliasson 2009).  
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Therefore patients should be informed during the consent process that obstructive 
sleep apnoea may persist postoperatively (Greenburg, Lettieri and Eliasson 2009). 
 
Body mass Index (BMI) 
In Buchwald’s landmark meta-analysis the mean percentage of excess weight loss at 
the time point the status of comorbidity was assessed was 47.5% for gastric 
banding, 61.6% for gastric bypass, 68.2% for gastroplasty, and 70.1% for 
biliopancreatic diversion or duodenal switch (Buchwald, Avidor, Braunwald, Jensen, 
Pories, Fahrbach and Schoelles 2004).  The Swedish Obese Subjects study 
provides the best available comparison of weight loss between weight loss surgery 
and non-surgical management of obesity in the long term (Sjostrom et al 2007).  In 
the three surgical groups the total body weight loss was 25% ten years after gastric 
bypass, 16% after vertical-banded gastroplasty, and 14% after banding (Sjostrom et 
al 2007). In the non-surgical group weight remained within ±2% during the ten year 
period (Sjostrom et al 2007). 
 
Cardiovascular 
Weight loss is known to reduce cardiovascular risk.  However, metabolic surgery is 
associated with improvement in cardiac function and the reversal of obesity related 
cardiomyopathy (Ashrafian, le Roux, Darzi and Athanasiou 2008).  Improved cardiac 
function, ventricular remodelling and atherosclerotic load have also been 
demonstrated (Ashrafian, le Roux, Darzi and Athanasiou 2008). 
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Diabetes 
The effect of metabolic surgery on glucose metabolism is the subject of this thesis 
and will be described in detail in subsequent chapters.   
 
Economic 
The cost-effectiveness of metabolic surgical procedures for the health care systems 
will be described further in a separate section.  The benefit specifically to recipients 
of metabolic surgery has been shown in this study by Hawkins et al using data from 
Somerset, UK (Hawkins, Osborne, Finlay, Alagaratnam, Edmond and Welbourn 
2007).  They demonstrated that the number of individuals receiving income from 
work was increased postoperatively (Hawkins, Osborne, Finlay, Alagaratnam, 
Edmond and Welbourn 2007). The same group also showed that the number of 
hours worked was also increased and there was a reduction in state benefits claims 
postoperatively (Hawkins, Osborne, Finlay, Alagaratnam, Edmond and Welbourn 
2007). 
 
Functional 
Obesity is associated with poor function, physical illness and disability (Weil, 
Wachterman, McCarthy, Davis, O'Day, Iezzoni and Wee 2002; Ferraro and Booth 
1999).  Bergkvist et al studied populations of patients attending an orthopaedic 
department in both the emergency and the elective/chronic setting (Bergkvist, 
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Hekmat, Svensson and Dahlberg 2009).  Significant relationships between obesity 
and common orthopaedic conditions were demonstrated (Bergkvist, Hekmat, 
Svensson and Dahlberg 2009). 
 
Miller et al conducted a longitudinal, observational study of 28 morbidly obese 
individuals followed for 12 months after laparoscopic gastric bypass using the 
Fitness Arthritis and Seniors Trial disability questionnaire for the estimation of 
physical function, the Short Physical Performance Battery and a lateral mobility task 
to assess performance tasks and maximal isometric knee torque for measurement of 
strength (Miller, Nicklas, You and Fernandez 2009).   An increase in mobility and 
improvement in the performance of daily activities was demonstrated as early as 
three weeks postoperatively (Miller, Nicklas, You and Fernandez 2009).  
 
De Souza et al used the 6-minute walk test in a group of 51 patients undergoing 
weight loss surgery (de Souza, Faintuch, Fabris, Nampo, Luz, Fabio, Sitta and de 
Batista Fonseca IC 2009).  The test was performed preoperatively and seven to 
twelve months postoperatively and a significant improvement was reported. (de 
Souza, Faintuch, Fabris, Nampo, Luz, Fabio, Sitta and de Batista Fonseca IC 2009).   
 
Gonadal 
In a report from six centres participating in the Longitudinal Assessment of Bariatric 
Surgery-2 study a prevalence of polycystic ovary syndrome (PCOS) of 13.1% was 
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recorded (Gosman, King, Schrope, Steffen, Strain, Courcoulas, Flum, Pender and 
Simhan 2010).  Furthermore 41.9% experienced infertility and 61.4% had a live birth 
with a previous history of infertility (Gosman, King, Schrope, Steffen, Strain, 
Courcoulas, Flum, Pender and Simhan 2010).  In another study of 24 women with 
PCOS undergoing gastric bypass, a significant improvement of PCOS symptoms 
postoperatively was reported (Eid, Cottam, Velcu, Mattar, Korytkowski, Gosman, 
Hindi and Schauer 2005). 
 
I have recently shown that 23 out 149 (15.4%) consecutive women of child bearing 
age (18-45 years old) undergoing weight loss surgery at Musgrove Park Hospital, 
Taunton were diagnosed with PCOS (Pournaras, Manning, Bidgood, Fender, Mahon 
and Welbourn 2010).  Furthermore in the same population, for 11 of 149 (7.4%) 
women of childbearing age, subfertility was the main reason for undergoing weight 
loss surgery (Pournaras, Manning, Bidgood, Fender, Mahon and Welbourn 2010).  
 
It is well documented that maternal obesity is associated with a higher risk for both 
mother and fetus (Gross, Sokol and King 1980; Morin 1998).  A recent systematic 
review suggests that the risk of maternal complications, such as gestational diabetes 
and preeclampsia, as well as neonatal complications, such as premature delivery 
and low birth weight, are lower following weight loss surgery compared to obese 
individuals (Maggard 2008). 
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A study from George Fileding’s unit demonstrated that gastric banding is safe and 
well-tolerated during pregnancy with a lower incidence of gestational diabetes and 
maternal hypertension (Skull, Slater, Duncombe and Fielding 2004). 
 
Focusing on male fertility Shayeb et al studied 2035 men presenting to a fertility 
clinic and demonstrated that obese men were more likely to have lower semen 
volume and fewer morphologically normal spermatozoa than non-obese men 
(Shayeb, Harrild, Mathers and Bhattacharya 2011).  These findings are consistent 
with another study showing obesity is associated with a higher risk of low sperm 
quality (Hammoud, Wilde, Gibson, Parks, Carrell and Meikle 2008).  The effects of 
surgically induced weight loss on male fertility remain largely unknown.  
 
Health status perceived 
In the Swedish Obese Subjects study, health related quality of life improved 
significantly after weight loss surgery but not in the control group (Karlsson, Sjöström 
and Sullivan 1998).  Using the Short Form-36 (SF-36) O’Brien et al demonstrated in 
a randomised controlled trial comparing of gastric banding versus conservative 
management in patients with a BMI of 30-35, that quality of life improved significantly 
after gastric banding in all domains of the SF-36 (O'Brien et al 2006).  The above 
results are consistent with another prospective study comparing patients undergoing 
gastric bypass surgery with two control groups; patients who requested but did not 
undergo surgery and obese individuals (Kolotkin, Crosby, Gress, Hunt and Adams 
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2009).  Health related quality of life was improved in the surgical group compared to 
the controls groups (Kolotkin, Crosby, Gress, Hunt SC and Adams 2009) 
 
Image of body 
The Melbourne group demonstrated that super-obese patients undergoing gastric 
banding surgery have reduced evaluation of appearance preoperatively which is 
improved with weight loss after surgery (Dixon, Dixon and O'Brien 2002).  They also 
showed an associated psychological benefit with this improvement (Dixon, Dixon 
and O'Brien 2002).  In the SOS study, a small effect of surgery on social interaction 
was reported as measured by health-related limitations in social interaction within the 
family, among friends and in the community (Karlsson, Taft, Rydén, Sjöström and 
Sullivan 2007).  This was only present on patients who achieved a 10% weight loss 
or more (Karlsson, Taft, Rydén, Sjöström and Sullivan 2007).  An improvement in the 
scores of patients on body image dissatisfaction subscale three years after 
biliopancreatic diversion has been also reported (Adami, Gandolfo, Campostano, 
Meneghelli, Ravera and Scopinaro 1998) 
 
It has to be noted that individuals may face significant morbidity due to the severe 
change in body image and this needs to be accounted for, and aggressively treated 
appropriately.  The cosmetic outcomes of weight loss surgery may be very poor.  
These interventions are not cosmetic surgery.  A new field, post-bariatric body 
contouring surgery is emerging as a subspecialty of plastic surgery with the objective 
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to address specific cosmetic and occasionally functional issues amenable to plastic 
surgical interventions. 
 
 
Junction gastro-oesophagus (gastro-oesophageal reflux disease) 
A meta-analysis demonstrated that obesity is associated with a higher risk of gastro-
oesophageal reflux symptoms, erosive oesophagitis, and oesophageal 
adenocarcinoma (Hampel, Abraham and El-Serag 2005).  The same study showed a 
trend for progressive increase of the above with increasing weight (Hampel, 
Abraham and El-Serag 2005). 
 
Gastric bypass surgery leads to the improvement of gastro-oesophageal reflux 
symptoms and oesophageal exposure to acid (Mejía-Rivas, Herrera-López, 
Hernández-Calleros, Herrera and Valdovinos 2008).  This is to be expected 
considering that these procedures were initially designed for peptic ulcer disease in 
the era prior to pharmacological treatment.   
 
In a study of 100 patients, 73% were reported to have gastro-oesophageal reflux 
symptoms (Merrouche, Sabaté, Jouet, Harnois, Scaringi, Coffin and Msika 2007).  
The different effects of gastric bypass and gastric banding on oesophageal function 
were demonstrated, with worsening of pH-metric data and occasional severe 
dyskinesia after gastric banding Merrouche, Sabaté, Jouet, Harnois, Scaringi, Coffin 
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and Msika 2007).  Suter et al also demonstrated that postoperative oesophageal 
dysmotility and gastrooesophageal reflux are not uncommon after gastric banding 
suggesting routine preoperative evaluation (Suter, Dorta, Giusti and Calmes 2005).  
Low amplitude of contraction in the lower oesophagus and increased oesophageal 
acid exposure should be regarded as contraindications to gastric banding and 
patients with such findings should be offered an alternative weight loss surgical 
procedure (Suter, Dorta, Giusti and Calmes 2005).  George Fielding’s group propose 
the addition of routine repair of a hiatus hernia during gastric band placement when 
indicated as it significantly reduces the reoperation rate due to gastric prolapse and 
pouch dilatation (Gulkarov, Wetterau, Ren and Fielding 2008).  
 
Kidney 
Obesity is a risk factor for the progression of chronic kidney disease and a 
systematic review demonstrated that weight loss is associated with decreased 
proteinuria and microalbuminuria (Afshinnia, Wilt, Duval, Esmaeili and Ibrahim 
2010).  There were no available data regarding the durability of this decrease and 
the effect of weight loss on chronic kidney disease (Afshinnia, Wilt, Duval, Esmaeili 
and Ibrahim 2010).   
 
A report of a patient with end-stage renal disease who experienced dramatic 
improvement of renal function after gastric bypass surgery, obviating the need for 
dialysis and transplantation has led to increased interest in this renal effect of weight 
loss surgery (Tafti, Haghdoost, Alvarez, Curet and Melcher 2009).  Navarro-Dıaz et 
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al studied 61 obese patients undergoing weight loss surgery (Navarro-Díaz, Serra, 
Romero, Bonet, Bayés, Homs, Pérez and Bonal 2006).  All renal parameters 
improved in the first 12 months postoperatively when the majority of weight loss 
occurred (Navarro-Díaz, Serra, Romero, Bonet, Bayés, Homs, Pérez and Bonal 
2006).  However, 24-h albuminuria still improved during the second year of follow-up 
(Navarro-Díaz, Serra, Romero, Bonet, Bayés, Homs, Pérez and Bonal 2006).  The 
authors suggested that this decrease in 24-h albuminuria may not be related to 
glomerular filtration rate but possibly due to the decrease in BMI and the 
improvement of other metabolic factors (Navarro-Díaz, Serra, Romero, Bonet, 
Bayés, Homs, Pérez and Bonal 2006). 
 
Liver 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum ranging from fatty liver, 
followed by non-alcoholic steatohepatitis (NASH) and the more severe form being 
cirrhosis and progress to hepatocellular carcinoma or liver failure (Kim and Younossi 
2008).   Non-alcoholic fatty liver disease has become the most common form of liver 
disease (Kim and Younossi 2008).  
 
NAFLD and NASH appear to improve or completely resolve in the majority of 
patients after weight loss surgery (Mummadi, Kasturi, Chennareddygari and Sood 
2008; Mathurin et al 2009). 
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Metabolic surgery and cancer 
The effect of weight loss surgery on cancer incidence is not part of any scoring 
system of obesity (such as the Edmonton obesity staging system or the King’s 
College criteria).  However it is an effect of weight loss surgery which has been 
described and well documented.  A recent systematic review and meta-analysis of 
prospective observational studies confirmed that increased BMI is associated with 
increased risk of common and less common cancers (Renehan, Tyson, Egger, 
Heller and Zwahlen 2008).  In men, a 5 kg/m2 increase in BMI was associated with 
oesophageal adenocarcinoma, thyroid cancer, colonic cancer and renal cancer.  In 
women, a 5 kg/m2 increase in BMI was associated with endometrial cancer, 
gallbladder cancer, oesophageal adenocarcinoma and renal cancer (Renehan, 
Tyson, Egger, Heller and Zwahlen 2008).  Furthermore weaker positive associations 
were recorded between increased BMI and rectal cancer and malignant melanoma 
in men; postmenopausal breast, pancreatic, thyroid, and colon cancers in women; 
and leukaemia, multiple myeloma, and non-Hodgkin lymphoma in both sexes 
(Renehan, Tyson, Egger, Heller and Zwahlen 2008) . 
 
Adams et al demonstrated that all cause mortality after gastric bypass surgery was 
significantly reduced when compared with obese controls (Adams, Gress, Smith, 
Halverson, Simper, Rosamond, Lamonte, Stroup and Hunt 2007).  This was a study 
comparing 7925 patients undergoing gastric bypass surgery and 7925 obese 
individuals applying for a driver's license in Utah matched for age, sex, and BMI 
(Adams, Gress, Smith, Halverson, Simper, Rosamond, Lamonte, Stroup and Hunt 
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2007).  Cancer specific mortality was reduced by 60% (Adams, Gress, Smith, 
Halverson, Simper, Rosamond, Lamonte, Stroup and Hunt 2007). 
 
 Adams et al investigated this effect further in another study by using cancer 
incidence and mortality data through 2007 from the Utah Cancer Registry (Adams, 
Stroup, Gress, Adams, Calle, Smith, Halverson, Simper, Hopkins and Hunt 2009).  
They compared 6,596 Utah patients who had gastric bypass in Utah and 9,442 
severely obese individuals applying for a Utah Driver’s License (Adams, Stroup, 
Gress, Adams, Calle, Smith, Halverson, Simper, Hopkins and Hunt 2009).  The 
follow-up was in excess of 24 years with a mean of 12.5 years (Adams, Stroup, 
Gress, Adams, Calle, Smith, Halverson, Simper, Hopkins and Hunt 2009).  Total 
cancer incidence was significantly lower in the surgical group with a hazard ratio of 
0.76 (Adams, Stroup, Gress, Adams, Calle, Smith, Halverson, Simper, Hopkins and 
Hunt 2009).  Cancer specific mortality was decreased in patients undergoing gastric 
bypass surgery with a hazard ratio of 0.54 (Adams, Stroup, Gress, Adams, Calle, 
Smith, Halverson, Simper, Hopkins and Hunt 2009).  An intriguing finding of this 
study was that reduced mortality was observed for all cancers, not only the obesity 
related ones (Adams, Stroup, Gress, Adams, Calle, Smith, Halverson, Simper, 
Hopkins and Hunt 2009).  
 
In the same issue of the New England Journal of Medicine in which Adams study 
was published, the Swedish Obese Subject study trial reported that weight loss 
surgery is associated with long-term weight loss and decreased overall mortality 
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(Sjöström et al 2007).  Sjostrom et al intended to perform a randomised control trial 
comparing weight loss surgery with best medical treatment.  However the study was 
not approved by the Ethics Committee due to the high risk associated with weight 
loss surgery.  The fact that a similar trial is currently considered not ethical due to the 
high risk associated with non-surgical treatment following the reported outcomes of 
the SOS trial highlights the unique contribution of this study in the field.  The study 
performed was a prospective, matched control trial including 4047 obese subjects; 
2010 undergoing weight loss surgery and 2037 undergoing conventional treatment, 
recruited over a 13.4-year period and follow-up for a mean of 10.9±3.5 years 
(Sjöström et al 2007).  The follow-up in terms of vital status was complete for 
participants with exception of three, achieving an impressive rate of 99.9% (Sjöström 
et al 2007).  Two participants were deleted from the records upon their request and 
one withdrew from the study and subsequently obtained an unlisted social security 
number (Sjöström et al 2007).  In the weight loss surgery group 101 deaths were 
recorded compared to 129 deaths in the control group with an unadjusted overall 
hazard ratio of 0.76 and with the most common cause of death myocardial infarction 
and cancer (Sjöström et al 2007). 
 
A report on cancer incidence in the SOS trial was published in 2009 (Sjöström et al 
2009).  In the weight loss surgery group 117 cancers were detected compared 169 in 
the control group with a hazard ratio 0.67 (Sjöström et al 2009).  In females 
incidence of cancer was lower in the surgical group compared to the control group, 
but there was no difference in males (Sjöström et al 2009).  However the number of 
male participants was lower (Sjöström et al 2009).  
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Weight loss surgery is associated with a protective effect on cancer, although the 
mechanism of this interaction remains to be elucidated.  Abdominal obesity is linked 
to alterations in insulin and the insulin-like growth factor-1 (IGF-1), sex steroids and 
adipokines (Sjöström et al 2009; Renehan, Frystyk and Flyvbjerg 2006; Key, 
Appleby, Reeves, Roddam et al 2003; Barb, Williams, Neuwirth and Mantzoros 
2007).  In the SOS study baseline sagittal trunk diameter came out as a strong 
multiple cancer predictor.  In contrast weight and BMI did not.  More importantly 
these findings highlight the fact the favourable effect of metabolic surgery is 
extended well beyond weight loss. 
 
Cost effectiveness 
Although the effect of metabolic surgery on comorbidity is slowly recognised by the 
scientific community there is still debate about the cost effectiveness of this type of 
surgery.  In fact the surgical management of obesity and obesity related 
comorbidities is associated with polarised opinions among general surgeons not 
performing weight loss surgery, physicians and the public.   
 
Nicholas Christou’s group in Montreal performed a comparison in terms of health-
related costs between 1035 patients undergoing weight loss surgery and to 5746 
age- and sex-matched controls (Sampalis, Liberman, Auger and Christou 2004).  
The follow-up period was five years and the endpoint was all-cause hospitalisation 
with the cost of the surgical procedure included (Sampalis, Liberman, Auger and 
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Christou 2004).  The total hospitalization cost was higher in the surgical group in the 
first year, however at 5 years the cost was higher for the control group allowing the 
authors to conclude that weight loss surgery decreases long-term direct health-care 
costs and the initial cost of this treatment can be recovered over a period of 3.5 
years (Sampalis, Liberman, Auger and Christou 2004).  Of note is the fact that the 
majority of the patients in the surgical group underwent open gastric bypass surgery 
(Sampalis, Liberman, Auger and Christou 2004).  With the use of the laparoscopic 
approach the comparison may be more favourable for weight loss surgery 
(Sampalis, Liberman, Auger and Christou 2004). 
  
Focusing on medication cost in another study from the USA 78 patients aged 55 to 
75 undergoing laparoscopic gastric bypass surgery were assessed preoperatively 
and 6 months, 1 year, and yearly postoperatively thereafter (Snow, Weinstein, 
Hannon, Lane, Ringold, Hansen and Pointer 2004).  The number of medications per 
patient fell by 66% (Snow, Weinstein, Hannon, Lane, Ringold, Hansen and Pointer 
2004).  With the cost of the surgical intervention as one-off, the crossover point for 
cost effectiveness was at 2.5 years (Snow, Weinstein, Hannon, Lane, Ringold, 
Hansen and Pointer 2004; Welbourn and Pournaras 2010). 
 
The Health Technology Assessment report used for the 2002 National Institute of 
Clinical Excellence Guidelines for weight loss surgery estimated that the incremental 
cost effectiveness ratios per quality-adjusted life year were £8527 for gastric banding 
and £6289 for gastric bypass (Clegg, Colquitt, Sidhu, Royle, Loveman and Walker 
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2002; Welbourn and Pournaras 2010).   Both of these were well below the 
conventional threshold of £30 000 often used by the National Institute of Clinical 
Excellence to determine cost effectiveness (Clegg, Colquitt, Sidhu, Royle, Loveman 
and Walker 2002; Welbourn and Pournaras 2010).   
 
An updated Health Technology Assessment systematic review assessed the cost-
effectiveness of weight loss surgery in 2009 (Picot, Jones, Colquitt, 
Gospodarevskaya, Loveman, Baxter and Clegg 2009).  Picot el al reported that 
weight loss surgery was cost-effective compared to non-surgical treatment 
modalities in the published estimates of cost-effectiveness (Picot, Jones, Colquitt, 
Gospodarevskaya, Loveman, Baxter and Clegg 2009).  However, these estimates 
were likely to be unreliable according to the authors (Picot, Jones, Colquitt, 
Gospodarevskaya, Loveman, Baxter and Clegg 2009).  Hence they developed a 
novel economic model.  According to this the cost of weight loss surgery was higher 
than non-surgical treatment the three patient populations used for analysis, but was 
associated with an improved effect (Picot, Jones, Colquitt, Gospodarevskaya, 
Loveman, Baxter and Clegg 2009).  For morbid obesity incremental cost-
effectiveness ratios ranged between £2000 and £4000 per quality-adjusted life year 
gained (Picot, Jones, Colquitt, Gospodarevskaya, Loveman, Baxter and Clegg 
2009).  These figures remain within the range regarded as cost-effective by National 
Institute of Clinical Excellence. 
 
Cost effectiveness and type 2 diabetes 
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Focusing on type 2 diabetes related outcomes, O’Brien and his group in Melbourne 
reported cost-effectiveness results from a randomised control trial comparing gastric 
banding versus best medical treatment for type 2 diabetes (Keating, Dixon, Moodie, 
Peeters, Playfair and O'Brien 2009).  The incremental cost effectiveness ratio for 
gastric banding was lower than the comparable figure for conventional therapy 
suggesting that within a 2-year period gastric banding was below the currently 
accepted cost-effectiveness threshold in Australia (Keating, Dixon, Moodie, Peeters, 
Playfair and O'Brien 2009). 
 
Klein et al examined the administrative claims database of privately insured patients 
in the US covering 8.5 million lives 1999-2007, identified obese patients with 
diabetes, aged 18-65 years, who were treated with weight loss surgery and matched 
them with controls for demographic characteristics, comorbidities, and health-care 
costs (Klein, Ghosh, Cremieux, Eapen and McGavock 2011).  The cost of 
laparoscopic surgery was fully recovered at 26 months (Klein, Ghosh, Cremieux, 
Eapen and McGavock 2011).  Within one month medication costs were significantly 
lower for the surgical group (Klein, Ghosh, Cremieux, Eapen and McGavock 2011).  
 
 
Conclusion 
Weight loss surgery leads to an improvement in a number of obesity related 
comorbidites secondary to the weight loss itself but also due to weight loss 
independent effects.   
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Gut hormones and bile acids 
  
Energy homeostasis 
Energy intake and expenditure are regulated by the mechanisms of energy 
homeostasis and lead to a stable body mass over time (Morton, Cummings, Baskin, 
Barsh and Schwartz 2006; Flier 2004; Pournaras and le Roux 2009).  From an 
evolutionary point of view one can hypothesise that survival in an environment with 
limited availability of food provided selection bias towards homeostatic systems 
which are more sensitive to reduced energy intake rather than energy excess 
(Schwartz, Woods, Seeley, Barsh, Baskin and Leibel 2003; Pournaras and le Roux 
2009).  This phenomenon may perhaps explain the current obesity epidemic 
(Pournaras and le Roux 2009).  Non-surgical weight loss is associated with 
increased hunger and reduced metabolic rate which is a physiological response to 
reduced energy intake.  Leptin and insulin are the key messengers of the status of 
energy stores from the periphery to the central nervous system (Morton, Cummings, 
Baskin, Barsh and Schwartz 2006; Flier 2004; Pournaras and le Roux 2009). 
 
The central melanocortin system, which plays a crucial role in the regulation of 
energy homeostasis, is influenced by signals mediated through gut hormones 
(Ellacott, Halatchev and Cone 2006; Pournaras and le Roux 2009).  These 
molecules cause hunger and postprandial satiety and hence regulate appetite 
control (Pournaras and le Roux 2009).  
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Weight loss procedures were developed with the objective to cause weight loss due 
to the reduction of gastric volume (laparoscopic adjustable gastric banding, 
laparoscopic sleeve gastrectomy), malabsorption of nutrients (biliopancreatic 
diversion, duodenal switch) or the effect of both (Roux-en-Y gastric bypass) 
(Pournaras and le Roux 2009).  There is no evidence that calorie or protein 
malabsorption occurs after gastric bypass.  It has been demonstrated that negating 
the effect of the satiety gut hormone change with octeotride is associated with 
increased food intake and reduced satiety (le Roux, Welbourn, Werling, Osborne, 
Kokkinos, Laurenius, Lonroth, Fandriks, Ghatei, Bloom and Olbers 2007).  A number 
of studies have suggested that gut hormone concentrations change after gastric 
bypass leading to the establishment of the concept of the gut-brain axis.  The 
available data will be reviewed below.  
 
Gut hormones 
In this chapter anorexigenic and orexigenic gut hormones are reviewed in 
decreasing order in terms of level of evidence regarding their role in the mechanism 
of action of weight loss surgery namely peptide YY (PYY), glucagon-like peptide-1 
(GLP-1), ghrelin, cholecystokinin (CCK), glucose-dependent insulinotropic 
polypeptide (GIP), oxyntomodulin (OXM) and pancreatic polypeptide (PP).  
 
Peptide YY (PYY) 
Peptide YY is 36-amino-acid peptide, member of the PP-fold peptide family.  Y is the 
abbreviation for tyrosine.  PYY was found throughout the small gut in very low 
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concentrations in the duodenum and jejunum increasing in the terminal ileum and 
even higher concentrations throughout the colon with the maximum in the rectum 
(Adrian, Ferri, Bacarese-Hamilton, Fuessl, Polak and Bloom 1985).  Basal plasma 
concentrations of PYY were low but rose in response to food, remaining elevated for 
several hours postprandially (Adrian, Ferri, Bacarese-Hamilton, Fuessl, Polak and 
Bloom 1985).  PYY levels are not altered by gastric distension (Oesch, Rüegg, 
Fischer, Degen and Beglinger 2006).  PYY decreases appetite and reduces food 
intake by 33% over 24 hours in non obese individuals (Batterham, Cowley, Small, 
Herzog, Cohen, Dakin, Wren, Brynes, Low, Ghatei, Cone and Bloom 2002).  
Furthermore obese individuals are not resistant to the anorectic effects of PYY and 
have lower endogenous PYY suggesting that PYY deficiency may contribute to the 
pathogenesis of obesity (Batterham, Cohen, Ellis, Le Roux, Withers, Frost, Ghatei 
and Bloom 2003).  
 
Glucagon-like peptide-1 (GLP-1) 
GLP-1 is released postprandially by the same endocrine L-cells as PYY and OXM 
(Cummings and Overduin 2007).  GLP-1 and PYY inhibit food intake additively 
(Neary, Small, Druce, Park, Ellis, Semjonous, Dakin, Filipsson, Wang, Kent, Frost, 
Ghatei and Bloom 2005).  GLP-1 has an additional role as an incretin, a hormone 
which is secreted from gastrointestinal tract cells into the systemic circulation in 
response to the presence of nutrients intraluminally (Baggio and Drucker 2007).  
GLP-1 leads to glucose-dependent insulin secretion, induction of ß-cell proliferation 
and enhanced resistance to apoptosis (Baggio and Drucker 2007).  GLP-1 has 
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further effects on glucose regulation with slowing of gastric emptying and glucose-
dependent inhibition of glucagon secretion (Baggio and Drucker 2007).   
 
Ghrelin 
The only known orexigenic gut hormone is ghrelin, is a 28-amino acid peptide 
produced from the fundus of the stomach and the proximal intestine (Kojima, 
Hosoda, Date, Nakazato, Matsuo and Kangawa 1999; Frühbeck, Diez Caballero and 
Gil 2004).  Central and peripheral administration leads to increased food intake 
(Wren, Small, Abbott, Dhillo, Seal, Cohen, Batterham, Taheri, Stanley, Ghatei and 
Bloom 2001; Wren, Seal, Cohen, Brynes, Frost, Murphy, Dhillo, Ghatei and Bloom 
2001).  The preprandial elevation and the postprandial fall in ghrelin levels suggest 
that ghrelin may play a physiological role in meal initiation (Cummings, Purnell, 
Frayo, Schmidova, Wisse and Weigle 2001).  Diet induced weight loss of 17% of 
initial body weight was associated with a 24% increase in the 24 hour ghrelin profile 
suggesting that ghrelin may also have a role in the long-term regulation of body 
weight (Cummings, Weigle, Frayo, Breen, Ma, Dellinger and Purnell 2002).  Data 
from Imperial demonstrate that obese individuals have lower fasting ghrelin levels 
and reduced postprandial ghrelin suppression compared to normal weight individuals 
(le Roux, Patterson, Vincent, Hunt, Ghatei and Bloom 2005). 
 
Cholecystokinin (CCK) 
CCK is secreted by I cells located in the duodenum, jejunum, and proximal ileum in 
response to a meal (Chandra and Liddle 2007).  CCK has been implicated in gastric 
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emptying and distension, gallbladder contraction, pancreatic secretion, and intestinal 
motility as well as postprandial satiety (Chandra and Liddle 2007; Kellum, 
Kuemmerle, O’Dorisio, Rayford, Martin, Engle, Wolf and Sugerman 1990).  
Intraperitoneal administration of CCK in mice diminished food intake by 90% (Kopin, 
Mathes, McBride, Nguyen, Al-Haider, Schmitz, Bonner-Weir, Kanarek and Beinborn 
1999).  In contrast intraperitoneal administration of CCK in mice, lacking CCK-A 
receptors did not reduce food intake (Kopin, Mathes, McBride, Nguyen, Al-Haider, 
Schmitz, Bonner-Weir, Kanarek and Beinborn 1999).  The latter group of mice had 
the same weight as wild-type mice and Kopin et al suggested that CCK plays a role 
in appetite but is not essential for homeostasis (Kopin, Mathes, McBride, Nguyen, Al-
Haider, Schmitz, Bonner-Weir, Kanarek and Beinborn 1999). 
 
Glucose-dependent insulinotropic peptide or Gastric Inhibitory Peptide 
GIP is also an incretin with similar to GLP-1 effect on islet β-cells acting through 
structurally distinct yet related receptors (Yip and Wolfe 2000).  It is produced in the 
proximal gut and is released postprandially (Yip and Wolfe 2000).  It was initially 
named so due to the gastric acid inhibitory properties, but the effect on insulin seems 
to be more important from a physiological point of view (Yip and Wolfe 2000).  
 
Oxyntomodulin (OXM) 
Infusion of OXM reduced ad libitum energy intake at a buffet meal and also reduced 
hunger scores without causing nausea or affecting food palatability (Cohen, Ellis, Le 
Roux, Batterham, Park, Patterson, Frost, Ghatei and Bloom 2003).  In a randomised, 
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double-blind human trial the effect of OXM treatment was tested with self 
administered injections of OXM three times daily 30 minutes before each meal.  In 
the treatment group body weight was reduced by 2.3 kg compared to 0.5 kg in the 
control group (Wynne, Park, Small, Patterson, Ellis, Murphy, Wren, Frost, Meeran, 
Ghatei and Bloom 2005).  
 
Pancreatic polypeptide (PP) 
PP is a gut hormone released from the pancreas in response to nutrients.  Plasma 
levels of PP increased rapidly after a meal in healthy volunteers and remained 
elevated after six hours (Adrian, Bloom, Bryant, Polak, Heitz and Barnes 1976).  
Plasma PP has been shown to be reduced in conditions associated with increased 
food intake such as Prader-Willi syndrome (Zipf, O'Dorisio, Cataland and Sotos 
1981). Plasma PP has been shown to be increased in anorexia nervosa (Uhe, 
Szmukler, Collier, Hansky, O'Dea and Young 1992).  Infusion of PP leads to 
decreased appetite and food intake (Batterham, le Roux, Cohen, Park, Ellis, 
Patterson, Frost, Ghatei and Bloom 2003). 
 
Bile acids 
Bile consists of bile acids, cholesterol, phosphatidylcholine and bilirubin.  The 
primary bile acids in humans are cholic acid and chenodeoxycholic acid (Vlahcevic, 
Pandak and Stravitz 1999).  They are synthesized with the aid of enzymes found in 
the endoplasmic reticulum, cytosol, mitochondria, and peroxisomes and they are 
conjugated to glycine or taurine before they are secreted into bile canaliculi 
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(Vlahcevic, Pandak and Stravitz 1999).  Conjugated bile acids are the major solutes 
in bile; they are less toxic and are more efficient promoters of intestinal absorption of 
dietary lipid than unconjugated bile acids (Vessey, Crissey and Zakim 1977; Pircher, 
Kitto, Petrowski, Tangirala, Bischoff, Schulman and Westin 2003).  
 
Following a meal, bile flows into the duodenum and proximal gut (Houten, Watanabe 
and Auwerx 2006).  Bile acids are absorbed by both passive diffusion and active 
transport in the terminal ileum, and then transported to the liver via the portal vein in 
the so called enterohepatic recirculation (Houten, Watanabe and Auwerx 2006).  
They are subsequently taken up at the basolateral sinusoidal membrane and 
exported again at the apical canalicular membrane of the hepatocytes into the bile 
canaliculus (Houten, Watanabe and Auwerx 2006).  Each BA molecule may 
complete 4–12 cycles between the liver and intestine per day (Houten, Watanabe 
and Auwerx 2006). 
 
Bile acids have been recently recognised as potential targets for drug treatment in 
obesity and diabetes.  However this concept is not entirely novel.  The use of bile 
acids as appetite suppressants was first reported in 1968 (Bray and Gallagher 1968).   
 
In a randomized, double-blind, crossover study of cholestyramine compared with 
placebo for a period of 6 weeks each 21 patients with type 2 diabetes mellitus were 
included (Garg and Grundy 1994).  The aim was to assess efficacy and tolerability of 
the bile acid sequestrant cholestyramine (Garg and Grundy 1994).  Unexpectedly in 
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the post hoc analysis improved glycaemic control with mean plasma glucose values 
lowered by 13% and a median reduction in urinary glucose excretion were reported 
as well as a trend for lower glycated haemoglobin (Garg and Grundy 1994).   
 
Suzuki et al compared a different bile acid sequestrant, colestimide, to acarbose in a 
randomised open label study and showed a significant decrease in glucose levels 
(Suzuki, Oba, Futami, Suzuki, Ouchi, Igari, Matsumura, Watanabe, Kigawa and 
Nakano 2006).  Zieve et al showed in a double blind, placebo controlled study that a 
12-week treatment with colesevelam, another bile acid sequestrant, in addition to 
oral antihyperglycaemic medications, was associated with a significant reduction in 
HbA1c compared to placebo (Zieve, Kalin, Schwartz, Jones and Bailey 2007).  In 
another study comparing colestimide to pravastin, using a randomised open label 
design, colestimide therapy for three months led to reduced HbA1c and fasting 
glucose levels (Yamakawa, Takano, Utsunomiya, Kadonosono and Okamura 2007). 
 
Three similar multicenter studies assessed the efficacy of colevesham in patients not 
adequately controlled receiving insulin therapy alone or in combination with oral 
antidiabetic agents in one, receiving sulfonylurea monotherapy or sulfonylurea in 
combination with additional oral antidiabetic agents in the second and receiving 
metformin monotherapy or metformin in combination with additional oral antidiabetic 
agents in the third (Goldberg, Fonseca, Truitt and Jones 2008; Fonseca, 
Rosenstock, Wang, Truitt and Jones 2008; Bays, Goldberg, Truitt and Jones 2008).  
A prospective, randomized, double-blind, placebo-controlled, parallel-group design 
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was used in all studies and all three confirmed that colesevelam improved glycaemic 
control (Goldberg, Fonseca, Truitt and Jones 2008; Fonseca, Rosenstock, Wang, 
Truitt and Jones 2008; Bays, Goldberg, Truitt and Jones 2008).   
 
Different possible mechanisms have been suggested in attempt to dissect the effects 
of bile acids on glucose metabolism.  Disruption of enterohepatic circulation of bile 
acids may have an effect on the Farnesoid X Receptor (FXR) pathway, the 
intracellular signalling pathway for bile acids (Guzelian and Boyer 1974).  Bile acids 
promote GLP-1 secretion through TGR5 in STC-1 cells (Katsuma, Hirasawa and 
Tsujimoto 2005).  The effect of GLP-1 on glucose metabolism has already been 
described in the GLP-1 section.  Bile acids inhibit gluconeogenesis in both FXR 
dependent and independent manner (Thomas, Pellicciari, Pruzanski, Auwerx and 
Schoonjans 2008; De Fabiani, Mitro, Gilardi, Caruso, Galli and Crestani 2003; 
Yamagata, Daitoku, Shimamoto, Matsuzaki, Hirota, Ishida and Fukamizu 2004; Ma, 
Saha, Chan and Moore 2006).  Bile acids increase energy expenditure and therefore 
reduce insulin resistance.  This effect is dependent on induction of the cyclic-AMP-
dependent thyroid hormone activating the enzyme type 2 iodothyronine deiodinase 
(D2) (Watanabe, Houten, Mataki, Christoffolete, Kim, Sato, Messaddeq, Harney, 
Ezaki, Kodama, Schoonjans, Bianco and Auwerx 2006).  In addition bile acids act via 
the phosphatidylinositol 3 (PI3) kinase/AKT/glycogen synthase (kinase) 3 
(GSK3)/glycogen synthase (GS) pathway (Han, Studer, Gupta, Fang, Qiao, Li, 
Grant, Hylemon and Dent 2004).  Through this pathway bile acids cooperate with 
insulin in the regulation of glucose storage in hepatocytes (Han, Studer, Gupta, 
Fang, Qiao, Li, Grant, Hylemon and Dent 2004).  Bile acids through fibroblast growth 
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factor 19 (FGF19) may cause increased metabolic rate and decreased adiposity as 
well as increased energy expenditure (Tomlinson, Fu, John, Hultgren, Huang, Renz, 
Stephan, Tsai, Powell-Braxton, French and Stewart 2002).  All these are beneficial 
for insulin sensitivity.  FGF19 also regulates hepatic protein and glycogen 
metabolism in an insulin-independent manner (Kir, Beddow, Samuel, Miller, Previs, 
Suino-Powell, Xu, Shulman, Kliewer and Mangelsdorf DJ 2011).   
 
The effect of metabolic surgery on gut hormones and bile acids  
The changes in gut hormones and bile acids after RYGB, the commonest weight 
loss operation are summarised in Table 1. 
 
Metabolic Surgery and PYY 
In both a human model of gastric bypass and a rodent model of jejuno-intestinal 
bypass increased postprandial PYY responses were shown (le Roux, Aylwin, 
Batterham, Borg, Coyle, Prasad, Shurey, Ghatei, Patel and Bloom 2006).  In an a 
follow-up study it was confirmed that gastric bypass leads to enhanced postprandial 
PYY and GLP-1 responses in the first week after surgery (le Roux, Welbourn, 
Werling, Osborne, Kokkinos, Laurenius, Lönroth, Fändriks, Ghatei, Bloom and 
Olbers 2007).  This was associated with enhanced postprandial satiety as measured 
with visual analogue scores (le Roux, Welbourn, Werling, Osborne, Kokkinos, 
Laurenius, Lönroth, Fändriks, Ghatei, Bloom and Olbers 2007).  In a comparison of 
good versus poor responders to gastric bypass, the poor responders had attenuated 
PYY and GLP-1 postprandial responses compared to patients with good weight loss 
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(le Roux, Welbourn, Werling, Osborne, Kokkinos, Laurenius, Lönroth, Fändriks, 
Ghatei, Bloom and Olbers 2007).  These findings demonstrated an association 
between the enhanced postprandial satiety gut hormone response and appetite 
control after gastric bypass surgery.   
 
In the same study causation was shown with another experiment (le Roux, 
Welbourn, Werling, Osborne, Kokkinos, Laurenius, Lönroth, Fändriks, Ghatei, Bloom 
and Olbers 2007).  Using a randomised double-blind saline controlled design and 
including patients who had undergone gastric bypass and were weight stable, 
inhibition of the gut hormone response with the somatostatin analogue octeotride led 
to increased food intake and reduced satiety (le Roux, Welbourn, Werling, Osborne, 
Kokkinos, Laurenius, Lönroth, Fändriks, Ghatei, Bloom and Olbers 2007).  
Octeotride had no effect on patients who had previously undergone gastric banding 
and acted as a control group (le Roux, Welbourn, Werling, Osborne, Kokkinos, 
Laurenius, Lönroth, Fändriks, Ghatei, Bloom and Olbers 2007).  Hence gastric 
bypass can be considered a surgically induced a behavioural modification (appetite 
control) which is due to the modulation of the satiety gut hormone response.  
 
Korner et al performed a prospective study of patients undergoing gastric bypass 
and gastric banding (Korner, Inabnet, Febres, Conwell, McMahon, Salas, Taveras, 
Schrope and Bessler 2009).  PYY levels were measured preoperatively, 26 and 52 
weeks postoperatively using a liquid mixed standard meal (Korner, Inabnet, Febres, 
Conwell, McMahon, Salas, Taveras, Schrope and Bessler 2009).  Although there 
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was no difference in fasting PYY levels at any time point, a progressive increase in 
fasting PYY in the gastric bypass was reported, which reached significance 
compared to preoperatively at the 52 week time point (Korner, Inabnet, Febres, 
Conwell, McMahon, Salas, Taveras, Schrope and Bessler 2009).  Postprandial 
levels of PYY (30 minutes) increased 3.5 times at both postoperative time points 
after gastric bypass and were significantly higher compared to the gastric banding 
group (Korner, Inabnet, Febres, Conwell, McMahon, Salas, Taveras, Schrope and 
Bessler 2009).  When postprandial PYY was assessed with the area under the curve 
(AUC), this was increased at 26 weeks and increased even further with a significant 
difference at 52 weeks (Korner, Inabnet, Febres, Conwell, McMahon, Salas, 
Taveras, Schrope and Bessler 2009).  Postprandial PYY AUC increased 26 weeks 
after gastric banding but not after 52 weeks (Korner, Inabnet, Febres, Conwell, 
McMahon, Salas, Taveras, Schrope and Bessler 2009).  Of note is that the two 
groups were not matched for BMI preoperatively as the patients in the gastric bypass 
group were heavier, but both groups had similar BMI at 26 and 52 weeks making the 
findings of this study an important contribution in the evidence base of PYY increase 
after gastric bypass surgery (Korner, Inabnet, Febres, Conwell, McMahon, Salas, 
Taveras, Schrope and Bessler 2009). 
 
Laferrère’s group performed a similar comparative study in which participants 
underwent gastric bypass or gastric banding (Bose, Machineni, Oliván, Teixeira, 
McGinty, Bawa, Koshy, Colarusso and Laferrère 2010).  The two groups were 
matched for preoperative weight and age.  They were studied preoperatively, 
postoperatively following weight loss of 12 kg and at one year postoperatively with a 
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50 g (in 200 mL) oral glucose test being used (Bose, Machineni, Oliván, Teixeira, 
McGinty, Bawa, Koshy, Colarusso and Laferrère 2010).  Postprandial PYY levels 
increased at the fist postoperative time point following gastric bypass but not gastric 
banding (Bose, Machineni, Oliván, Teixeira, McGinty, Bawa, Koshy, Colarusso and 
Laferrère 2010).  No further changes were noted at 12 months (Bose, Machineni, 
Oliván, Teixeira, McGinty, Bawa, Koshy, Colarusso and Laferrère 2010).  This study 
demonstrated that gastric bypass leads to an increased postprandial PYY response 
controlling for the effect of surgery and weight loss by using a matched control group 
and matching for similar weight loss at the first postoperative time point (Bose, 
Machineni, Oliván, Teixeira, McGinty, Bawa, Koshy, Colarusso and Laferrère 2010).   
 
The same group performed a comparative study of the effect of equivalent weight 
loss (10kg) after gastric bypass and diet on PYY (Oliván, Teixeira, Bose, Bawa, 
Chang, Summe, Lee and Laferrère 2009).  Again the PYY response to an oral 
glucose tolerance test was enhanced following bypass but not after diet again 
controlling for the effect of weight loss (Oliván, Teixeira, Bose, Bawa, Chang, 
Summe, Lee and Laferrère 2009). 
 
Exploring the effects of other procedures on PYY, Garcia-Fuentes et al showed 
increased PYY fasting levels 7 months after biliopancreatic diversion compared to 
preoperatively and there was a significant difference compared to patients 
undergoing gastric bypass (Garcia-Fuentes, Garrido-Sanchez, Garcia-Almeida, 
Garcia-Arnes, Gallego-Perales, Rivas-Marin, Morcillo, Cardona and Soriguer 2008). 
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Sleeve gastrectomy has also been suggested to have an effect on PYY.   
Karamanakos et al performed a prospective double blind study comparing gastric 
bypass and sleeve gastrectomy (Karamanakos, Vagenas, Kalfarentzos and 
Alexandrides 2008).  Time points were preoperatively and 1, 3, 6, and 12 months 
postoperatively (Karamanakos, Vagenas, Kalfarentzos and Alexandrides 2008).  
Fasting PYY levels increased significantly after sleeve gastrectomy as well as gastric 
bypass (Karamanakos, Vagenas, Kalfarentzos and Alexandrides 2008).  In a 
subgroup of patients, samples were collected 2 hours after a standard 420 kcal 
mixed meal and PYY postprandial levels increased significantly after both sleeve 
gastrectomy and gastric bypass compared to fasting levels (Karamanakos, Vagenas, 
Kalfarentzos and Alexandrides 2008). 
 
Peterli et al performed a similar randomized, prospective study comparing gastric 
bypass and sleeve gastrectomy (Peterli, Wölnerhanssen, Peters, Devaux, Kern, 
Christoffel-Courtin, Drewe, von Flüe and Beglinger 2009).  In this study preoperative 
fasting PYY levels were higher in the bypass group compared to gastric banding with 
no significant difference (Peterli, Wölnerhanssen, Peters, Devaux, Kern, Christoffel-
Courtin, Drewe, von Flüe and Beglinger 2009).  Fasting PYY levels decreased 
postoperatively in both groups (Peterli, Wölnerhanssen, Peters, Devaux, Kern, 
Christoffel-Courtin, Drewe, von Flüe and Beglinger 2009).  However an increased 
postprandial PYY response was reported one week after both sleeve gastrectomy 
and gastric bypass (Peterli, Wölnerhanssen, Peters, Devaux, Kern, Christoffel-
Courtin, Drewe, von Flüe and Beglinger 2009). 
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Metabolic Surgery and GLP-1 
As expected, in accordance to the PYY response, the postprandial GLP-1 response 
is also enhanced after gastric bypass.  Rubino et al showed no difference in fasting 
GLP-1 levels in a group of patients, both diabetic and non diabetic undergoing 
gastric bypass (Rubino, Gagner, Gentileschi, Kini, Fukuyama, Feng and Diamond 
2004).  Morinigo et al performed two prospective studies of patients undergoing 
gastric bypass (Morínigo, Moizé, Musri, Lacy, Navarro, Marín, Delgado, Casamitjana 
and Vidal 2006; Morínigo, Lacy, Casamitjana, Delgado, Gomis and Vidal 2006).  
Fasting GLP-1 did not increase at the 6 week or the 12 month time point.   
 
De Carvalho et al investigated prospectively eleven normal glucose tolerant and 
eight abnormal glucose metabolism obese patients undergoing initially diet-
restriction followed by gastric bypass with a silastic ring around the gastric pouch, 
the FOBI procedure (de Carvalho, Marin, de Souza, Pareja, Chaim, de Barros 
Mazon, da Silva, Geloneze, Muscelli and Alegre 2009).  GLP-1 levels at 30 and 60 
min after a glucose tolerance test increased nine months postoperatively. 
 
Laferrère et al investigated a group of nine obese, type 2 diabetic women who 
underwent gastric bypass (Laferrère, Teixeira, McGinty, Tran, Egger, Colarusso, 
Kovack, Bawa, Koshy, Lee, Yapp and Olivan 2008).  They used a group of matched 
individuals who were on low calorie diet as controls.  A 50-gr oral glucose test was 
performed prior to the intervention and one month afterwards.  In addition to GLP-1 
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levels, the incretin effect was also calculated.  Fasting GLP-1 levels remained 
unchanged in both groups.  Both the postprandial GLP-1 and the incretin effect were 
increased following gastric bypass but not after diet-induced weight loss.   
 
The same group studied 11 participants with type 2 diabetes preoperatively and 1, 6, 
and 12 months after gastric bypass (Bose, Teixeira, Olivan, Bawa, Arias, Machineni, 
Pi-Sunyer, Scherer and Laferrère 2010).  The blunted incretin effect improved at 1 
month and remained unchanged at 6 and 12 months after gastric bypass. The 
blunted GLP-1 levels followed a similar response after gastric bypass with the 
improvement at 1 month remaining unchanged at 12 months.  
 
Morinigo et al showed on their study of 9 patients undergoing gastric bypass that a 
significant increase in the GLP-1 postprandial response using a standard mixed 
liquid meal (Morínigo, Moizé, Musri, Lacy, Navarro, Marín, Delgado, Casamitjana 
and Vidal 2006).  In a subsequent study from the same group, a 12-month 
prospective study using the same standard test meal, participants had normal 
glucose tolerance, impaired glucose tolerance or type 2 diabetes (Morínigo, Lacy, 
Casamitjana, Delgado, Gomis and Vidal 2006).  Postprandial GLP-1 was increased 
at the 6-week time point for participants with normal or impaired glucose tolerance 
but not in participants with type 2 diabetes.  The postprandial GLP-1 response was 
similar among the three groups at 12 months. 
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Lugari et al studied 22 non-diabetic patients undergoing biliopancreatic diversion  
and 9 age-matched healthy volunteers using a mixed meal preoperatively and 
postoperatively when patients reached 50% excess weight loss (Lugari, Dei Cas, 
Ugolotti, Barilli, Camellini, Ganzerla, Luciani, Salerni, Mittenperger, Nodari, Gnudi 
and Zandomeneghi 2004).  An overall increase in circulating GLP-1 levels was 
reported whilst plasma DPP-IV activity remained abnormally increased 
postoperatively. 
 
Further work on the effect of biliopancreatic diversion on GLP-1 was performed by 
Valverde et al (Valverde, Puente, Martín-Duce, Molina, Lozano, Sancho, Malaisse 
and Villanueva-Peñacarrillo 2005).  An oral glucose tolerance test was used in 
patients at 1, 3 and 6 months after biliopancreatic diversion.  As a control group 
participants were also tested 6 months after vertical banded gastroplasty.  One 
month after biliopancreatic diversion the postprandial GLP-1 response was 
increased.  Both the basal plasma GLP-1 concentration and its incremental area 
during the oral glucose tolerance test continued to increase.  However a more 
pronounced increase in basal and incremental plasma GLP-1 was observed after 
biliopancreatic diversion compared to vertical banded gastroplasty.  
 
Mingrone’s group studied 10 patients with type 2 diabetes undergoing biliopancreatic 
diversion (Guidone, Manco, Valera-Mora, Iaconelli, Gniuli, Mari, Nanni, Castagneto, 
Calvani and Mingrone 2006).  Following an oral glucose tolerance test postprandial 
55 
 
GLP-1 response increased one week postoperatively and did not increase further at 
4 weeks. 
 
The effect of sleeve gastrectomy on GLP-1 was studied in the randomised control 
trial of gastric bypass vs. sleeve gastrectomy by Peterli et al (Peterli, 
Wölnerhanssen, Peters, Devaux, Kern, Christoffel-Courtin, Drewe, von Flüe and 
Beglinger 2009).  The postprandial GLP-1 response was more enhanced one week 
after gastric bypass compared to sleeve gastrectomy.  This exaggerated GLP-1 
response remained unchanged 3 months after gastric bypass but increased further 
after sleeve gastrectomy. 
 
Varderas et al performed a prospective study of non-diabetic undergoing sleeve 
gastrectomy using a standard liquid meal preoperatively and two months 
postoperatively (Valderas, Irribarra, Rubio, Boza, Escalona, Liberona, Matamala and 
Maiz 2011).  The incremental area under the curve of GLP-1 increased after sleeve 
gastrectomy.    
 
A study from the USA showed no change in fasting GLP-1 levels 6 and 12 months 
after gastric banding (Shak, Roper, Perez-Perez, Tseng, Francois, Gamagaris, 
Patterson, Weinshel, Fielding, Ren and Blaser 2008). 
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Usinger et al investigated the GLP-1 response in 10 patients before and 6 weeks 
after gastric banding also using 75 g-oral glucose tolerance test (Usinger, Hansen, 
Kristiansen, Larsen, Holst and Knop 2011).  This study did not show any change in 
fasting or postprandial GLP-1.    
 
Finally in Korner’s comparative study fasting levels and 30minute postprandial levels 
of GLP-1 did not change 26 and 52 weeks after gastric banding (Korner, Inabnet, 
Febres, Conwell, McMahon, Salas, Taveras, Schrope and Bessler 2009). 
 
Metabolic Surgery and Ghrelin 
Cummings et al showed in a landmark study, which led to great interest in the 
interaction of weight loss surgery and gut hormones, a profound suppression of 
ghrelin levels post gastric bypass (Cummings, Weigle, Frayo, Breen, Ma, Dellinger 
and Purnell 2002).  Data from other centres have been heterogeneous (Pournaras, 
le Roux 2009).  Studies showed decreased fasting and postprandial (Geloneze, 
Tambascia, Pilla, Geloneze, Repetto and Pareja 2003; Morínigo, Casamitjana, 
Moizé, Lacy, Delgado, Gomis and Vidal 2004), unchanged fasting and postprandial 
(le Roux, Welbourn, Werling, Osborne, Kokkinos, Laurenius, Lönroth, Fändriks, 
Ghatei, Bloom and Olbers 2007; Faraj, Havel, Phélis, Blank, Sniderman and 
Cianflone 2003; Stoeckli, Chanda, Langer and Keller 2004) and increased fasting 
ghrelin levels after gastric bypass (Vendrell, Broch, Vilarrasa, Molina, Gómez, 
Gutiérrez, Simón, Soler and Richart 2004).   
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Lin et al showed that the divided gastroplasty creating a small proximal gastric 
pouch, as part of gastric bypass, results in an early decline in circulating ghrelin 
levels that are not observed with other gastric procedures (Lin, Gletsu, Fugate, 
McClusky, Gu, Zhu, Ramshaw, Papanicolaou, Ziegler and Smith 2004).  An intact 
vagus nerve is required for exogenous ghrelin to increase appetite and food intake 
(le Roux, Neary, Halsey, Small, Martinez-Isla, Ghatei, Theodorou and Bloom 2005).  
Perioperative factors may play a role.  Sundbom et al showed that ghrelin levels fall 
transiently on postoperative day 1 after gastric bypass, increased after 1 month to 
preoperative levels, and rose further at 6 and 12 months (Sundbom, Holdstock, 
Engström and Karlsson 2007).  The authors suggest that this is due to vagal 
dysfunction (Sundbom, Holdstock, Engström and Karlsson 2007).  Differences in the 
surgical technique may also contribute to the variation in the results as with a vertical 
pouch, ghrelin producing cells are more likely to be excluded, compared to a 
horizontal pouch (Pories 2008).  In obese individuals, insulin resistance and 
hyperinsulinaemia are inversely associated with ghrelin concentrations (McLaughlin, 
Abbasi, Lamendola, Frayo and Cummings 2004).  A potential hypothesis is that 
preoperative differences as well as differences in the postoperative improvement in 
of insulin and insulin resistance may affect ghrelin levels and hence contribute to the 
variation in results (Pournaras and le Roux 2009).   
 
Finally, the different assays used for ghrelin may be responsible for the diversity in 
the results published in the literature (Chandarana, Drew, Emmanuel, Karra, 
Gelegen, Chan, Cron and Batterham 2009).  Serine-3 of ghrelin is acylated with an 
eight carbon fatty acid, octanoate (Yang, Brown, Liang, Grishin and Goldstein 2008).  
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This is essential for ghrelin’s effects.  De Vriese et al demonstrated in a human study 
that ghrelin is degraded by several esterases (De Vriese, Gregoire, Lema-Kisoka, 
Waelbroeck, Robberecht and Delporte 2004).  This process renders ghrelin inactive 
(De Vriese, Gregoire, Lema-Kisoka, Waelbroeck, Robberecht and Delporte 2004). 
 
Chandarana et al showed that fasting plasma acyl-ghrelin concentrations were 
markedly higher in samples processed with 4-(2-aminoethyl)-benzenesulfonyl 
fluoride hydrochloride in addition to hydrochloric acid and aprotinin compared to 
samples processed with hydrochloric acid and aprotinin or aprotinin alone 
(Chandarana, Drew, Emmanuel, Karra, Gelegen, Chan, Cron and Batterham 2009).  
Furthermore they detected higher acyl-ghrelin levels in hydrochloric acid and 
aprotinin samples compared to aprotinin only samples.  These subtle differences in 
the processing of the samples may explain the different results amongst different 
centres. 
 
Despite the fact that ghrelin has led to considerable interest in the gut brain axis, the 
inconsistent response among studies and centres have made a challenging 
candidate for elucidating the mechanism of metabolic surgery.  
 
Metabolic Surgery and CCK 
Rubino et al showed no change in fasting CCK three weeks after gastric bypass 
(Rubino, Gagner, Gentileschi, Kini, Fukuyama, Feng and Diamond 2004).  Kellum et 
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al studied patients before and six months after gastric bypass and vertical banded 
gastroplasty showing no change in the CCK response to a glucose meal (Kellum, 
Kuemmerle, O'Dorisio, Rayford, Martin, Engle, Wolf and Sugerman 1990).  
 
Foschi et al studied eight patients before and after weight loss of 20% of the initial 
BMI following vertical banded gastroplasty (Foschi, Corsi, Pisoni, Vago, Bevilacqua, 
Asti, Righi and Trabucchi 2004).  A control group of healthy volunteers was used.  
There was no difference in basal CCK levels between the two groups.  Following an 
acidified liquid meal peak CCK levels were increased after vertical banded 
gastroplasty.   
 
Naslund et al showed increased basal CCK levels 20 years after jejuno-ileal bypass 
(Naslund, Gryback, Hellstrom, Jacobsson, Holst, Theodorsson and Backman 1997).   
 
The same group studied eight patients before and 9 months after jejuno-ileal bypass 
using a standard mixed meal (Naslund, Melin, Gryback, Hagg, Hellstrom, 
Jacobsson, Theodorsson, Rössner and Backman 1997).  Postprandial CCK levels 
were lower than non-obese controls both pre and postoperatively. 
 
Metabolic Surgery and GIP 
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Rubino et al studied the GIP response in diabetic and non-diabetic patients before 
and three weeks after gastric bypass (Rubino, Gagner, Gentileschi, Kini, Fukuyama, 
Feng and Diamond 2004).  Gastric bypass led to reduced fasting GIP levels in 
diabetic patients whereas no changes in GIP levels were found in non-diabetics.  
Bose et al also showed no difference in fasting GIP levels after gastric bypass (Bose, 
Teixeira, Olivan, Bawa, Arias, Machineni, Pi-Sunyer, Scherer and Laferrère 2010).  
Work from Phil Schauer’s unit in accordance with the findings of the previous studies 
showed no change in fasting GIP one and four weeks following gastric bypass 
(Kashyap, Daud, Kelly, Gastaldelli, Win, Brethauer, Kirwan and Schauer 2010).  
Breitman et al showed no change in fasting GIP two and eight weeks after gastric 
bypass (Breitman, Saraf, Kakade, Yellumahanthi, White, Hackett and Clements 
2011).   
 
In the work by Blandine Laferrere GIP levels in response to an oral glucose tolerance 
test increased at one month and remained at this levels 6 and 12 months after 
gastric bypass (Laferrère, Heshka, Wang, Khan, McGinty, Teixeira, Hart and Olivan 
2007; Bose, Teixeira, Olivan, Bawa, Arias, Machineni, Pi-Sunyer, Scherer and 
Laferrère 2010).   
 
Guidone et al studied 10 patients with type 2 diabetes before and one and four 
weeks after biliopancreatic diversion using an oral glucose tolerance test (Guidone, 
Manco, Valera-Mora, Iaconelli, Gniuli, Mari, Nanni, Castagneto, Calvani and 
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Mingrone 2006).  Fasting GIP levels as well as the postprandial GIP response 
decreased one week postoperatively and remained unchanged at four weeks.   
 
Fasting GIP levels do not change six weeks after gastric banding according to study 
by Usinger et al (Usinger, Hansen, Kristiansen, Larsen, Holst and Knop 2011).  Shak 
et al showed no change in fasting GIP 6 and 12 months after gastric banding (Shak, 
Roper, Perez-Perez, Tseng, Francois, Gamagaris, Patterson, Weinshel, Fielding, 
Ren and Blaser 2008).   
 
 
Metabolic Surgery and Enteroglucagon and OXM 
Kellum et al showed that gastric bypass was associated with an exaggerated 
enteroglucagon response to glucose (Kellum, Kuemmerle, O'Dorisio, Rayford, 
Martin, Engle, Wolf and Sugerman 1990).  Furthermore enteroglucagon appears to 
be a marker of the dumping syndrome after gastric bypass.  Laferrère et al 
demonstrated a 2-fold peak of OXM levels rose in response to oral glucose and the 
peak of OXM was significantly correlated with GLP-1 and PYY (Laferrère, Swerdlow, 
Bawa, Arias, Bose, Oliván, Teixeira, McGinty and Rother 2010). 
 
Metabolic Surgery and PP 
No changes in PP were detected after gastric bypass in one study (le Roux, Aylwin, 
Batterham, Borg, Coyle, Prasad, Shurey, Ghatei, Patel and Bloom 2006).  Sundbom 
62 
 
et al showed that PP concentrations decreased on day 1 after gastric bypass and 
subsequently returned to preoperative levels (Sundbom, Holdstock, Engström and 
Karlsson 2007).  A prospective study of patients undergoing gastric banding showed 
that a low PP meal response preoperatively was associated with greater weight loss 
postoperatively (Dixon, le Roux, Ghatei, Bloom, McGee and Dixon 2011).  The 
findings allowed the authors to hypothesise that low PP postprandial response may 
be a predictor of greater weight loss after gastric banding. 
 
 
Metabolic Surgery and bile acids 
Patti et al has shown in a cross-sectional study of three groups; patients after gastric 
bypass, individuals matched to preoperative BMI and individuals matched to current 
BMI (Patti, Houten, Bianco, Bernier, Larsen, Holst, Badman, Maratos-Flier, Mun, 
Pihlajamaki, Auwerx and Goldfine 2009).  Total serum bile acid concentrations were 
higher after gastric bypass and were inversely correlated with 2-h post-meal glucose 
and fasting triglycerides as well as positively correlated with adiponectin and peak 
GLP-1.  Total bile acids strongly correlated inversely with thyrotrophic hormone. 
 
The increase in plasma bile acids was reflected in both primary and secondary bile 
acids.  The authors found no change in FGF19, a marker of bile acid absorption from 
the ileum and regulator of bile acids synthesis.  The main limitation of this study was 
the cross-sectional design.  Although control groups matched for preoperative and 
postoperative weight loss, the effect of rapid weight loss itself cannot be excluded.  
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Hence prospective studies need to be conducted to establish the role of bile acids in 
the effect of metabolic surgery.  
64 
 
Table 3: Summary of gut hormone changes after RYGB (Pournaras and le 
Roux 2010). 
 
 
Gut hormone Basal level Postprandial 
GLP-1 Unchanged Increased 
PYY Unchanged Increased 
Ghrelin Inconclusive Decreased 
CCK Unchanged Unchanged 
GIP Decreased Unknown 
PP Unchanged Unchanged 
Bile acids Increased Unknown 
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Hypothesis 
This thesis deals with the following hypotheses.  Firstly I hypothesise that gastric 
bypass leads to improved glycaemic control in a weight loss independent manner.  
Secondly, that one of the mechanisms for this observation involves gut hormones 
and particularly the incretin GLP-1.  Finally, I hypothesise that another mechanism is 
the change in bile flow which contributes to improved glucose metabolism. 
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2. Glycaemic control after metabolic surgery 
 
2.1 Introduction 
 
The purpose of this chapter is to provide the evidence that the effect of gastric 
bypass on glycaemic control is not only related to weight loss.  During the period of 
the research undertaken, the concept of diabetes remission was introduced and 
subsequently new criteria were proposed.  Initially the discontinuation of medication 
with acceptable measurements of fasting glucose was reported (Pories, Swanson, 
MacDonald, Long, Morris, Brown, Barakat, deRamon, Israel and Dolezal 1995).  
Anecdotally this could lead to patients stopping their medication as they considered 
themselves “cured”.  There were also conflicts within the multidisciplinary team with 
diabetologists being sceptical regarding the effects of metabolic surgery and 
metabolic surgeons being over enthusiastic regarding the effects of surgery on 
diabetes.  The lack of a strict definition did not help this.  The common example of 
patients remaining postoperatively on Metformin, an effective and proven cost-
effective treatment, and hence not considered on remission was associated with 
disappointment of patients and surgeons.  More important was the issue of follow-up 
from a diabetes point of view.  A patient who is regularly told that they are cured of 
their diabetes are likely to forego life-saving follow up such as regular BP recordings, 
eye tests, renal function test.    
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A consensus group comprising experts in endocrinology, diabetes education, 
transplantation, metabolism, metabolic surgery and haematology–oncology 
proposed new definitions of partial and complete remission of type 2 diabetes (Buse, 
Caprio, Cefalu, Ceriello, Del Prato, Inzucchi, McLaughlin, Phillips, Robertson, 
Rubino, Kahn and Kirkman 2009).  The input of haematologists and oncologists was 
deemed valuable as they do deal with the concept of remission of cancer in their 
routine practice.  The implication of these recommendations was that a standard 
metric was proposed for reporting rates of diabetes remission allowing comparison 
between different procedures from different units in future.  Secondly, the more strict 
criteria for glycaemic control remission may affect treatment options suggesting that 
patients may benefit from hypoglycaemic treatment after metabolic surgery.  Finally 
opening the debate of optimal glycaemic control after metabolic surgery can now be 
facilitated. 
 
The remission rate after metabolic surgery using the new criteria was established for 
the first time in the second study described in this chapter. 
 
2.2 Methods 
 
Study 1: Glycaemic control after gastric bypass and gastric banding  
This study was performed according to the principles of the Declaration of Helsinki.  
The Somerset Research and Ethics committee approved the study (LREC Protocol 
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Number: 05/Q2202/96).  Exclusion criteria were pregnancy, substance abuse, more 
than two alcoholic drinks per day.  Written informed consent was obtained from all 
participants.  
 
Selection criteria for study 1 included patients with type 2 diabetes undergoing either 
gastric bypass or gastric banding operations.  This was not a randomised study.  
Data were collected prospectively on 34 consecutive patients with type 2 diabetes.  
All operations were performed by the same surgeon in one centre within a period of 
three years.  It was patient’s choice which determined the type of operation 
performed.  Participants were informed about the different operations by the 
physicians, the surgeons and the dieticians as part of the preoperative consultation.  
They were also encouraged to attend patient support groups organised by the British 
Obesity Surgery Patients Association.    
 
Fasting glucose, HbA1c, and dosage of anti-diabetic medication were recorded pre-
operatively and during follow-up at 3, 6, 12, 18, 24 and 36 months.  Remission of 
type 2 diabetes was previously defined as being off diabetes medications with 
normal fasting blood glucose (5.6 mmol/l) or HbA1c of less than 6% (Buchwald, 
Avidor, Braunwald, Jensen, Pories, Fahrbach and Schoelles 2004; Buchwald, Estok, 
Fahrbach, Banel, Jensen, Pories, Bantle and Sledge 2009).  This definition was used 
in meta-analyses estimating the effect of weight loss surgery on type 2 diabetes 
(Buchwald, Avidor, Braunwald, Jensen, Pories, Fahrbach and Schoelles 2004; 
Buchwald, Estok, Fahrbach, Banel, Jensen, Pories, Bantle and Sledge 2009). 
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In this study (study 1) remission of type 2 diabetes was defined using the WHO 
definition of type 2 diabetes.  Therefore remission was achieved when all the below 
criteria were met: 
1. Fasting plasma glucose below 7 mmol/L in the absence of medical treatment for at 
least 3 days.  
2. A two hour plasma glucose below 11.1 mmol/L following an oral glucose tolerance 
test as specified by the World Health Organisation (Report of a WHO Consultation, 
Definition, diagnosis and classification of diabetes mellitus and its complications. 
Part 1 Diagnosis and classification of diabetes mellitus. World Health Organization, 
Department of Noncommunicable Disease Surveillance, Geneva, 1999).  
3. HbA1c below 6% after 3 months of last hypoglycaemic agent usage.  This criterion 
was added as it was often used in the surgical literature at the time of designing the 
experiment (Buchwald, Avidor, Braunwald, Jensen, Pories, Fahrbach and Schoelles 
2004; Buchwald, Estok, Fahrbach, Banel, Jensen, Pories, Bantle and Sledge 2009; 
O'Brien, Dixon, Laurie, Skinner, Proietto, McNeil, Strauss, Marks, Schachter, 
Chapman and Anderson 2006;  Schauer, Burguera, Ikramuddin, Cottam, Gourash, 
Hamad, Eid, Mattar, Ramanathan, Barinas-Mitchel, Rao, Kuller and Kelley 2003).  
 
The technique used for the bypass was a combination of linear stapler and hand 
sewn enterotomy closure for both the gastrojejunostomy and jejuno-jejunostomy, in 
an antegastric-retrocolic configuration (Higa, Boone, Ho and Davies 2000).  This was 
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a modification of the technique first described by Higa et al (Higa, Boone, Ho and 
Davies 2000).   
 
A preoperative low-calorie, low-carbohydrate diet was used for 2 weeks aiming to 
reduce perioperative risk by reducing liver size and improving intraoperative 
exposure.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 500mg 
metronidazole at induction was routinely used (Pournaras, Jafferbhoy, Titcomb, 
Humadi, Edmond, Mahon and Welbourn 2010).   
 
Reverse Trendelenburg position was used with the operating on the right of the 
patient and assistant positioned between the legs of the patient.  Pneumoperitoneum 
was obtained with a Verres needle inserted below the left costal margin at the mid-
clavicular line.  Thromboprophylaxis included the routine use of TED stockings and 
40 mg of low molecular weight heparin preoperatively and then for 7 days 
postoperatively and lower limb pneumatic compression devices intraoperatively.  
Five ports were used.  An isolated lesser curve-based, 15–20-ml gastric pouch was 
created and a retrocolic antegastric Roux limb was made 100 cm long for patients 
with a BMI equal to or less than 50 kg/m2 and 150 cm long for patients with BMI of 
more than 50 kg/m2.  The bilio-pancreatic limb was 25 cm.  The gastrojejunostomy 
was closed over a 34 Fr bougie.  A blue dye leak test via a nasogastric tube was 
routinely performed.  All hernia defects (jejunojejunostomy, Petersen’s and 
mesocolon) were routinely closed with a purse-string suture.   
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An enhanced recovery protocol was used with patients being offered a glass of water 
in the recovery room progressing to free fluids on postoperative day 1 and a soft diet 
thereafter.  The first routine postoperative review in the outpatient department was 6 
weeks after discharge with a minimum regular follow-up program for uncomplicated 
patients afterwards of 6 months, 12 months postoperatively, and yearly thereafter, 
and more intensive follow-up for complex patients. 
 
The surgical technique used for gastric banding was the pars flaccida described by 
the Melbourne group (O'Brien, Dixon, Laurie and Anderson 2005).  A preoperative 
low-calorie, low-carbohydrate diet was used for 2 weeks aiming to reduce 
perioperative risk by reducing liver size and improving intraoperative exposure as 
with the gastric bypass.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 
500mg metronidazole at induction was routinely used (Pournaras, Jafferbhoy, 
Titcomb, Humadi, Edmond, Mahon and Welbourn 2010).  Thromboprophylaxis 
included the routine use of TED stockings and 40 mg of low molecular weight 
heparin preoperatively and then for 7 days postoperatively.  Lower limb pneumatic 
compression devices intraoperatively. Five ports were used.  The Swedish 
Adjustable Gastric band® (Ethicon Endo-Surgery) and the LAP-BAND® (Allergan) 
bands were used for all gastric banding procedures.  The pars flaccida dissection 
technique with gastro-gastric tunnelling sutures was the operative method utilised 
(O'Brien, Dixon, Laurie and Anderson 2005).  The same enhanced recovery protocol 
as the one sued for gastric bypass was used with patients being offered a glass of 
water in the recovery room progressing to free fluids on postoperative day 1 and a 
soft diet thereafter.  Follow-up was also similar with the first postoperative review in 
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the outpatient department 6 weeks after discharge.  Patients were then seen monthly 
and adjustments were performed until optimal reduction in hunger or restriction was 
achieved.  The adjustments were performed using the indicators described by 
Favretti et al (Favretti, O'Brien and Dixon 2002) as seen in table 4.  Patients were 
seen at least six times in the first year and then once a year minimum (Pournaras, 
Osborne, Hawkins, Vincent, Mahon, Ewings, Ghatei, Bloom, Welbourn and le Roux 
2010).  
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Table 4. Protocol used for band adjustments from Favretti, O'Brien, Dixon 
2002). 
 
Consider adding 
fluid 
Adjustment not 
required 
Consider removing fluid 
Inadequate weight 
loss 
Adequate rate of 
weight loss 
Vomiting, heartburn, reflux into the 
mouth 
Rapid loss of satiety 
after meals 
Eating reasonable 
range of food 
Coughing spells, wheezing and 
choking, especially at night 
Increased volume of 
meals 
No negative 
symptoms 
Difficulty coping with broad range of 
foods 
Hunger between 
meals 
 Maladaptive eating behaviour 
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Latest follow-up (24-36 months) data were collected.  No patient was lost to follow 
up.   
 
Study 2:  Diabetes remission with the new criteria. 
For this study data collection was prospective in three different centres.  These were 
Imperial Weight Centre, Imperial College, London, UK; Musgrove Park Hospital, 
Taunton, UK; Department of Gastrointestinal Surgery, Oslo University Hospital, Aker, 
Oslo, Norway.  Permission was obtained from the Imperial College Healthcare NHS 
Trust Clinical Governance & Patient Safety Committee (Ref:09/808).   
  
All participants were operated between August 2004 and July 2009.  Inclusion 
criteria were preoperative diagnosis of type 2 diabetes and weight loss surgery.  
Patients were reviewed 6 weeks, 6 months and 12 months postoperatively.  Median 
follow-up was 23 months (range 12-75 months).  
 
According to the 2009 consensus of the American Diabetes Association partial 
remission of diabetes was defined as hyperglycaemia (HbA1c<6.5% and fasting 
glucose 5.6–6.9 mmol/l) at least 1 year after surgery in the absence of active 
hypoglycaemic pharmacologic therapy or ongoing procedures.  Complete remission 
was defined as a return to normal measures of glucose metabolism (HbA1c < 6%, 
fasting glucose < 5.6 mmol/l) at least 1 year after surgery without hypoglycaemic 
pharmacologic therapy or ongoing procedures (Buse, Caprio, Cefalu, Ceriello, Del 
Prato, Inzucchi, McLaughlin, Phillips, Robertson, Rubino, Kahn and Kirkman 2009).   
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Statistical analysis 
 
Data were analyzed using SPSS version 14 (SPSS Inc., Chicago, IL).  Results were 
expressed as number (%), mean ± SD or median (range).  Time to glucose below 7 
mmol/L (below the World Health Organization definition of diabetes which includes 
fasting plasma glucose ≥ 7.0 mmol/l) off all medication was compared between 
operative groups by log-rank test (study 1).  The Mann-Whitney test was used for 
non-parametric demographic data and the unpaired t-test was used for parametric 
demographic data in study 1.  Fisher’s exact test and the Freeman-Halton extension 
of the Fisher’s exact test were used to compare categorical data and one-way 
ANOVA was used to compare continuous data for study 2.  A p value of ≤ 0.05 was 
considered significant.  
 
2.3 Results 
 
Study 1: Glycaemic control after gastric bypass and gastric banding  
 
The number of diabetic and non diabetic patients undergoing gastric bypass (n = 
109) and gastric banding (n = 107) during the study period (between January 2004 
and January 2007) was similar suggesting that the clinicians involved in the patients 
care and particularly the surgeon did not have a preference for one procedure versus 
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the other, hence reducing although not eliminating the risk of bias.  Thirty four 
consecutive patients with type 2 diabetes on hypoglycaemic treatment presenting for 
weight loss surgery were identified (16%).  Twenty two of these chose to undergo 
Roux-en-Y gastric bypass and 12 laparoscopic adjustable gastric banding.  The two 
groups were well matched for demographic characteristics, duration of diabetes or 
pre- and post-operative BMI (Table 5).  
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Table 5.  Study 1: Patient characteristics presented as Mean (standard 
deviation) except where the median (range) is indicated. *p<0.05 (t-test, Mann-
Whitney, Fisher’s exact test). 
   
 Bypass Banding *p value 
Age (years) 46.0 ± 9.6 47.4 ± 10.9 0.71 
Pre-op Weight (kg) 137.4 ± 22.9 137.7 ± 31.8 0.97 
Pre-op BMI  47.4 ± 7.2 47.1 ± 7.1 0.90 
Pre-op HbA1c  9.1 ± 1.9 8.4 ± 1.7 0.29 
Duration of diabetes (years) 7.0 (1-18) 5.5 (1-14) 0.61 
Proportion on insulin pre-op (%) 12/22 (54%) 4/12 (33%) 0.04 
Follow-up (months) 29.5 ± 8.0 33.0 ± 7.5 0.21 
% Total Weight Loss 29.5 ± 8.4 28.5 ± 10.0 0.76 
% Excess BMI Loss 63.3 (30.8-
103.2) 
62.3(45.1-105.9) 0.92 
BMI at follow-up 33.0 ± 5.2 32.6 ± 5.1 0.80 
HbA1c at follow-up 6.2 ± 1.2 6.5 ± 1.2 0.59 
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Although patients lost weight postoperatively they remained in the obese state with a 
mean BMI of 33 ± 5.2 kg/m2 after gastric bypass and 32.6 ± 5.1 kg/m2 after gastric 
banding.  There was no statistically significant difference between the two groups in 
weight at 3, 6, 12, 18, 24 and 36 months (Figure 1).  
 
HbA1c improved significantly after both procedures (p < 0.001 compared to 
preoperatively for both groups).  Fasting plasma glucose levels were 6.6 ± 2.7 
mmol/L and 7.3 ± 2.4 mmol/L for the gastric bypass and gastric banding groups 
respectively (p = 0.43) at latest follow-up.  The time to a fasting plasma glucose 
below 7 mmol/L off all medication was significantly shorter for gastric bypass than 
gastric banding, with a hazard ratio of 8.2, (p = 0.001, 95% confidence interval 1.8 to 
36.7).  
 
Fifteen out of 22 patients undergoing gastric bypass patients (68%) were in 
remission as defined for study 1 at 12 months postoperatively (Figure 2).  In contrast 
no gastric banding patients achieved remission and this was a statistically significant 
difference at the level of p<0.001.  Weight loss at the same time point was similar 
(p=0.14) between the groups with 25.2 ± 8.2 % for gastric bypass and 20.4 ± 9.1 % 
for gastric banding.  Sixteen out of 22 patients undergoing gastric bypass (72%) 
were in remission compared to two gastric band patients (17%) at maximum follow 
up and again this was significant (p = 0.01).  However weight loss remained similar 
(p = 0.76) between the groups with 29.5 ± 8.4 % for gastric bypass and 28.5 ± 10 % 
for gastric banding.  There was no correlation between weight loss and HbA1c 
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improvement after gastric bypass with Pearson r of 0.3196, 95% confidence interval 
-0.1180 to 0.6532 and p of 0.1471 (Figure 3). 
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Figure 1.  Weight loss over time for gastric bypass (n = 22) and gastric banding 
(n = 12) patients over a 3 year period.  
Gastric bypass
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Months 0 3 6 12 24 36 
Band n=22 12 12 12 12 12 8 
Bypass n=12 22 22 22 22 22 11 
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Figure 2.  Kaplan-Meier curve for time to remission of type 2 diabetes in 
patients who had gastric bypass (solid line) or gastric banding (broken line) 
over a 3 year period. 
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Months 0 3 6 12 24 36 
Band n=22 12 12 12 12 12 8 
Bypass n=12 22 22 22 22 22 11 
p=0.001 
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Figure 3.  Correlation between  % weight loss and HbA1c improvement after 
gastric bypass.  Pearson r=0.3196, 95% confidence interval -0.1180 to 0.6532, 
p=0.1471. 
 
0 10 20 30 40 50
0
2
4
6
8
% weight loss
H
b
A
1
c
 i
m
p
ro
v
e
m
e
n
t
 
 
 
 
 
 
 
 
 
 
83 
 
The severity of diabetes as demonstrated by the number of patients on insulin 
treatment preoperatively was worse in the bypass group (12 of 22 gastric, 54% 
compared to the gastric banding group (4 of the 12, 33%) (p = 0.04).   
 
In terms of length of stay there was no difference in median length of stay for gastric 
bypass between patients with diabetes (n = 22, 4 days range 1-114) or without 
diabetes (n = 87, 3 days range 1- 44) (p=0.47).  For gastric banding there was no 
difference in median length of stay between patients with diabetes (n = 12, 1 day 
range 1-2) or without diabetes (n = 95, 1 day range 1-3) (p=0.68).  Diabetic and non 
diabetic patients after bypass stayed longer in hospital than patients after banding (p 
<0.001). 
 
There was one early complication in a diabetic patient who was re-operated on day 1 
post gastric bypass for a small bowel enterotomy.  The patient made a full recovery 
and was discharged following a 114-day stay (Pournaras, Jafferbhoy, Titcomb, 
Humadi, Edmond, Mahon and Welbourn 2010).  The non diabetic patient that 
required hospital admission for 44 days had an anastomotic leak and also made a 
full recovery (Pournaras, Jafferbhoy, Titcomb, Humadi, Edmond, Mahon and 
Welbourn 2010).   
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Study 2:  Diabetes remission with the new American Diabetes Association criteria. 
The demographic characteristics of the 209 patients included in this study can be 
seen on Table 6.  The prevalence of type 2 diabetes before surgery was 36 out of 
136 patients (26%) at Oslo University Hospital Aker, 93 out of 551 (17%) at 
Musgrove Park Hospital and 80 out of 319 (25%) at Imperial College Healthcare 
NHS Trust. 
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Table 6. Patient characteristics and type 2 diabetes remission rates 23 months 
(range 12-75) postoperatively.  
 
 
Total 
n=209 
Gastric 
bypass 
n=160 
Sleeve 
gastrectomy 
n=19 
Gastric 
banding 
n=30 
 
 
p values 
Age (years) 48 ± 10 47 ± 9 53 ± 14 46 ± 10 0.041 
Women, N (%) 
137 
(66%) 
105 
(66%) 
11 (58%) 21 (70%) 0.695 
Insulin usage before 
surgery, N (%) 
63 (30%) 51 (32%) 6 (32%) 6 (19%) 0.457 
BMI (kg/m2) 
     before surgery 
     after surgery 
 
48 ± 7 
35 ± 7 
 
48 ± 7 
34 ± 6 
 
50 ± 8 
42 ± 6 
 
47 ± 9 
36 ± 8 
 
0.390 
0.002 
Fasting glucose (mmol/L) 
     before surgery  
     after surgery  
 
9.6 ± 3.6 
6.3 ± 2.6 
 
9.8 ± 3.6 
6.0 ± 2.1 
 
8.9 ± 4.2 
8.0 ± 5.3 
 
7.4 ± 0.7 
6.5 ± 2.1 
 
0.144 
0.004 
HbA1C (%) 
     before surgery  
     after surgery  
 
8.0 ± 1.9 
6.2 ± 1.2 
 
8.1 ± 1.9 
6.2 ± 1.2 
 
7.5 ± 1.5 
6.8 ± 1.7 
 
7.7 ± 1.5 
6.3 ± 0.7 
 
0.388 
0.081 
Complete remission with 
2009 criteria, N (%) 
72 (34%) 65 (41%) 5 (26%) 2 (7%) 0.0004 
Partial remission with 
2009 criteria, N (%) 
28 (13%) 25 (16%) 1 (5%) 2 (7%) 0.301 
Remission with previous 
definition, N (%) 
103 
(49%) 
92 (58%) 6 (32%) 5 (17%) <0.0001 
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The remission rate of type 2 diabetes following after weight loss surgery was 
significantly lower with the new criteria (72 of 209 patients, 34%) than with the 
previous definition (103 of 209, 49%) (p=0.003).  As seen on figure 4, the newly 
defined remission rate was 41% after gastric bypass (65 of 160 patients), 26% for 
sleeve gastrectomy (five of 19 patients) and 7% for gastric banding (two of 30 
patients).  The remission rate after gastric bypass was significantly lower compared 
to the previous definition used (p=0.003).   
 
There was a significant improvement in HbA1c levels for all groups postoperatively 
(p<0.001) and HbA1c levels were 6.2 ± 1.2% after gastric bypass, 6.8 ± 1.7% after 
sleeve gastrectomy and 6.3 ± 0.7% after gastric banding (p=0.081 between groups).  
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Figure 4. Diabetes remission for gastric bypass, sleeve gastrectomy and 
gastric banding with the new American Diabetes Association definition and the 
previous definition. * p<0.001 between groups # p<0.01 compared to previous 
definition 
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 2.4 Discussion 
In study 1 we performed a comparison in glycaemic control and diabetes remission 
in patients undergoing gastric bypass and gastric banding in a single centre.  
Although this was not a randomised trial, both groups were matched for age, sex and 
BMI before and after surgery.  At latest follow up significantly more patients had 
fasting plasma glucose concentration below 7 mmol/L without hypoglycaemic 
treatment after gastric bypass than after gastric banding (72% vs 17%).  Furthermore 
the diabetes remission rate over time was more rapid after gastric bypass.  The 
findings of this study suggest that the improved glycaemic control may be 
independent of weight loss.   
 
Different studies comparing glycaemic control after gastric bypass and gastric 
banding also suggested that glycaemic and diabetes related outcomes were more 
favourable after gastric bypass (Bowne, Julliard, Castro, Shah, Morgenthal and 
Ferzli 2006; Parikh, Ayoung-Chee, Romanos, Lewis, Pachter, Fielding G and Ren 
2007).  The remission rate for the gastric bypass group is comparable to other 
studies; however the remission rate for the gastric banding group was lower than 
previously published O’Brien, Dixon, Laurie, Skinner, Proietto, McNeil, Strauss, 
Marks, Schachter, Chapman and Anderson 2006;  Schauer,  Burguera, Ikramuddin, 
Cottam, Gourash, Hamad, Eid, Mattar, Ramanathan, Barinas-Mitchel, Rao, Kuller 
and Kelley 2003; Bowne, Julliard, Castro, Shah, Morgenthal and Ferzli 2006; Parikh, 
Ayoung-Chee, Romanos, Lewis, Pachter, Fielding and Ren 2007; Kim, Daud, Ude, 
DiGiorgi, Olivero-Rivera, Schrope, Davis, Inabnet and Bessler 2006; Weber, Mueller, 
Bucher, Wildi, Dindo, Horber, Hauser and Clavien 2004; Dixon and O’Brien 2002).  
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This can be explained by the stricter definition used for the remission of type 2 
diabetes in comparison to other studies (le Roux, Welbourn, Werling, Osborne, 
Kokkinos, Laurenius, Lönroth, Fändriks, Ghatei, Bloom and Olbers 2007; Parikh, 
Ayoung-Chee, Romanos, Lewis, Pachter, Fielding G and Ren 2007; Kim, Daud, 
Ude, DiGiorgi, Olivero-Rivera, Schrope, Davis, Inabnet and Bessler 2006; Weber, 
Mueller, Bucher, Wildi, Dindo, Horber, Hauser and Clavien 2004; Dixon and O’Brien 
2002; Levy, Fried and Santini 2007).  Remission for this study was defined as fasting 
plasma glucose below 7 mmol/L and 2 hour post oral glucose tolerance test plasma 
glucose below 11.1 mmol/L with a HbA1c below 6% being off all hypoglycaemic 
treatment.  Also all participants required antihyperglycaemic agents and a significant 
proportion of them needed insulin reflecting severe disease with reduced beta cell 
reserve.  The duration of the disease prior to surgery was prolonged in our 
population with a median of 7 years in the bypass group and 5.5 years in the 
banding group.  All these factors are associated with inferior outcomes after weight 
loss surgery (Schauer, Burguera, Ikramuddin, Cottam, Gourash, Hamad, Eid, Mattar, 
Ramanathan, Barinas-Mitchel, Rao, Kuller and Kelley 2003).  
 
Schauer et al reported inferior weight loss after gastric bypass in diabetic patients 
compared to non diabetic patients, although the reason for this has not been 
elucidated (Schauer, Burguera, Ikramuddin, Cottam, Gourash, Hamad, Eid, Mattar, 
Ramanathan, Barinas-Mitchel, Rao, Kuller and Kelley 2003).  This may explain the 
similar weight loss between the two groups in this study.  It is recognised that 
frequent follow-up for band adjustments is associated with better weight loss and this 
may also be the cause of the similar weight loss between the groups (Shen, Dugay, 
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Rajaram, Cabrera, Siegel and Ren 2004).  Finally Kim et al reported similar weight 
loss between banding and bypass although their population was not diabetic (Kim, 
Daud, Ude, DiGiorgi, Olivero-Rivera, Schrope, Davis, Inabnet and Bessler 2006).   
 
Limitations of study 1 are the lack of randomisation, and the relatively small size of 
the groups.  However the groups were well matched. 
 
Study 2 is the first report evaluating the effect of the 2009 criteria on diabetes 
remission rates after weight loss surgery.  The complete diabetes remission rate was 
significantly lower than the previously defined remission rate on the same population.  
Glycaemic control as measure with HbA1c was similar between different procedures 
although there was a significant difference in the usage of hypoglycaemic 
medication. 
 
The concept of remission changed throughout the period of this research project.  
Although for study 1 we used a very strict definition, the 2009 criteria are robust and 
are rapidly becoming accepted as the gold standard (Buse, Caprio, Cefalu, Ceriello, 
Del Prato, Inzucchi, McLaughlin, Phillips, Robertson, Rubino, Kahn and Kirkman 
2009).  The impressive outcomes of weight loss surgery, the reported remission of 
type 2 diabetes and the introduction of “metabolic surgery” have led to increased 
interest in the field and study 1 has contributed to the evidence base supporting the 
weight loss independent effect of gastric bypass on glucose metabolism.  It is study 
2, however, that can lead to a more rational approach in the field of metabolic 
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surgery with realistic expectations from surgeons, diabetologists and patients.  
Furthermore the findings of study 2 may lead to a focus on achieving good glycaemic 
control rather than remission from type 2 diabetes.  And more importantly a shift in 
the metabolic surgical literature away from glycaemic control and aiming towards the 
reduction of microvascular and macrovascular complications associated with 
diabetes (UKPDS 33 1998; Ray, Seshasai, Wijesuriya, Sivakumaran, Nethercott, 
Preiss, Erqou and Sattar 2009).  
 
Remission may be low in this population due to the reduced beta cell reserve.  
Patients treated in the NHS tend to have a higher comorbidity burden, with long 
standing type 2 diabetes, often on insulin.  Data regarding these characteristics were 
not available for study 2, but from study 1 the above statement can be supported.  
Patients on the early stages of type 2 diabetes are more likely to achieve remission 
Schauer, Burguera, Ikramuddin, Cottam, Gourash, Hamad, Eid, Mattar, 
Ramanathan, Barinas-Mitchel, Rao, Kuller and Kelley 2003).  On the other hand, 
patients with long standing, difficult to control type 2 diabetes may benefit more from 
surgery as other treatment options are limited and less likely to succeed.  Operating 
on this population may be associated with a higher perioperative risk.  Identifying the 
patients who are likely to benefit more from metabolic surgery, calculate the risk and 
optimise outcomes remain burning issues in the field. 
 
Limitations of the study include the relatively low numbers of type 2 diabetes patients 
in the gastric banding and sleeve gastrectomy groups and the lack of randomisation.  
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Also there was no data available on the duration of diabetes.  The 20.8% prevalence 
of patients with diabetes is similar to the one reported in other studies (Buchwald, 
Avidor, Braunwald, Jensen, Pories, Fahrbach and Schoelles 2004; Buchwald, Estok, 
Fahrbach, Banel, Jensen, Pories, Bantle and Sledge 2009).  The proportion of 
patients with insulin treated type 2 diabetes was similar to the one reported in the UK 
& Ireland National Bariatric Surgery Registry (Welbourn, Fiennes, Kinsman and 
Walton 2011).   
 
In conclusion, gastric bypass leads to the remission of type 2 diabetes in a weight 
loss independent manner.  The 2009 criteria are associated with a lower remission 
rates after metabolic surgery than previously thought.  However metabolic surgery 
leads to improved glycaemic control.  
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3. The mechanism of action of metabolic surgery is partly due to gut hormone 
modulation. 
 
3.1 Introduction 
 
The question raised from chapter 2 is that if it is not the weight loss which leads to 
the remission of type 2 diabetes then what the mechanism is.  In a group of patients 
for whom access to the gastric remnant was available, I was able to test two different 
routes of a meal test controlling for weight loss.  I hypothesised that the first 
postoperative days, before any substantial weight loss has occurred, is the period 
when most of these changes occur.  Therefore I investigated the postprandial 
changes in glucose, insulin and gut hormones in the first weeks after gastric bypass.  
Finally establishing the long term effect of gastric bypass was possible in the third 
study of this chapter. 
 
3.2 Methods 
 
Study 1: The effect of the altered nutrient route in glucose metabolism and the gut 
hormone response 
This study was approved by the Clinical Governance and Patient Safety committee 
of Imperial College Healthcare NHS Trust (reference number: 10/807) and was 
performed according to the declaration of Helsinki.  Informed consent was obtained 
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from five patients who had undergone gastric bypass in the Imperial Weight Centre.  
All patients were type 2 diabetic prior to surgery and were in remission, achieving 
normoglycaemia with no hypoglycaemic medication at the time of participation in the 
study.  The weight loss achieved was 29.9 ± 4.6 % and the mean BMI was reduced 
from 43.2 ± 1.9 preoperatively to 29.9 ± 2.4 kg/m2 (p=0.001).  
 
Secondary to surgical complications participants in this study were unable to feed 
using the enteral route and hence all had a functioning gastrostomy tube providing 
access to the gastric remnant, duodenum and proximal jejunum.  The causes of the 
surgical complications are listed in table 7.  All participants had fully recovered 
(tolerating an oral diet and sustaining a stable weight) by the time they entered the 
study (14 ± 4 months postoperatively, range 9-24 months) following conservative or 
surgical treatment.  
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Table 7: List of complications leading to inability to feed with the enteral route. 
  
Patient 1 Münchausen syndrome 
Patient 2 Twist at the gastro-eosophageal junction 
causing severe dysphagia. 
Patient 3 Twist at the gastro-eosophageal junction 
causing severe dysphagia. 
Patient 4 Twist at the gastro-eosophageal junction 
causing severe dysphagia. 
Patient 5 Twist at the gastro-eosophageal junction 
causing severe dysphagia. 
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Participants were examined at 08.00 following an overnight fast on two different 
occasions with a 3 to 6 day-interval.  A 410ml solution containing 75 g of glucose, 
287 kcal (Lucozade Energy Original, GlaxoSmithKline) was given orally on day one 
(to ensure that participants could tolerate the volume orally), and via gastrostomy on 
the second occasion.  Figure 5 is a schematic illustration of the gastrointestinal 
glucose route after oral and gastrostomy loading.  A venous catheter was placed in a 
large vein and blood samples were collected prior to and 15, 30, 60, 90, 120, 150 
and 180 minutes following the glucose test.  All samples were collected in tubes 
containing EDTA and aprotinin and were immediately centrifuged and stored in a -
80°C freezer until further analysis.   
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Figure 5: Glucose route after oral (black arrows) and after gastrostomy load 
(empty arrows). 
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Glucose levels were measured with an automated glucose analyser (Abbott 
laboratories, Chicago USA) and insulin levels with an automated chemiluminescent 
immunoassay (Abbott laboratories, Chicago, USA).  
 
For the measurement of gut hormones all samples were assayed in duplicate.  PYY-
like immunoreactivity was measured with a specific and sensitive radioimmunoassay 
(Savage, Adrian, Carolan, Chatterjee and Bloom 1987).  The assay measured the 
biologically active components, the full length (PYY1-36) and the fragment (PYY3-36).  
Antiserum (Y21) was produced in a rabbit against synthetic porcine PYY (Bachem, 
UK) coupled to bovine serum albumin with glutaraldehyde and used at a final dilution 
of 1:50000.  This antibody cross-reacts fully with the biologically active circulating 
forms of human PYY, but not with pancreatic polypeptide, neuropeptide Y, or any 
other known gastrointestinal hormone (Adrian, Ferri, Bacarese-Hamilton, Fuessl, 
Polak and Bloom 1985).  125I-labeled PYY was prepared by the Iodogen method and 
purified by high pressure liquid chromatography.  The specific activity of the 125I-
labelled PYY was 54 Bq per femtomole.  The assay was performed in a total volume 
of 700 µL of 0.06 M phosphate buffer, pH 7.26, containing 0.3 % bovine serum 
albumin.  The samples were incubated for 3 days at 4 ºC before separation of free 
and antibody-bound label by sheep anti-rabbit antibody.  Two hundred µL of plasma 
was assayed, while 200 µL of PYY-free, Haemacel colloid fluid was added to 
standards and other reference tubes to neutrilise any non-specific assay 
interference.  The assay has been reported to detect changes of 2 pmol/L, with an 
intra-assay coefficient of variation (CV) of 5.8 % and an interassay CV of 9.8 %.  
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Plasma GLP-1 was measured in duplicate by an established in-house 
radioimmunoassay.  The GLP-1 assay detected changes of 7.5 pmol/L, with an intra-
assay CV of 6.1 % (Kreymann, Williams, Ghatei and Bloom 1987).  
 
Study 2: Changes in glucose metabolism and the gut hormone response in the initial 
postoperative period after gastric bypass.    
This study was performed according to the principles of the Declaration of Helsinki. 
The Somerset Research and Ethics committee approved the study (LREC Protocol 
Number: 05/Q2202/96).  Exclusion criteria included pregnancy, substance abuse, 
more than 2 alcoholic drinks per day.  Written informed consent was obtained from 
all participants.  
 
A group of type 2 diabetic, morbidly obese patients undergoing gastric bypass in the 
Department of Bariatric and Metabolic Surgery, Musgrove Park Hospital, Taunton 
(n=17), were compared with three different control groups including patients a) with 
type 2 diabetes and obesity undergoing gastric banding (n=9) to control for the effect 
of general anaesthetic, laparoscopy and surgical trauma b) patients with type 2 
diabetes and obesity undergoing very low calorie diet for one week (n=15) to control 
for the effect of reduced food intake in the immediate postoperative period and c) 
non insulin resistant obese subjects undergoing gastric bypass (n=5).  All 
participants underwent a two week diet of 1000 kcal prior to the intervention.  
Diabetic patients were optimised in terms of glycaemic control with the aid of 
pharmacotherapy and lifestyle intervention under the guidance of physicians with a 
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special interest in obesity and type 2 diabetes for a minimum six month period 
preoperatively.  None of the participants was on insulin therapy during the period of 
the study.  Furthermore there was no difference in the usage of oral hypoglycaemic 
treatment between the groups including patients with diabetes.  Time points were 
pre-operatively and day 2, 4, 7 and 42 postoperatively.  For the very low calorie diet 
group there was no 42 day time point as this intervention only lasted for one week.  
 
The technique used for the bypass was a combination of linear stapler and hand 
sewn enterotomy closure for both the gastrojejunostomy and jejuno-jejunostomy, in 
an antegastric-retrocolic configuration (Higa, Boone, Ho and Davies 2000).  This was 
a modification of the technique first described by Higa et al (Higa, Boone, Ho and 
Davies 2000).   
 
A preoperative low-calorie, low-carbohydrate diet was used for 2 weeks aiming to 
reduce perioperative risk by reducing liver size and improving intraoperative 
exposure.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 500mg 
metronidazole at induction was routinely used (Pournaras, Jafferbhoy, Titcomb, 
Humadi, Edmond, Mahon and Welbourn 2010).   
 
Reverse Trendelenburg position was used with the operating on the right of the 
patient and assistant positioned between the legs of the patient.  Pneumoperitoneum 
was obtained with a Verres needle inserted below the left costal margin at the mid-
clavicular line.  Thromboprophylaxis included the routine use of TED stockings and 
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40 mg of low molecular weight heparin preoperatively and then for 7 days 
postoperatively and lower limb pneumatic compression devices intraoperatively.  
Five ports were used.  An isolated lesser curve-based, 15–20-ml gastric pouch was 
created and a retrocolic antegastric Roux limb was made 100 cm long for patients 
with a BMI equal to or less than 50 kg/m2 and 150 cm long for patients with BMI of 
more than 50 kg/m2.  The bilio-pancreatic limb was 25 cm.  The gastrojejunostomy 
was closed over a 34 Fr bougie.  A blue dye leak test via a nasogastric tube was 
routinely performed.  All hernia defects (jejunojejunostomy, Petersen’s and 
mesocolon) were routinely closed with a purse-string suture.   
 
An enhanced recovery protocol was used with patients being offered a glass of water 
in the recovery room progressing to free fluids on postoperative day 1 and a soft diet 
thereafter.  The first routine postoperative review in the outpatient department was 6 
weeks after discharge with a minimum regular follow-up program for uncomplicated 
patients afterwards of 6 months, 12 months postoperatively, and yearly thereafter, 
and more intensive follow-up for complex patients. 
 
The surgical technique used for gastric banding was the pars flaccida described by 
the Melbourne group (O'Brien, Dixon, Laurie and Anderson 2005).  A preoperative 
low-calorie, low-carbohydrate diet was used for 2 weeks aiming to reduce 
perioperative risk by reducing liver size and improving intraoperative exposure as 
with the gastric bypass.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 
500mg metronidazole at induction was routinely used (Pournaras, Jafferbhoy, 
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Titcomb, Humadi, Edmond, Mahon and Welbourn 2010).  Thromboprophylaxis 
included the routine use of TED stockings and 40 mg of low molecular weight 
heparin preoperatively and then for 7 days postoperatively.  Lower limb pneumatic 
compression devices intraoperatively. Five ports were used.  The Swedish 
Adjustable Gastric band® (Ethicon Endo-Surgery) and the LAP-BAND® (Allergan) 
bands were used for all gastric banding procedures.  The pars flaccida dissection 
technique with gastro-gastric tunnelling sutures was the operative method utilised 
(O'Brien, Dixon, Laurie and Anderson 2005).  The same enhanced recovery protocol 
as the one sued for gastric bypass was used with patients being offered a glass of 
water in the recovery room progressing to free fluids on postoperative day 1 and a 
soft diet thereafter.  Follow-up was also similar with the first postoperative review in 
the outpatient department 6 weeks after discharge.  Patients were then seen monthly 
and adjustments were performed until optimal reduction in hunger or restriction was 
achieved.  The adjustments were performed using the indicators described by 
Favretti et al (Favretti, O'Brien and Dixon 2002) as seen in table 4.  Patients were 
seen at least six times in the first year and then once a year minimum (Pournaras, 
Osborne, Hawkins, Vincent, Mahon, Ewings, Ghatei, Bloom, Welbourn and le Roux 
2010).  
 
Following a 12 hour fast, a venous catheter was placed in a large vein and blood 
samples were collected.  For the bypass surgery group further samples were 
obtained at 15, 30, 60, 90, 120, 150 and 180 minutes following a standard semi-
liquid meal containing 400 kcal.  The meal macronutrient content was 48.8% 
carbohydrate, 10.2% protein and 41% fat.  All samples were collected in tubes 
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containing EDTA and aprotinin and were immediately centrifuged and stored in a -
80°C freezer until further analysis.  Glucose levels were measured with an 
automated glucose analyser (Abbott laboratories, Chicago USA) and insulin levels 
with an automated chemiluminescent immunoassay (Abbott laboratories, Chicago, 
USA).  Delta insulin was defined as the difference between a 0 minute and 15 minute 
insulin measurement (le Roux, Welbourn, Werling, Osborne, Kokkinos, Laurenius, 
Lönroth, Fändriks, Ghatei, Bloom and Olbers 2007). Insulin resistance was 
measured with the Homeostatic Model Assessment (HOMA-IR) Matthews, Hosker, 
Rudenski, Naylor, Treacher and Turner 1985). 
 
Plasma GLP-1 was measured in duplicate by an established in-house 
radioimmunoassay.  The GLP-1 assay detected changes of 7.5 pmol/L, with an intra-
assay CV of 6.1 % (Kreymann, Williams, Ghatei and Bloom 1987).  
 
 
Study 3: The long term gut hormone response after gastric bypass.   
This study was also performed according to the principles of the Declaration of 
Helsinki.  The Somerset Research and Ethics committee approved the study (LREC 
Protocol Number: 05/Q2202/96).  Exclusion criteria included pregnancy, substance 
abuse, more than two alcoholic drinks per day and aerobic exercise for more than 30 
min three times per week.  Written informed consent was obtained from all 
participants.  
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Thirty-four participants were studied cross-sectionally at four different time points, 
preoperatively (n=17), and 12 (n=6), 18 (n=5) and 24 (n=6) months after gastric 
bypass.  Another group of patients (n=6) were studied prospectively.   
 
The technique used for the bypass was a combination of linear stapler and hand 
sewn enterotomy closure for both the gastrojejunostomy and jejuno-jejunostomy, in 
an antegastric-retrocolic configuration (Higa, Boone, Ho and Davies 2000).  This was 
a modification of the technique first described by Higa et al (Higa, Boone, Ho and 
Davies 2000).   
 
A preoperative low-calorie, low-carbohydrate diet was used for 2 weeks aiming to 
reduce perioperative risk by reducing liver size and improving intraoperative 
exposure.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 500mg 
metronidazole at induction was routinely used (Pournaras, Jafferbhoy, Titcomb, 
Humadi, Edmond, Mahon and Welbourn 2010).   
 
Reverse Trendelenburg position was used with the operating on the right of the 
patient and assistant positioned between the legs of the patient (Pournaras, 
Jafferbhoy, Titcomb, Humadi, Edmond, Mahon and Welbourn 2010).  
Pneumoperitoneum was obtained with a Verres needle inserted below the left costal 
margin at the mid-clavicular line.  Thromboprophylaxis included the routine use of 
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TED stockings and 40 mg of low molecular weight heparin preoperatively and then 
for 7 days postoperatively and lower limb pneumatic compression devices 
intraoperatively.  Five ports were used.  An isolated lesser curve-based, 15–20-ml 
gastric pouch was created and a retrocolic antegastric Roux limb was made 100 cm 
long for patients with a BMI equal to or less than 50 kg/m2 and 150 cm long for 
patients with BMI of more than 50 kg/m2 (.  The bilio-pancreatic limb was 25 cm .  
The gastrojejunostomy was closed over a 34 Fr bougie.  A blue dye leak test via a 
nasogastric tube was routinely performed.  All hernia defects (jejunojejunostomy, 
Petersen’s and mesocolon) were routinely closed with a purse-string suture 
(Pournaras, Jafferbhoy, Titcomb, Humadi, Edmond, Mahon and Welbourn 2010).   
 
An enhanced recovery protocol was used with patients being offered a glass of water 
in the recovery room progressing to free fluids on postoperative day 1 and a soft diet 
thereafter (Pournaras, Jafferbhoy, Titcomb, Humadi, Edmond, Mahon and Welbourn 
2010).   
 
Following a 12 hour fast, a venous catheter was placed in a large vein and blood 
samples were collected.  For the bypass surgery group further samples were 
obtained at 15, 30, 60, 90, 120, 150 and 180 minutes following a standard semi-
liquid meal containing 400 kcal.  The meal macronutrient content was 48.8% 
carbohydrate, 10.2% protein and 41% fat.  All samples were collected in tubes 
containing EDTA and aprotinin and were immediately centrifuged and stored in a -
80°C freezer until further analysis.  GLP-1 and PYY levels were measure as 
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described in study 2.  Visual analogue scales (VAS) were used to measure hunger 
and satiety immediately before consumption of the meal and at 60, 120, and 180 
minutes later.  The VAS can be seen in Figure 6. 
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Figure 6.  Visual Analogue Scales for hunger and satiety. 
Please put a mark crossing the line at the point that best describes your responses 
to these two questions.  A mark at 0 would indicate that you have no hunger at all or 
that you feel completely empty.  A mark at 100 would indicate that you feel extremely 
hungry or that you feel completely full. 
How hungry do you feel? 
 
            
   
0        100 
(not hungry at all)     (extremely hungry) 
 
How full do you feel? 
 
 
 
0        100 
(completely empty)     (completely full) 
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For the measurement of gut hormones all samples were assayed in duplicate.  PYY-
like immunoreactivity was measured with a specific and sensitive radioimmunoassay 
(Savage, Adrian, Carolan, Chatterjee and Bloom 1987).  The assay measured the 
biologically active components, the full length (PYY1-36) and the fragment (PYY3-36).  
Antiserum (Y21) was produced in a rabbit against synthetic porcine PYY (Bachem, 
UK) coupled to bovine serum albumin with glutaraldehyde and used at a final dilution 
of 1:50000.  This antibody cross-reacts fully with the biologically active circulating 
forms of human PYY, but not with pancreatic polypeptide, neuropeptide Y, or any 
other known gastrointestinal hormone (Adrian, Ferri, Bacarese-Hamilton, Fuessl, 
Polak and Bloom 1985).  125I-labeled PYY was prepared by the Iodogen method and 
purified by high pressure liquid chromatography.  The specific activity of the 125I-
labelled PYY was 54 Bq per femtomole.  The assay was performed in a total volume 
of 700 µL of 0.06 M phosphate buffer, pH 7.26, containing 0.3 % bovine serum 
albumin.  The samples were incubated for 3 days at 4 ºC before separation of free 
and antibody-bound label by sheep anti-rabbit antibody.  Two hundred µL of plasma 
was assayed, while 200 µL of PYY-free, Haemacel colloid fluid was added to 
standards and other reference tubes to neutrilise any non-specific assay 
interference.  The assay has been reported to detect changes of 2 pmol/L, with an 
intra-assay coefficient of variation (CV) of 5.8 % and an interassay CV of 9.8 %.  
 
Plasma GLP-1 was measured in duplicate by an established in-house 
radioimmunoassay.  The GLP-1 assay detected changes of 7.5 pmol/L, with an intra-
assay CV of 6.1 % (Kreymann, Williams, Ghatei and Bloom 1987).  
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Statistical analysis 
 
For studies 1 and 2 results were analysed using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego, California, USA).  Data were expressed 
as mean ± SEM.  Values for the area under the curve were calculated with the use of 
the trapezoidal rule.  For study 1 analysis of variance (ANOVA) with post hoc 
Dunnett test were used for HOMA-IR, delta insulin and GLP-1 responses.  For study 
2 plasma levels of insulin, GLP-1, PYY and glucose following the two glucose 
loadings were analyzed with a two-way group (between subjects) x time (within 
subjects) ANOVA.  Post-hoc Bonferroni tests for each concentration were applied 
when there was a significant group x time interaction.  For study 3 results were 
analysed using SPSS statistical software (SPSS Inc., Chicago, IL).  End points were 
compared with the use of 2-tailed, paired Student t tests or ANOVA.  A p≤0.05 was 
considered significant for all three studies.   
 
3.3 Results 
 
Study 1: The effect of the altered nutrient route in glucose metabolism and the gut 
hormone response 
There was a significant difference in plasma insulin, GLP-1 and PYY (all p<0.01) 
between the oral and gastrostomy glucose loading (Figures 7a, b, c and d and table 
8).  There was a significant main effect of time and a significant group x time 
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interaction for insulin, GLP-1 and PYY (all p<0.001).  Glucose levels recovered to 
baseline earlier after the oral route compared to gastrostomy (p<0.001).  There was 
a significant group x time interaction (p<0.001), but no significant main group effect 
for glucose levels (p=0.84).  
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Table 8: Two-way ANOVA values comparing oral and gastrostomy tube 
glucose load as a function of group and time for glucose, insulin, insulin, GLP-
1 and PYY plasma levels following oral and gastrostomy tube glucose load as 
a function of group and time. 
 
 
 
Time Group 
Time  
X Group  
Glucose F(7,57)=5.81; p<0.001 F(1,57=0.04; p=0.84 
F(7;57)=4.26; 
p<0.001 
Insulin F(7,57)=7.64; p<0.001 F(1,57)=8.88; p=0.004 
F(7,57)=5.87; 
p<0.001 
GLP-1 
F(7,58)=10.51; 
p<0.001 
F(1,58)=32.08; 
p<0.001 
F(7,58)=9.10; 
p<0.001 
PYY  F(7,58)=8,79; p<0.001 
F(1,58)=96.77; 
p<0.001 
F(7,58)=7.61; 
p<0.001 
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Figure 7: Plasma levels of (a) glucose, (b) insulin, (c) GLP-1 and (d) PYY 
following oral (black circles) and gastrostomy (open circles) glucose load. 
Data are expressed as mean ± SEM.  When two-way ANOVA revealed a 
significant group x time interaction, post-hoc Bonferroni test was used for 
time point to time point analysis between the two groups (*p<0.05, ***p<0.001). 
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Study 2: Changes in glucose metabolism and the gut hormone response in the initial 
postoperative period after gastric bypass.    
The demographic characteristics of the participants of the different groups are 
summarised in Table 9.  Insulin resistance was reduced by 44% at 7 days after 
gastric bypass in the diabetic patients (Figure 8).  As early as day 4, there was a 
significant difference in the HOMA-IR between the bypass and the banding group 
(p<0.05).  Insulin resistance did not change after gastric banding or a 1000 kcal diet. 
(Fig. 2).  HOMA-IR remained unchanged within the normal range in the non-diabetic 
gastric bypass group (Figure 8).  The insulin response as measured with delta insulin 
increased at 2 days after gastric bypass in both diabetic and non-diabetic groups as 
seen in Figure 9.  In accordance with the enhanced insulin production, the 
postprandial GLP-1 response also increased in both groups (Figure 10).  
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Table 9.  Demographic characteristics of patients undergoing standard meal 
tests pre-operatively and at day 2, 4, 7 and 42.  Comparisons were made 
between patients with diabetes (DM) who had very low calorie diet, gastric 
banding, gastric bypass or patients who did not have diabetes but underwent 
gastric bypass. 
 
 Diet + DM Band + DM Bypass + DM Bypass 
non DM 
p-
value 
Number 15 9 17 5  
Age (years) 43.7 ± 10 48.1 ± 8.7 48.3 ± 8.6 42.4 ± 
6.9 
NS 
Pre-op Weight 
(kg) 
139.0 ± 37.5 129.5 ± 
28.2 
138.9  ± 35.5 143.8 ± 
21.6 
NS 
Pre-op BMI 46.9 ± 8.1 43.5 ± 11.7 48.0 ±  5.7 52.2 ± 
3.3 
NS 
Pre-op glucose 5.9 ± 1.1  6.1 ± 1.2 7.1 ± 2 5.9  ± 
1.1 
NS 
Pre-op HOMA-IR 7.1 ± 3 8.8 ± 9.6 9.2 ± 7.8 2.1 ± 0.4 <0.05 
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Figure 8.  Insulin resistance measure with HOMA in patients with type 2 
diabetes following a 1000 kcal diet with no surgery over 7 days (n=15) and 
gastric band (n=9), gastric bypass (n=17) and patients without diabetes 
following gastric bypass (n=5) over a period of 42 days.  The solid line 
indicates the level at which HOMA-IR is considered to indicate insulin 
resistance. 
* p<0.05 compared to pre-operative state 
# p<0.05 compared with gastric banding at same time point 
† p<0.05 compared to very low calorie diet at same time point 
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Figure 9. Delta insulin defined as the difference between fasting and 15 min 
postprandial insulin after gastric bypass in patients with type 2 diabetes (n=17) 
and without type 2 diabetes (n=5). * p<0.05 compared to pre-operative state for 
both groups.   
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Figure 10.  Postprandial GLP-1 response after a 400 kcal meal following gastric 
bypass in patients with type 2 diabetes (n=17) and without type 2 diabetes 
(n=5). Measured with the area under the curve over a 3-hour period.  * p<0.05 
compared to pre-operative state for both groups.   
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Study 3: The long term gut hormone response after gastric bypass.   
The demographic characteristics of the groups of this study are demonstrated in 
Table 10.  The BMI in the postoperative groups was significantly lower than the 
preoperative group, but there was no significant difference between the three 
postoperative groups (Figure 11).  The PYY postprandial response curve was 
increased postoperatively in both the cross-sectional and the prospective 
comparisons, (p<0.05) (Figure 12 and Figure 13).  This was not the case for the 
GLP-1 response (p=0.189 for the prospective comparison) (Figure 14 and Figure 
15).  Satiety was increased postoperatively (p<0.05) (Figure 16). 
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Table 10: Demographic characteristics of patients in cross-sectional study and 
prospective study. 
Group Number (n) Age Sex (No of women) 
preoperative  17 47.8 ± 2.0 11 
12 month postoperatively 6 45.2 ± 4.0 5 
18 months postoperative 5 49.6 ± 3.3 3 
24 months postoperative 6 43.3 ± 4.1 6 
prospective study 6 47.8 ± 2.0 5 
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Figure 11. BMI before and 12, 18 and 24 months after gastric bypass.  
* p<0.05 compared to the pre-operative group 
BMI (kg/m2)  
 
 
*           *              *  
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Figure 12.  The PYY postprandial response in the cross-sectional study (12, 18 
and 24 months). 
* p<0.05 compared to the pre-operative group 
PYY (pmol/L/min) 
 
  *           *            *  
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Figure 13.  The PYY postprandial response in the prospective study (18-24 
months). 
PYY (pmol/L/min) 
 
             *       
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Figure 14.  The GLP-1 response in the cross-sectional study (12, 18 and 24 
months). 
GLP-1 (pmol/L/min) 
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Figure 15.  The GLP-1 postprandial response in the prospective study (18-24 
months). 
GLP-1 (pmol/L/min) 
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Figure 16.  Satiety as measured with the VAS in the prospective study. 
* p<0.05 compared to the pre-operative group 
VAS (mm) 
 
*          *             *  
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3.4 Discussion 
 
Gastric bypass has an effect on glucose handling which is independent of weight 
loss and study 1 offers confirmation for this.  Gastric bypass leads to the 
improvement of glycaemic control via a dual mechanism of increased insulin 
production and at the same time reduced insulin resistance in the first week after 
surgery as demonstrated in study 2.  The increased insulin production is associated 
with an enhanced GLP-1 response.  This improved glucose homeostasis can be 
explained in part by the altered nutrient delivery as seen in study 1.  Finally the 
enhanced gut hormone response seen in the above studies is sustained in the long 
term, accompanied by increased postprandial satiety demonstrated in both the 
cross-sectional and prospective designs of study 3. 
   
The paradoxical reduction in insulin resistance is independent of weight loss, the 
effect of the surgical trauma, which usually leads to increased insulin resistance and 
reduced food intake (Robertson, Bickerton, Dennis, Vidal, Jewell and Frayn 2005).  
This weight loss independent effect suggested in the chapter two of this thesis and 
further evidenced by the data from studies 1 and 2 in this chapter has been 
attributed to alterations in the hormonal milieu (Rubino, Gagner, Gentileschi, Kini, 
Fukuyama, Feng and Diamond 2004; Rubino, Forgione, Cummings, Vix, Gnuli, 
Mingrone, Castagneto and Marescaux 2006).  However the findings of this study are 
in contrast to a study by WJ Lee et al who showed reduced insulin resistance after 
banding and diet comparable to gastric bypass (Lee, Lee, Ser, Chen, and Chen 
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2008).  Of note is the fact that the time point used by Lee et al was four weeks when 
the effect of weight loss may have caused bias (Lee, Lee, Ser, Chen, and Chen 
2008).  
 
The enhanced insulin response as measured with delta insulin is associated with 
enhanced GLP-1 response supporting the hypothesis that the increased GLP-1 
response is responsible in part for the effect of bypass on insulin production.  On the 
other hand, the increase in insulin production is marked and perhaps other 
mechanisms may contribute.  In addition the reduced insulin resistance measured at 
fasting is associated with unchanged fasting GLP-1 levels and therefore cannot be 
explained by the GLP-1 response. 
 
The concept of proximal gut exclusion was first suggested in an animal model, the 
Goto-Kakizaki, a type of non-obese rats who spontaneously develop type 2 diabetes 
(Rubino, Forgione, Cummings, Vix, Gnuli, Mingrone, Castagneto and Marescaux 
2006).   Rubino demonstrated in a landmark experiment that glucose homeostasis 
improved after duodenal-jejunal bypass, compared to gastrojejunostomy (Rubino, 
Forgione, Cummings, Vix, Gnuli, Mingrone, Castagneto and Marescaux 2006).  
When the gastrojejunostomy group underwent a procedure which excluded the 
duodenum, these rats experienced improved glucose tolerance (Rubino, Forgione, 
Cummings, Vix, Gnuli, Mingrone, Castagneto and Marescaux 2006).  And when the 
duodenal passage of nutrients was restored in the former group, impaired glucose 
tolerance recurred supporting the proximal gut hypothesis further.  
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Previously a report of a single case of a patient similar to our cohort has been 
described in the literature (Dirksen, Hansen, Madsbad, Hvolris, Naver, Holst and 
Worm 2010).  The authors presented results similar to ours comparing the oral and 
the gastrostomy tube route of nutrients (Dirksen, Hansen, Madsbad, Hvolris, Naver, 
Holst and Worm 2010).   
 
Cross-sectional studies have previously suggested that gastric bypass is associated 
with an enhanced PYY and GLP-1 postprandial response (Korner, Bessler, Cirilo, 
Conwell, Daud, Restuccia and Wardlaw 2005; Rodieux, Giusti, D'Alessio, Suter and 
Tappy 2008; Vidal, Nicolau, Romero, Casamitjana, Momblan, Conget, Morínigo and 
Lacy 2009).  Fasting levels of PYY have been showed to increase post gastric 
bypass as demonstrated in prospective studies (Reinehr, Roth, Schernthaner, Kopp, 
Kriwanek and Schernthaner 2007; Garcia-Fuentes, Garrido-Sanchez, Garcia-
Almeida, Garcia-Arnes, Gallego-Perales, Rivas-Marin, Morcillo, Cardona and 
Soriguer 2008) whilst there are also data showing increased postprandial PYY (Borg, 
le Roux, Ghatei, Bloom, Patel and Aylwin 2006; Stratis, Alexandrides, Vagenas and 
Kalfarentzos 2006; Karamanakos, Vagenas, Kalfarentzos and Alexandrides 2008; 
Morínigo, Vidal, Lacy, Delgado, Casamitjana and Gomis 2008) and GLP-1 (Borg, le 
Roux, Ghatei, Bloom, Patel and Aylwin 2006; Laferrère, Teixeira, McGinty, Tran, 
Egger, Colarusso, Kovack, Bawa, Koshy, Lee, Yapp and Olivan 2008; de Carvalho, 
Marin, de Souza, Pareja, Chaim, de Barros Mazon, da Silva, Geloneze, Muscelli and 
Alegre 2009; Morínigo, Lacy, Casamitjana, Delgado, Gomis and Vidal 2006) levels 
up to 12 months postoperatively. 
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For the first study the non random allocation of the oral and gastrostomy route of the 
glucose load is a limitation.  However, it was important to ensure that patients can 
tolerate the glucose load orally and taking into consideration any possible intolerance 
or hypoglycaemic episodes.  Therefore instead of the standard dose, the same 
glucose load could be given to the participants.  This was not necessary in the study 
as all participants tolerated the standard load.  All tests were performed within 6 days 
for each participant minimising the effect of bias or changes in glucose homeostasis.  
Limitations of study 2 include the use of HOMA-IR as a marker of insulin resistance 
instead of the gold standard, the Hyperinsulinaemic Euglycaemic Glucose Clamp.  
Although this approach would have been more accurate, particularly in elucidating 
the effect of the bypass on insulin resistance postprandially, it was deemed more 
invasive and associated with considerably higher risk in the initial postoperative 
period.  Furthermore electing a time point and therefore reducing repeated 
measurement would not have been possible as there was no available information 
regarding the time scale of the change of insulin resistance after gastric bypass.  
Finally for the long term investigation of the gut hormone response the limitations are 
the small number of participants and the cross-sectional design.  This may be 
responsible for the lack of statistical difference in the GLP-1 response.  The 
prospective part of the study confirmed the findings of the cross-sectional study.  
 
In conclusion gastric bypass leads increased insulin production and reduced insulin 
resistance.  The increased insulin production is associated with an increased 
postprandial incretin response.  Furthermore gastric bypass leads to increased 
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postprandial gut hormone response, associated with increased satiety in the long 
term.  However the mechanism of this increased gut hormone response as well as 
the weight loss independent reduction in insulin resistance has not been investigated 
in the above experiments and this is the topic of the next chapter. 
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4. The role of bile acids in improving glycaemic control after metabolic 
surgery. 
 
4.1 Introduction 
 
Following the results presented in the previous chapters I hypothesised that the 
altered anatomy after gastric bypass affects bile delivery to the terminal ileum and 
leads to elevated plasma bile acids after gastric bypass surgery. Changes in bile flow 
result in increased satiety gut hormone responses, reduced food intake and weight 
loss.  In this chapter this hypothesis was tested in humans after gastric bypass 
surgery and two animal models of altered bile flow were used in order to explore the 
potential mechanisms involved further.  
 
4.2 Methods 
 
The canine studies were approved by the ethics committee of Onderstepoort 
Vetinary School, University of Pretoria, South Africa and the rat studies were 
approved by the Home Office UK (PL 70-6669).  
 
Study 1: Human model 
The human study was approved by the Somerset Research and Ethics committee 
approved the study (LREC Protocol Number: 05/Q2202/96) and was performed 
according to the principles of the Declaration of Helsinki.  Written informed consent 
was obtained from all participants.  Exclusion criteria included pregnancy, substance 
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abuse, more than 2 alcoholic drinks per day.  Twelve patients undergoing gastric 
bypass (seven females and five males) with a mean age of 45.2 ± 2.7 years and a 
mean BMI of 49.8 ± 1.5 were recruited.  Six patients undergoing gastric banding 
(four females and 2 males), with a mean age of 45.4 ± 2.6 years and a mean BMI of 
44 ± 2.0 kg/m2 were used as a control group.  All procedures were performed 
laparoscopically by one surgeon.   
 
The technique used for the bypass was a combination of linear stapler and hand 
sewn enterotomy closure for both the gastrojejunostomy and jejuno-jejunostomy, in 
an antegastric-retrocolic configuration (Higa, Boone, Ho and Davies 2000).  This was 
a modification of the technique first described by Higa et al (Higa, Boone, Ho and 
Davies 2000).   
 
A preoperative low-calorie, low-carbohydrate diet was used for 2 weeks aiming to 
reduce perioperative risk by reducing liver size and improving intraoperative 
exposure.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 500mg 
metronidazole at induction was routinely used (Pournaras, Jafferbhoy, Titcomb, 
Humadi, Edmond, Mahon and Welbourn 2010).   
 
Reverse Trendelenburg position was used with the operating on the right of the 
patient and assistant positioned between the legs of the patient.  Pneumoperitoneum 
was obtained with a Verres needle inserted below the left costal margin at the mid-
clavicular line.  Thromboprophylaxis included the routine use of TED stockings and 
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40 mg of low molecular weight heparin preoperatively and then for 7 days 
postoperatively and lower limb pneumatic compression devices intraoperatively.  
Five ports were used.  An isolated lesser curve-based, 15–20-ml gastric pouch was 
created and a retrocolic antegastric Roux limb was made 100 cm long for patients 
with a BMI equal to or less than 50 kg/m2 and 150 cm long for patients with BMI of 
more than 50 kg/m2.  The bilio-pancreatic limb was 25 cm.  The gastrojejunostomy 
was closed over a 34 Fr bougie.  A blue dye leak test via a nasogastric tube was 
routinely performed.  All hernia defects (jejunojejunostomy, Petersen’s and 
mesocolon) were routinely closed with a purse-string suture.   
 
An enhanced recovery protocol was used with patients being offered a glass of water 
in the recovery room progressing to free fluids on postoperative day 1 and a soft diet 
thereafter.  The first routine postoperative review in the outpatient department was 6 
weeks after discharge with a minimum regular follow-up program for uncomplicated 
patients afterwards of 6 months, 12 months postoperatively, and yearly thereafter, 
and more intensive follow-up for complex patients. 
 
The surgical technique used for gastric banding was the pars flaccida described by 
the Melbourne group (O'Brien, Dixon, Laurie and Anderson 2005).  A preoperative 
low-calorie, low-carbohydrate diet was used for 2 weeks aiming to reduce 
perioperative risk by reducing liver size and improving intraoperative exposure as 
with the gastric bypass.  Intravenous antibiotic prophylaxis with 1.5g cefuroxime and 
500mg metronidazole at induction was routinely used (Pournaras, Jafferbhoy, 
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Titcomb, Humadi, Edmond, Mahon and Welbourn 2010).  Thromboprophylaxis 
included the routine use of TED stockings and 40 mg of low molecular weight 
heparin preoperatively and then for 7 days postoperatively.  Lower limb pneumatic 
compression devices intraoperatively. Five ports were used.  The Swedish 
Adjustable Gastric band® (Ethicon Endo-Surgery) and the LAP-BAND® (Allergan) 
bands were used for all gastric banding procedures.  The pars flaccida dissection 
technique with gastro-gastric tunnelling sutures was the operative method utilised 
(O'Brien, Dixon, Laurie and Anderson 2005).  The same enhanced recovery protocol 
as the one sued for gastric bypass was used with patients being offered a glass of 
water in the recovery room progressing to free fluids on postoperative day 1 and a 
soft diet thereafter.  Follow-up was also similar with the first postoperative review in 
the outpatient department 6 weeks after discharge.  Patients were then seen monthly 
and adjustments were performed until optimal reduction in hunger or restriction was 
achieved.  The adjustments were performed using the indicators described by 
Favretti et al (Favretti, O'Brien and Dixon 2002) as seen in table 4.  Patients were 
seen at least six times in the first year and then once a year minimum (Pournaras, 
Osborne, Hawkins, Vincent, Mahon, Ewings, Ghatei, Bloom, Welbourn and le Roux 
2010).  
 
Following a 12 hour fast, blood was obtained in tubes containing EDTA and 
aprotinin.  Samples were immediately centrifuged and stored in a -80°C freezer until 
analysis. 
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Plasma FGF19 concentration was measured using a quantitative sandwich enzyme 
linked immunosorbent assay (ELISA) technique (FGF19 Quantikine ELISA kit, 
Catalogue Number DF1900; R&D Systems, Minneapolis, MN 55413, USA).  
 
The FGF19 Quantikine ELISA method utilises a 96 well polystyrene microplate pre-
coated with a mouse monoclonal antibody specific for FGF19.  FGF19 standards 
were provided by the manufacturer (10ng of recombinant human FGF-19 in a 
buffered protein solution, with preservatives, lyophilized).  Serum samples (10ng) 
were pipetted into the microplate wells.  FGF-19 molecules were bound to the 
immobilised antibody during a 2 hour incubation period.  Buffer concentrate (21mL of 
a concentrated solution of buffered surfactant with preservatives) was utilised to 
wash unbound molecules.  An enzyme-linked polyclonal antibody specific for FGF-
19 (21mL of polyclonal antibody against FGF19 conjugated to horseradish 
peroxidise with preservatives) was added to the wells for an incubation period of 2 
hours.  Following further wash with the objective to remove unbound antibody-
enzyme reagent, a substrate solution formed of colour reagents (12.5mL of stabilised 
hydrogen peroxide and 12.5mL of stabilised chromogen) was added to the wells for 
a 30 minute period. 
  
Colour development in proportion to the amount of FGF19 bound in the initial step 
was observed at this stage.  The colour development was terminated with the use of 
an acid based stop solution.  The optical density of each well was then measured 
with a microplate reader capable of measuring absorbance at 450nm, with the 
correction wavelength set at 540nm or 570nm.  The assay was conducted according 
to the manufacturer’s guidelines.  Prior to the assay commencement, the unopened 
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kit was stored between 2-8ºC as recommended.  All serum samples were measured 
in duplicate.  The assay results lead to generation of a standard curve, plotting 
optical density for the standards versus the concentrations of the standards.  These 
data were transformed linearised using the log/log paper and regression analysis 
applied to the log transformation.  The FGF19 concentration in each sample was 
then calculated using the absorbance values obtained by the assays on the standard 
curve and reading the corresponding concentration.  
 
In order to avoid cross contamination during the procedure, pipette tips were 
changed between additions of each standard level, between sample additions, and 
between reagent additions.  Separate reservoirs were used for each reagent.  
Washing of the plates was completed using an automatic plate washer, and to 
ensure accuracy plate sealers were suitably employed during incubation steps. 
 
The EDTA plasma samples were analysed for fractionated bile acids using high-
performance liquid chromatography (HPLC) tandem mass spectrometry.  The 
method was based on that of Tagliocozzi et al and developed using an Ascentis 
Express fused core C18 analytical column (Sigma-Aldrich Co., Poole, UK) on a 
JascoTM LC 2000 HPLC system (Tokyo, Japan) coupled to a triple quadruple mass 
spectrometer API 3200TM (Applied Biosystems, Cheshire, UK) (Tagliacozzi, Mozzi, 
Casetta, Bertucci, Bernardini, Di Ilio, Urbani and Federici 2003).  Bile acids were 
quantified using peak area analysis corrected by comparison to the respective 
internal standard, glycine, taurine or unconjugated deuterium-labelled DCA.  Bile 
acids analysed were chenodeoxycholic acid, DCA, cholic acid and their respective 
glycine and taurine conjugates.  The method was linear between 0.1 and 10 mmol/L 
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for all bile acids and their conjugates with coefficients of variation ranging from 3.6% 
to 8.0% at the lower limit of quantitation (0.1 mmol/L). 
 
Multiple batches were used; interassay coefficient of variations ranging from 1.5% to 
6.8% for these bile acids and their conjugates.  The method allowed 12 different bile 
acids to be measured within the range of 0.1-10μM.  The two main plasma bile acids 
in humans, glycochenodeoxycholic acid (GCDC) and Glycocholic acid (GCA) were 
compared as well as total bile acids, total unconjugated bile acids, total glycine-
conjugated bile acids and total taurine-conjugated bile acids. 
 
Study 2: Canine model 
Four male and four female Beagles were fasted overnight and then given a standard 
400 g test meal of dog chow (Husky, Purina, South Africa).  The composition of the 
test meal was 7.5% protein, 2% fat, 1% fibre, 7.5% crude ash and 82% moisture.  
Five mL of blood were collected every 30 minutes from 30 minutes before the meal 
up to 150 minutes postprandially.  
 
The following day a fentanyl patch was placed and food was withheld overnight.  
Following laparotomy the common bile duct was transacted and an 8 French Foley 
catheter was placed into the gall bladder.  An 8 French feeding tube was advanced 
through the pylorus to the duodenum with the most distal point being 5-8 cm distal to 
the pylorus.  The altered anatomy can be seen in Figure 17.  For the first 12 hours 
postoperatively the dogs were given ad libitum access to water but not to food. 
 
138 
 
Figure 17. Illustration of the anatomy of the canine experiment showing the 
canulation.  A Gastrostomy tube was placed into the duodenum close to the 
Ampulla of Vater.  The common bile duct was ligated and the gallbladder was 
canulated to allow drainage of bile. 
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One dog was terminated due to signs of jaundice and infection.  The other dogs 
received the standard meal of 400 g normal chow at the start of the light phase.  At 
this time point, as much bile as possible was aspirated from the Foley catheter and 
injected through the gastrostomy tube, followed by a 5 mL flush of saline.  The 
objective was to prevent jaundice and enable as close as normal digestion. 
 
On day 4, 5 and 6 the dogs were randomised to a 180-minute cross over designed 
protocol of venous blood collection every 30 minutes, following a standard meal of 
400 g dog food only without bile, bile only, without food or 400 g of dog food and bile 
in combination.   
 
For the measurement of gut hormones all samples were assayed in duplicate.  PYY-
like immunoreactivity was measured with a specific and sensitive radioimmunoassay 
(Savage, Adrian, Carolan, Chatterjee and Bloom 1987).  The assay measured the 
biologically active components, the full length (PYY1-36) and the fragment (PYY3-36).  
Antiserum (Y21) was produced in a rabbit against synthetic porcine PYY (Bachem, 
UK) coupled to bovine serum albumin with glutaraldehyde and used at a final dilution 
of 1:50000.  This antibody cross-reacts fully with the biologically active circulating 
forms of human PYY, but not with pancreatic polypeptide, neuropeptide Y, or any 
other known gastrointestinal hormone (Adrian, Ferri, Bacarese-Hamilton, Fuessl, 
Polak and Bloom 1985).  125I-labeled PYY was prepared by the Iodogen method and 
purified by high pressure liquid chromatography.  The specific activity of the 125I-
labelled PYY was 54 Bq per femtomole.  The assay was performed in a total volume 
of 700 µL of 0.06 M phosphate buffer, pH 7.26, containing 0.3 % bovine serum 
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albumin.  The samples were incubated for 3 days at 4 ºC before separation of free 
and antibody-bound label by sheep anti-rabbit antibody.  Two hundred µL of plasma 
was assayed, while 200 µL of PYY-free, Haemacel colloid fluid was added to 
standards and other reference tubes to neutrilise any non-specific assay 
interference.  The assay has been reported to detect changes of 2 pmol/L, with an 
intra-assay coefficient of variation (CV) of 5.8 % and an interassay CV of 9.8 %.  
 
Plasma GLP-1 was measured in duplicate by an established in-house 
radioimmunoassay.  The GLP-1 assay detected changes of 7.5 pmol/L, with an intra-
assay CV of 6.1 % (Kreymann, Williams, Ghatei and Bloom 1987).  
 
Study 3: Rodent model 
 
Sixteen male Wistar obese rats were randomised to a sham operation which 
maintained the normal bile delivery to the duodenum or to an operation that would 
deliver bile to the ileum.   The bile in duodenum group underwent transections 1 cm 
proximal and distal to the drainage point of the common bile duct and reanastomosis 
to maintain the normal anatomy but allow for a similar surgical insult.  The bile in 
ileum group had the same transection of the duodenum, but the proximal and distal 
ends of the transected duodenum were anastomosed end to end and continuity 
restored.  The segment of the duodenum containing the common bile duct was 
anastomosed side to side to the distal jejunum, 10 cm proximally to the terminal 
ileum.  This allowed bile and pancreatic juices to bypass the duodenum and most of 
the jejunum.  The altered anatomy can be seen in Figure 18. 
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Figure 18.  Illustration of the functional anatomy of the bile in ileum group.  
Transections 1 cm proximal and distal to the drainage point of the common 
bile duct were performed.  The proximal and distal ends of the transected 
duodenum were anastomosed end to end and continuity of the gastrointestinal 
tract was restored.   The segment of the duodenum containing the common 
bile duct was anastomosed side to side to the distal jejunum, 10 cm proximally 
to the terminal ileum. 
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Body weight and food consumption was measured daily at the beginning of the light 
phase for 28 days.  Faeces were collected over a 24 hour period on day 25.  The 
rats were then fasted for 12 h before they were terminated and blood samples were 
collected.     
 
To evaluate nutrient absorption, faeces were collected over 24 hours on 
postoperative days 25 from all rats.  The ballistic bomb calorimeter used was 
designed by Miller and Payne in the 1950s (Miller and Payne 1959).  The process 
consisted of three steps.  The sample was initially prepared, then a defined amount 
of sample was burnt in excess of oxygen and finally the peak temperature detected 
was compared with the temperature when a standard material was burnt.    
 
The preparation of the sample, rodent faeces for this experiment, was done over a 
48-hour period.  Rats were kept separate in single cages and on a predetermined 
day all saw dust was removed for a 24 hour period.  The faeces were collected at the 
end of this period in sterile containers and kept at 4 °C until further analysis.  The 
samples were dried overnight in an oven.  The next day the specimen from each rat 
was ground producing a fine powder with the objective to enable satisfactory mixing.  
A representative sample weighing 400 mg was placed in a clean crucible. 
 
Due to the low bulk density samples typically were compacted to ensure uniform and 
complete combustion.  Five hundred µL of water was added and the crucible was 
placed on a hot plate to allow evaporation of the water and a formation of a cake like 
substrate.  
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Significant malabsorption can cause high fat content in the samples, thus causing a 
release that may exceed the measurement capability of the instruments rendering 
the measurement invalid.  With the recommended oxygen pressure of 25 
atmospheres the sample should burn completely without causing a high pressure in 
the bomb.  With the above considerations a sample weighing 400 mg was selected.   
 
The crucible was then placed on the pillar of the bomb and a standard 5 cm length 
sewing cotton was fitted to the firing wire with its free end in contact with the sample.  
The bomb body was fitted and the thermocouple inserted.  Oxygen was admitted to 
a pressure of 25 atmospheres.  The galvanometer zeroed and the firing button was 
pushed.  The peak reading from the galvanometer was recorded during a 30 second 
period.  The gas pressure was released and the bomb body was removed and 
allowed to cool in cold water awaiting assessment of the following sample (Jackson, 
Davis and Macdonald 1977). 
 
For the assessment of inflammation serum CRP levels were measured (Rat Serum 
CRP ELISA kit Catalogue Number 1010; Alpha Diagnostics International, 6203 
Wooldake Center Drive, San Antonio, Texas 78244, USA). 
 
For the measurement of gut hormones all samples were assayed in duplicate.  PYY-
like immunoreactivity was measured with a specific and sensitive radioimmunoassay 
(Savage, Adrian, Carolan, Chatterjee and Bloom 1987).  The assay measured the 
biologically active components, the full length (PYY1-36) and the fragment (PYY3-36).  
Antiserum (Y21) was produced in a rabbit against synthetic porcine PYY (Bachem, 
UK) coupled to bovine serum albumin with glutaraldehyde and used at a final dilution 
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of 1:50000.  This antibody cross-reacts fully with the biologically active circulating 
forms of human PYY, but not with pancreatic polypeptide, neuropeptide Y, or any 
other known gastrointestinal hormone (Adrian, Ferri, Bacarese-Hamilton, Fuessl, 
Polak and Bloom 1985).  125I-labeled PYY was prepared by the Iodogen method and 
purified by high pressure liquid chromatography.  The specific activity of the 125I-
labelled PYY was 54 Bq per femtomole.  The assay was performed in a total volume 
of 700 µL of 0.06 M phosphate buffer, pH 7.26, containing 0.3 % bovine serum 
albumin.  The samples were incubated for 3 days at 4 ºC before separation of free 
and antibody-bound label by sheep anti-rabbit antibody.  Two hundred µL of plasma 
was assayed, while 200 µL of PYY-free, Haemacel colloid fluid was added to 
standards and other reference tubes to neutrilise any non-specific assay 
interference.  The assay has been reported to detect changes of 2 pmol/L, with an 
intra-assay coefficient of variation (CV) of 5.8 % and an interassay CV of 9.8 %.  
 
Plasma GLP-1 was measured in duplicate by an established in-house 
radioimmunoassay.  The GLP-1 assay detected changes of 7.5 pmol/L, with an intra-
assay CV of 6.1 % (Kreymann, Williams, Ghatei and Bloom 1987).  
 
Statistical Analysis 
 
Results were analysed using GraphPad Prism version 5.00 for Windows, GraphPad 
Software, San Diego California USA.  Data were expressed as means ± standard 
error of the mean (SEM) when the data follow a Gaussian distribution.  When the 
data did not follow a Gaussian distribution the median (range) was used.  Values for 
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the area under the curve were calculated with the use of the trapezoidal rule.  End 
points were compared with the use of 2-tailed, paired Student t tests for parametric 
data and Mann-Whitney U test for non parametric data.  Results were considered 
significant if p < 0.05.     
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4.3 Results 
 
Study 1: Human model  
There was no statistically significant difference in fasting plasma FGF19 levels 
between patients undergoing gastric banding [140ng/L (26-466)] and gastric bypass 
[123ng/L (41-406)] preoperatively (p=0.37).  FGF19 levels were lower than those 
recorded in non-obese individuals (Walters, Tasleem, Omer, Brydon, Dew and le 
Roux CW 2009).  In the gastric banding group there was no significant change 
between preoperative levels of fasting FGF19 and day 4 or 42 postoperatively.  After 
gastric bypass, fasting levels of plasma FGF19 were significantly increased as early 
as day 4 postoperatively compared to preoperatively (p<0.01) as seen in Figure 19.  
The enhanced FGF19 levels remained high 42 days postoperatively (p<0.05). 
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Figure 19.  Fasting plasma FGF19 concentrations (median and interquartile 
ranges) at day 0, 4 and 42 in six gastric banding patients (white bars) and 
twelve gastric bypass patients (black bars). * p<0.05 Mann Whitney U test. 
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Levels of fasting total plasma bile acids measured in patients undergoing gastric 
banding and gastric bypass preoperatively were similar.  On day 4 fasting plasma 
bile acids were increased after gastric bypass and there was a significant difference 
compared to the gastric banding group.  On day 42 after gastric bypass fasting 
plasma total bile acid levels were higher compared to preoperative levels as seen in 
Figure 20.  There was no difference in fasting plasma total bile acid levels before and 
42 days after gastric banding.   
 
Similar results with and an increase in the gastric bypass group but not in the gastric 
banding group were observed for GLP-1 in the same subjects as seen in Chapter 3, 
study 2. 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 20.  Fasting total plasma bile acid concentrations at day 0, 4 and 42 in 
seven gastric banding patients (white bars) and twelve gastric bypass patients 
(black bars). * p<0.05 Mann Whitney U test.  
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Study 2: Canine model 
The responses of GLP-1 and PYY were investigated in this canine model after 
stimulation with food alone, bile alone, or a combination of both.  At the time of these 
experiments, no assay for canine FGF19 level measurement was available.  
Baseline GLP-1 and PYY levels were the same preoperatively and postoperatively 
validating this model (6936 vs. 7290 for GLP-1 and 6386 vs. 5856 for PYY).  Figure 
21 shows the area under the curve (AUC) over 180 minutes for the postprandial 
GLP-1 response after the standard meal of 400 g dog and Figure 22 for PYY.  In the 
operated dogs both food alone and bile alone lead to a significant GLP-1 and PYY 
response from baseline, although the responses were attenuated.  The response to 
bile and or food alone was inferior to the combination of food and bile either pre- or 
post-operatively. 
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Figure 21.  The shows the area under the curve (AUC) for the postprandial 
GLP-1 response after 400 g of food in dogs pre-operatively or postoperatively 
either receiving food alone without bile (Food), bile alone without food (Bile) or 
food and bile in combination (Food+Bile).* p < 0.05 
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Figure 22.  The shows the area under the curve (AUC) for the postprandial PYY 
response after 400 g of food in dogs pre-operatively or postoperatively either 
receiving food alone without bile (Food), bile alone without food (Bile) or food 
and bile in combination (Food+Bile).* p < 0.05 
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Study 3: Rodent model 
In this rodent model, rats had bile draining into their ileum or duodenum.  Both the 
plasma GLP-1 levels (Figure 23) and the plasma PYY levels (Figure 24) were higher 
in the bile in ileum group than in the bile in duodenum group (p <0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
 
Figure 23.  Plasma GLP-1 levels in rats with bile draining into their duodenum 
or bile draining into their ileum.  * p < 0.05. 
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Figure 24.  Plasma PYY levels in rats with bile draining into their duodenum or 
bile draining into their ileum.  * p < 0.05.  
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Both the bile in ileum and bile in duodenum groups lost a similar initial amount of 
weight during the first four days while recovering from surgery as seen in Figure 25.  
The bile in duodenum group however reached their pre-operative weight within 8 
days.  The bile in ileum group weighed significantly less than the bile in duodenum 
group on day six (p <0.05) and continued to have a lower bodyweight for the duration 
of the study (p <0.05).  Furthermore Figure 26 shows the rats in the bile in ileum 
group ate significantly less than the bile in duodenum group (p <0.05).  
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Figure 25.  The weight of rats in bile in duodenum (solid line) and bile in ileum 
(broken line) groups before and 28 days after surgery.  * p < 0.05. 
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Figure 26.  Food intake of bile in duodenum (solid line) and bile in ileum 
(broken line) rats before and 28 days after surgery. * p < 0.05. 
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Faecal parameters 25 days postoperatively did not reveal differences between the 
bile in the ileum and the bile in the duodenum groups at the end of the experiment in 
dry weight (4.12 g ±0.20 vs. 4.28 ± 0.18, p = 0.55) or in calorific content (3.58 
faecal kcal/24 h ± 0.4 vs. 3.58 ± 0.4, p = 0.91).  No increase in inflammation in the 
bile in the ileum group was detected compared with the bile in the duodenum group 
as evidenced by the similarity in the white cell count (11.5 ± 0.32 x1000/microlitre vs. 
11.64 ± 0.42, p = 0.79) or CRP levels (370.88 microg/litre ±26.03 vs. 378.5 
±21.71 microg/litre, p = 0.83). 
 
4.4 Discussion  
 
Fasting FGF 19 and plasma total bile acids were increased after gastric bypass, but 
not after gastric banding.   
 
Food and bile alone lead to the release of GLP-1 and PYY and this was 
demonstrated in study 2.  Food and bile together (before surgery or after surgery) 
resulted in a greater PYY response compared to food alone.  Furthermore a trend for 
increased GLP-1 levels when food and bile were given together was also observed 
but this did not reach statistical significance.   
 
In study 3, in the rodent model, draining endogenous bile and pancreatic fluid 10 cm 
proximally to the terminal ileum was associated with increased GLP-1 and PYY, 
reduced food intake and body weight.   
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These data allow me to hypothesise that one of the mechanisms by which a gastric 
bypass leads to the modification of the satiety gut hormone response could be due to 
the passage of undiluted bile via the biliopancreatic limb, a non-physiological 
phenomenon, or the altered delivery of bile to the terminal ileum, or a combination of 
both. 
 
Exogenous bile salts have been shown to stimulate the release of gut hormones 
from the endocrine L-cells such as PYY in rabbit colon explants, in vivo in conscious 
dogs and in humans (Ballantyne, Longo, Savoca, Adrian, Vukasin, Bilchik, Sussman 
and Modlin 1989; Izukura, Hashimoto, Gomez, Uchida, Greeley and Thompson 
1991; Adrian, Ballantyne, Longo, Bilchik, Graham, Basson, Tierney and Modlin 
1993).  The question of what arrives first in the terminal ileum after gastric bypass; 
bile, nutrients or both remains to be answered.   
 
Näslund el showed an increase in CCK after jejuno-ileal bypass (Näslund, Grybäck, 
Hellström, Jacobsson, Holst, Theodorsson and Backman 1997).  This may lead to 
increased flow of bile from the gallbladder or the liver (Näslund, Grybäck, Hellström, 
Jacobsson, Holst, Theodorsson and Backman 1997).   
 
Bile may flow in the biliopancreatic limb reaching the distal L-cells in an undiluted 
state.  Activation of TGR5 by bile acids leads to the stimulation of GLP-1 production 
in vitro and may explain the early and exaggerated release of incretin gut hormones 
such as GLP-1 and subsequently insulin (Katsuma, Hirasawa, and Tsujimoto 2005).  
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Bile acids may also affect glucose metabolism by weight loss.  This could be 
attributed the enhanced satiety facilitated by the increase in satiety gut hormones as 
seen in Chapter 3, studies 2 and 3.  Furthermore bile acids increase energy 
expenditure in brown adipose tissue, thus preventing obesity and insulin resistance 
via induction of the cyclic-AMP-dependent thyroid hormone activating enzyme type 2 
iodothyronine deiodinase (Watanabe, Houten, Mataki, Christoffolete, Kim, Sato, 
Messaddeq, Harney, Ezaki, Kodama, Schoonjans, Bianco and Auwerx 2006).  This 
is achieved via the TGR5 and is consistent with studies in rat models showing that 
gastric bypass prevented the decrease in energy expenditure after weight loss 
(Bueter, Löwenstein, Olbers, Wang, Cluny, Bloom, Sharkey, Lutz and le Roux 2010; 
Stylopoulos, Hoppin and Kaplan 2009).   
 
Activation of the FXRα may also mediate the effects of bile acids on energy 
homeostasis via FGF-19 released from ileal enterocytes, leading to improved 
metabolic rate and decreased adiposity (Inagaki, Choi, Moschetta, Peng, Cummins, 
McDonald, Luo, Jones, Goodwin, Richardson, Gerard, Repa, Mangelsdorf and 
Kliewer 2005; Holt, Luo, Billin, Bisi, McNeill, Kozarsky, Donahee, Wang, Mansfield, 
Kliewer, Goodwin, Jones 2003).  FGF-19 inhibits hepatic gluconeogenesis and 
works subsequent to insulin as a postprandial regulator of hepatic carbohydrate 
homeostasis (Potthoff, Boney-Montoya, Choi, He, Sunny, Satapati, Suino-Powell, 
Xu, Gerard, Finck, Burgess, Mangelsdorf and Kliewer 2011).  
 
A model of studying bile acid metabolism is the use of bile acid sequestrants in 
patients with type diabetes.  Bile acid sequestrants have been shown to be effective 
in improving glycaemic control in patients with type 2 diabetes (Garg and Grundy 
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1994; Fonseca, Rosenstock, Wang, Truitt and Jones 2008; Goldberg, Fonseca, 
Truitt and Jones 2008; Staels and Fonseca 2009).  Garg et al conducted a 
randomised, double blind, crossover study of cholestyramine compared with placebo 
with the objective to assess clinical efficacy and tolerability of cholestyramine in 
patients with dyslipidaemia and type 2 diabetes (Garg and Grundy 1994).  An 
unexpected finding was improved glycaemic control with lower mean plasma 
glucose, median reduction in urinary glucose excretion and a trend for lower glycated 
haemoglobin (Garg and Grundy 1994).  Following this observation a randomised, 
double blind, placebo controlled, multicentre study was conducted with the objective 
to assess the efficacy and safety of a new bile acid sequestrant, colesevelam in 
patients with type 2 diabetes with inadequate glycaemic control on sulfonylurea 
therapy (Fonseca, Rosenstock, Wang, Truitt and Jones 2008).  Colesevelam 
improved glycaemic control in this study and reduced LDL cholesterol levels 
(Fonseca, Rosenstock, Wang, Truitt and Jones 2008).  A similar study with identical 
design was conducted in patients with type 2 diabetes and inadequate glycaemic 
control on insulin therapy alone or in combination with oral hypoglycaemic agents 
(Goldberg, Fonseca, Truitt and Jones 2008).  Colesevelam was effective in these 
patients for both glycaemic control and lipid management (Goldberg, Fonseca, Truitt 
and Jones 2008).   
 
In fact the bile acid sequestrant colevesham has been approved for the treatment of 
hyperglycaemia in type 2 diabetes (Rodbard, Jellinger, Davidson, Einhorn, Garber, 
Grunberger, Handelsman, Horton, Lebovitz, Levy, Moghissi and Schwartz 2009).  
Thus, some of the beneficial metabolic effect of Roux-en-Y gastric bypass on 
glycaemic control may be attributed to changes in bile acids.  In study 1, the human 
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model, the previous cross sectional observation that fasting total plasma bile acids 
are elevated after gastric bypass surgery is confirmed in an experiment with 
prospective design (Patti, Houten, Bianco, Bernier, Larsen, Holst, Badman, Maratos-
Flier, Mun, Pihlajamaki, Auwerx, and Goldfine 2009).  Furthermore this observation 
was recorded at an earlier time point of 42 days after surgery reducing the bias of 
the effect of weight loss and reduced food intake.  The changes facilitated by bile 
may increase satiety and improved glycaemic control via gut hormones as well as a 
direct effect on insulin resistance.  Therefore bile may be one of the key products of 
the proximal gut which transfers a message to the distal gut and to other 
metabolically active tissues.  
 
A limitation of study 1, the human model, is fact that the two groups were not 
randomised.  However the groups were well matched for preoperative patient 
characteristics.  In study 2, the canine model, migration the feeding tube or the Foley 
catheter may have lead to chemical peritonitis and the resulting sepsis may have 
affected metabolic pathways.  Post-mortem examination of all subjects confirmed the 
correct position of both the feeding tube and the Foley catheter.  In study 3, the 
rodent model, the differential severity and insult of the two surgical procedures, and 
perhaps the subsequent dissimilar response to trauma may have led to a different 
inflammatory response.  This possibility can be excluded due the reported 
biochemical and histological markers of inflammation which were similar between the 
two groups. 
 
Gastric bypass leads to altered bile flow which subsequently leads to an increase in 
fasting total plasma bile acids levels and fasting FGF19.  These changes are 
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associated with enhanced postprandial GLP-1 and PYY responses.  Changes in the 
bile flow may be responsible for some of the metabolic effects observed after gastric 
bypass surgery. 
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 5. Summary and conclusion 
 
In this thesis the effect of metabolic surgery on glucose metabolism is investigated.  
First of all evidence on the weight loss independent effect of gastric bypass, the 
basis of the concept of metabolic surgery is provided.  Then this effect is dissected 
further demonstrating that gastric bypass has a favourable effect on both insulin 
production and insulin resistance. The change in insulin production is attributed to 
enhanced postprandial GLP-1 production galvanising the concept that gastric bypass 
is a gut hormone modulation leading to behavioural (appetite) and glycaemic 
modifications.  Finally in an attempt to explain the improved insulin resistance, which 
is unrelated to GLP-1, the role of bile acids is explored.  Bile flow changes after 
bypass and leads to a change in plasma bile acids.  Furthermore modifying the flow 
of bile has effects on the gut hormone response, on appetite and body weight. 
 
This thesis does not explain all the mechanism by which gastric bypass works on 
appetite control and glycaemic control.  However I have demonstrated that it is not 
malabsorption of calories and it is not weight loss alone.  Body weight is reduced 
after gastric bypass and it is a welcomed change for this population.  But weight 
changes alone cannot explain the dramatic effect on insulin resistance.  The change 
in bile acids provides an attractive theory, but this needs to be explored further.  
Previous attempts to explain the effects of gastric bypass have focused on the 
foregut theory (exclusion of duodenum) versus the hindgut theory (early delivery of 
nutrients and bile to the terminal ileum leading to the production of gut hormones).  
The data presented here suggest an alternative hypothesis combining the two, in 
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which a product of the proximal gut (bile) acts as a messenger, a hormone even, to 
the distal gut. 
 
This thesis also does not fully explain the increase in insulin production.  An 
enhanced GLP-1 postprandial response is associated with the increase in insulin 
production, but other factors may play a role, particularly as this increase is marked.  
Changes in Glucagon, GIP and even somatostatin may be responsible and further 
work is needed to explore this. 
 
This thesis on its own does not provide the evidence needed for metabolic surgery to 
become part of the treatment algorithm for type 2 diabetes.  There are no data 
available at the moment regarding the effect of gastric bypass on hard endpoints 
such as mortality and macrovascular complications.  And it will be the provision of 
this data that can only change the status quo of metabolic surgery. 
 
But what this thesis does show is that gastric bypass is an effective modality for 
glycaemic control.  And understanding how this operation works is the duty of the 
surgeon performing it.  Most surgeons want to know how their operations work.  And 
if they understand how gastric bypass works, they may be able to make it safer or 
more effective.   
 
Exploring the mechanism of action of gastric bypass is also intriguing for the 
physiologist as this procedure provides an excellent model of the disease and the 
reversal of it.  The role of the gut in glucose metabolism is coming into focus again, 
because it can now be studied appropriately, but more importantly understanding 
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how metabolic surgery works is useful for the diabetologists.  Because they are the 
ones who face the patients who experience the burden of the disease.  
Understanding how a treatment modality works will make it more available, removing 
some of the barriers in the use of metabolic surgery.   
 
The data presented in this thesis can be used to explore the role of the gut as a 
target for novel intervention for type 2 diabetes, pharmacological or not.  Perhaps it 
could lead to the consideration of randomised control trials to explore the role of 
metabolic surgery for type 2 diabetes.   
 
There is a distinct lack of level 1 evidence on any aspect of metabolic surgery.  The 
Holy Grail seems to be “head to head” comparative studies of metabolic surgery and 
best medical treatment as this is the gold standard.  These studies are more than 
welcomed and definitely very important.  But level 1 evidence is needed for the use 
of these operation in different populations (adolescents, elderly, obese women with 
subfertility, lower or higher BMI) and also the timing of the operations (early surgery, 
length of optimisation, newly diagnosed diabetics).  And the aim of this thesis is to 
provide a basis for discussion and collaboration. 
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Abstract Obesity is becoming the healthcare epidemic of
this century. Bariatric surgery is the only effective treat-
ment for morbid obesity. Gut hormones are key players in
the metabolic mechanisms causing obesity. In this review
we explore the role of these hormones as facilitators of
appetite control and weight loss after bariatric surgery, and
we describe the now established gut–brain axis.
Introduction
Obesity is a major cause of premature death, and its
prevalence is accelerating worldwide. Advice to the pop-
ulation to reduce food intake and take more exercise has
been manifestly unsuccessful. At present, surgical proce-
dures are the only effective therapy for long-term weight
loss [1]. Bariatric surgery also has profound effects on
obesity-related co-morbidities, such as type 2 diabetes,
hypertension, and sleep apnea [2]. The significantly
improved glycemic control in patients with type 2 diabetes
mellitus may have an even greater impact on morbidity and
mortality than weight loss.
The mechanism that leads to sustained weight loss as
well as diabetes remission after bariatric operations
remains to be elucidated. Gut hormones have been impli-
cated to play an important role in both weight loss and
diabetes improvement after weight loss surgery.
Energy homeostasis
Through the process of energy homeostasis, energy intake
and expenditure are adjusted, leading to remarkable sta-
bility in body mass over time [3–5]. From an evolutionary
standpoint, it is likely that survival in an environment with
constraints on the availability of food provided selection
bias toward homeostatic systems that respond to reduced
energy intake rather than energy excess [4–7]. Weight loss
leads to an increase in the perceived hunger and a decrease
in the metabolic rate. Leptin and insulin are the key mes-
sengers of the status of energy stores from the periphery to
the central nervous system [3].
The central melanocortin system, which plays a crucial
role in the regulation of energy homeostasis, is influenced
by signals mediated through peptides made in the gut and
released into the circulation [8]. These gut hormones cause
hunger and satiety effects and thus have an integral role in
appetite regulation.
Bariatric procedures were designed to promote weight
loss by the reduction of stomach volume (laparoscopic
adjustable gastric banding [LABG], laparoscopic sleeve
gastrectomy [LSG]), malabsorption of nutrients (biliopan-
creatic diversion [BPD], duodenal switch [DS]) or a com-
bination of both (Roux-en-Y gastric bypass [RYGB]). It is
now known that calorie malabsorbtion does not occur (with
the exception of the biliopancreatic diversion); however the
effects of bariatric procedures are not entirely due to the
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reduced stomach volume. A number of studies have shown
that changes in gut hormone concentrations may partially
explain the weight loss following bariatric surgery. The
purpose of this review is to explore this interaction.
Gut hormones
The discovery of appetite-signaling peptides, gut hormones,
has led to the establishment of the gut–brain axis. In this
article anorexigenic and orexigenic hormones are reviewed
in order of the level of evidence supporting their role after
bariatric surgery, namely: glucagon-like peptide-1 (GLP-1),
peptide YY (PYY), ghrelin, cholecystokinin (CCK), glu-
cose-dependent insulinotropic polypeptide (GIP), oxynto-
modulin (OXM), and pancreatic polypeptide (PP).
Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1), together with PYY and
OXM, is released postprandially by intestinal endocrine L-
cells [9]. These peptides act synergistically and cause
satiety. Both GLP-1 and PYY inhibit food intake additively
[10]. The former plays an important role in glucose
metabolism, acting as an incretin by augmenting the insulin
response to nutrients and also slowing gastric emptying and
inhibiting the glucagon secretion in a glucose-dependent
manner [11]. Incretins are hormones that are secreted from
the gastrointestinal tract into the circulation in response to
nutrient ingestion that enhances glucose-stimulated insulin
secretion [11]. In addition, GLP-1 also promotes satiety,
and sustained GLP-1–receptor activation is associated with
weight loss in both preclinical and clinical studies [11].
In animal models GLP-1 has been shown to expand islet
mass by stimulating pancreatic b-cell proliferation and
induction of islet neogenesis, and it also promotes cell dif-
ferentiation, from exocrine cells or immature islet progenitors
toward a more differentiated b-cell phenotype [12]. Further-
more GLP-1 exerts antiapoptotic actions in vivo, resulting in
preservation of b-cell mass [12]. The postprandial GLP-1
response is enhanced after RYGB, but not after LAGB in a
similar manner to the PYY response [13, 14]. GLP-1, both
fasting and postprandial, is elevated 20 years after JIB [15].
A recent study by Laferre`re et al. showed early after
RYGB, the greater GLP-1 and GIP release and improvement
of incretin effect are related not to weight loss but rather to
the surgical procedure itself, suggesting that this could
contribute to improved glycemic control after RYGB [16].
Peptide YY
Peptide YY is a 36-amino-acid peptide, and a member of
the PP-fold peptide family. The letter Y is the abbreviation
for tyrosine. The peptide is released postprandially by
intestinal endocrine L-cells in proportion to the calories
ingested, but it is not altered by gastric distension [17, 18].
It is present throughout the intestinal tract, with higher
concentrations in the distal segments [17], and it has an
inhibitory effect on gastrointestinal mobility as well as the
gastric, pancreatic, and intestinal secretion [19, 20]. It has
been shown to induce satiety and reduce food intake in
both the obese and the non-obese [21, 22]. Furthermore
obese individuals have a PYY deficiency that would reduce
satiety and could thus reinforce obesity [23].
Korner et al. showed an exaggerated postprandial PYY
response after RYGB, which may contribute to weight loss
and to the ability of an individual to maintain weight loss
postoperatively [24]. Another study on both a human model
of RYGB and a rodent model of jejuno-intestinal bypass
(JIB) demonstrated an increased postprandial PYY response
favoring enhanced satiety [13]. Mechanistic experiments on
the animal model suggested an additional to food-intake
effect of RYGB on weight loss, raising the possibility of
enhanced energy expenditure [13]. A prospective study of
patients undergoing RYGB confirmed an increased post-
prandial PYY response associated with increased satiety
observed as early as one month after operation [25]. The
authors suggested that a gut adaptive response occurs after
RYGB, which promotes satiety and is partially responsible
for the weight loss following RYGB [25].
A recent study demonstrated a causality link between
the exaggerated PYY and GLP-1 response and the
enhanced satiety after RYGB [14]. In that study increased
postprandial PYY and GLP-1 responses were seen within
days after RYGB, prior to any significant weight loss.
Furthermore, in a comparison of good versus poor
responders to RYGB in terms of weight loss, suboptimal
PYY and GLP-1 postprandial responses were associated
with the poor responders. Finally, in a randomized double-
blind saline controlled study of patients after RYGB and
LAGB, inhibition of the gut hormone response with oc-
teotride (a somatostatin analog) increased food intake in
the RYGB group but not in the LAGB group, suggesting
that gut hormones might play a key role in the reduced food
intake after RYGB [14].
Comparison of patients after LAGB with patients after
RYGB showed a reduced PYY response in the LAGB
group in a number of studies [13, 25, 26]. However a
prospective study of patients undergoing vertically banded
gastroplasty (VBG) compared to non-obese controls dem-
onstrated significantly lower PYY levels in the preopera-
tive, obese group [27]. This difference was eliminated after
VBG as PYY levels gradually increased to non-obese
levels [27]. In a recent double-blind comparison of LSG
and RYGB, PYY levels, both fasting and postprandial,
were equally increased following the two procedures [28].
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Appetite suppression, as well as weight loss was greater in
the LSG group, allowing the authors to hypothesize that the
sustained ghrelin reduction after LSG acts additively to the
PYY response to suppress appetite [28]. This is supported
by a recent animal study reporting that ghrelin attenuates
the anorectic effect of PYY and GLP-1 in a dose-dependent
manner [29].
Ghrelin
Ghrelin is a 28-amino acid peptide produced from the
fundus of the stomach and the proximal intestine [30, 31].
It is the only known orexigenic gut hormone. Central and
peripheral administration leads to increased food intake
[32, 33]. Ghrelin levels increase prior to meals and are
suppressed postprandially in proportion to the amount of
calories ingested, suggesting a possible role in meal initi-
ation [34, 35]. The 24-h profile of ghrelin increases fol-
lowing diet-induced weight loss, supporting the hypothesis
that ghrelin has a role in the long-term regulation of body
weight [36]. Obese individuals have lower fasting ghrelin
levels, and significantly reduced postprandial ghrelin sup-
pression compared to normal weight individuals [37].
The gene that encodes ghrelin is also responsible for the
encoding of another peptide named obestatin [38]. The role
of obestatin is currently controversial, although it might
have a role as an anti-appetite agent [38–40].
A landmark study by Cummings et al. showed a pro-
found suppression of ghrelin levels (24-h profile) following
RYGB [36]. However the data published since are heter-
ogeneous, with studies showing decreased fasting and
postprandial[41, 42], unchanged fasting and postpran-
dial[14, 43, 44], and increased fasting ghrelin levels after
RYGB [45, 46]. The reason for this inconsistency is
unclear, although multiple theories have been proposed. A
study that investigated the intraoperative changes in the
ghrelin levels during RYGB showed that complete division
of the stomach, forming a vertical pouch, contributes to the
decline in circulating ghrelin levels [47]. It is known that
an intact vagus nerve is required for ghrelin to have an
appetite effect [48]. Technical differences in the procedure
with regard to preservation of the vagus nerve might be
responsible for the differing effects, as shown by a study
that demonstrated a decrease in ghrelin levels on the first
postoperative day after RYGB, followed by an increase to
preoperative levels at 1 month and a further increase at
12 months [49]. An alternative explanation has been pro-
posed, suggesting that the different construction of the
pouch might be responsible: with a vertical pouch, ghrelin-
producing cells are more likely to be excluded than with a
horizontal pouch [50]. Finally, hyperisulinemia and insulin
resistance are associated with ghrelin suppression in obese
individuals [51]. Therefore preoperative differences in
these parameters, as well as differences in the postoperative
improvement, may cause this inconsistency.
A study of patients prior to and 5 days and 2 months after
BPD showed a similar response, with an initial reduction in
fasting ghrelin followed by a return to the preoperative
levels when food consumption resumed to almost preoper-
ative levels [52]. This finding supports the hypothesis that
although the primary source of ghrelin is the gastric mucosa,
small intestinal nutrient exposure is sufficient for food-
induced plasma ghrelin suppression in humans, and gastric
nutrient exposure is not necessary for suppression [53].
Schindler et al. showed an increase in fasting ghrelin
accompanied by a paradoxical decrease in hunger after
LAGB, suggesting that weight loss is independent of cir-
culating plasma ghrelin and relies on changes in eating
behavior induced by gastric restriction [54]. Comparative
studies of RYGB and restrictive procedures (LAGB and
VBG) demonstrated both increased fasting ghrelin [55] and
a blunted postprandial suppression of ghrelin in the
restrictive procedures [25, 56].
Laparoscopic sleeve gastrectomy is a relatively new
bariatric operation that was designed as a restrictive pro-
cedure. However, recent studies challenge this classifica-
tion, showing accelerated gastric emptying after LSG [57].
The fact that the fundus of the stomach, the main location
of ghrelin-producing cells, is excluded in the LSG proce-
dure led to speculation that ghrelin could play a role in the
mechanism of action. Two studies confirmed a decrease in
fasting ghrelin levels after LSG [58, 59]. A recent pro-
spective, double-blind study comparing RYGB and LSG
confirmed a significant postprandial suppression of ghrelin
postoperatively, whereas there was no change in the RYGB
group [28]. In the same study the marked suppression of
ghrelin levels after LSG was associated with greater
appetite reduction and excess weight loss during the first
postoperative year compared to RYGB [28].
The role of ghrelin in the success of bariatric surgery
remains to be further elucidated. However, a review of the
available data by Aylwin showed no correlation between
ghrelin suppression and the degree of success in terms of
weight loss, suggesting its role is only partial [60].
Cholecystokinin
Cholecystokinin (CCK) was the first gut peptide investi-
gated for its role in appetite control. It is secreted by I cells
located in the mucosa of the duodenum, jejunum, and
proximal ileum in response to a meal. The peptide has a
key regulatory role in the gut function: It has been impli-
cated in gastric emptying and distension, gallbladder con-
traction, pancreatic secretion, and intestinal motility [61].
In addition it is involved in the regulation of food intake by
inducing satiety following a meal [62].
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No changes in the CCK response to a meal have been
detected after RYGB or VBG in some studies, suggesting
that CCK is not a mediator of appetite control and weight
loss after bariatric surgery [62, 63]. However, in a different
study eight subjects were studied before and after VBG,
and six healthy lean volunteers were used as controls.
Although there were no differences between the two groups
in terms of basal CCK levels, the peak of CCK after the
meal was significantly higher in obese patients after VBG
than before VBG and when compared with the control
group [64]. These changes could contribute to the satiety
effects of gastric restrictive operations [64].
Glucose-dependent insulinotropic peptide or gastric
inhibitory peptide
Glucose-dependent insulinotropic peptide (GIP), also
known as gastric inhibitory peptide, is like GLP-1 in that it
has an incretin effect. The common actions shared by GIP
and GLP-1 on islet b-cells occur through structurally dis-
tinct yet related receptors. In addition, GIP promotes
energy storage via direct actions on adipose tissue and
enhances bone formation via stimulation of osteoblast
proliferation and inhibition of apoptosis [11].
Rubino et al. studied the GIP response in diabetic and
nondiabetic patients undergoing RYGB preoperatively and
3 weeks postoperatively. The RYGB procedure reduced
GIP levels in diabetic patients, whereas no changes in GIP
levels were found in the nondiabetics [64]. A study of
patients undergoing JIB demonstrated elevated postpran-
dial GIP levels postoperatively, whereas another study
demonstrated a reduction in GIP [15, 65]. A reduction in
GIP levels has also been detected after BPD [66].
Enteroglucagon and oxyntomodulin
Oyyntomodulin (OXM) belongs to the enteroglucagon
family of peptides [12]. In humans, intravenous OXM
infusion acutely decreases hunger and single-meal food
intake, without reducing the palatability of the meal or
causing nausea [67]. Furthermore, in a 4-week, double-
blind randomized human trial, repeated OXM injections
decreased body weight by 0.5 kg/week more than placebo
[68]. In another study, the enteroglucagon response to
glucose increased markedly after RYGB [62]. This
increase in enteroglucagon occurred at the same time as
development of dumping symptoms, which occurred
exclusively in RYGB patients after glucose intake.
Therefore enteroglucagon was proposed as a marker of the
dumping syndrome after RYGB. Furthermore enterogluc-
agon has been shown to be elevated following JIB and
BPD [66].
Pancreatic polypeptide
Pancreatic polypeptide (PP) is a gut hormone released from
the pancreas in response to ingestion of food. It has been
shown to be reduced in conditions associated with
increased food intake and elevated in anorexia nervosa.
Infusion of PP causes a sustained decrease in both appetite
and food intake [69].
No changes in PP were seen after RYGB, LAGB, or JIB
[13, 49, 65], suggesting that PP levels are not significantly
influenced by bariatric surgery.
The changes in gut hormones after RYGB, the com-
monest bariatric operation are summarized in Table 1.
Conclusions
Gut hormones are affected by bariatric surgical procedures
in multiple ways. It is impossible to approach bariatric
surgery outside the context of gut hormones and vice versa.
More importantly, on many occasions, the mode of action
of the bariatric operations is associated with gut hormone
pathways. Research on this interaction leads not only to
better understanding of these operations, but also offers
new insight into the regulatory systems of metabolism.
Further research will lead to refinement of the current
procedures, perhaps aiming at specific metabolic pathways.
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Remission of Type 2 Diabetes After Gastric Bypass and Banding
Mechanisms and 2 Year Outcomes
Dimitrios J. Pournaras, MRCS∗†, Alan Osborne, MRCS∗, Simon C. Hawkins, MRCS∗, Royce P. Vincent, MSc†,
David Mahon, MD, FRCS∗, Paul Ewings, PhD∗, Mohammad A. Ghatei, PhD†, Stephen R. Bloom, FRCP, DSc†,
Richard Welbourn, MD, FRCS∗, and Carel W. le Roux, MRCP, PhD†
Objective: To investigate the rate of type 2 diabetes remission after gastric
bypass and banding and establish the mechanism leading to remission of type
2 diabetes after bariatric surgery.
Summary Background Data: Glycemic control in type 2 diabetic patients is
improved after bariatric surgery.
Methods: In study 1, 34 obese type 2 diabetic patients undergoing either
gastric bypass or gastric banding were followed up for 36 months. Remission
of diabetes was defined as patients not requiring hypoglycemic medication,
fasting glucose below 7 mmol/L, 2 hour glucose after oral glucose tolerance
test below 11.1 mmol/L, and glycated haemoglobin (HbA1c) <6%. In study
2, 41 obese type 2 diabetic patients undergoing either bypass, banding, or very
low calorie diet were followed up for 42 days. Insulin resistance (HOMA-IR),
insulin production, and glucagon-like peptide 1 (GLP-1) responses after a
standard meal were measured.
Results: In study 1, HbA1c as a marker of glycemic control improved by
2.9% after gastric bypass and 1.9% after gastric banding at latest follow-up
(P < 0.001 for both groups). Despite similar weight loss, 72% (16/22) of
bypass and 17% (2/12) of banding patients (P= 0.001) fulfilled the definition
of remission at latest follow-up. In study 2, within days, only bypass patients
had improved insulin resistance, insulin production, and GLP-1 responses (all
P < 0.05).
Conclusions: With gastric bypass, type 2 diabetes can be improved and even
rapidly put into a state of remission irrespective of weight loss. Improved
insulin resistance within the first week after surgery remains unexplained, but
increased insulin production in the first week after surgery may be explained
by the enhanced postprandial GLP-1 responses.
(Ann Surg 2010;252:966–971)
T ype 2 diabetes mellitus is exponentially increasing because of thecurrent epidemic of obesity. Both these lethal conditions threaten
to overwhelm healthcare resources.1 The most effective treatment for
both type 2 diabetes and obesity is metabolic surgery.2,3 The 2 most
commonly performed metabolic surgery operations are the Roux-
en-Y gastric bypass described in 1967 and laparoscopic gastric band-
ing described in 1993.4 The vast improvement in glycemic control and
the concept of remission of type 2 diabetes aftermetabolic surgery has
been established, but the underlying mechanism remains unclear.3,5
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A meta-analysis reported improved glycemic control and re-
mission of type 2 diabetes in 83.8% of patients following gastric
bypass and 47.8% following gastric banding.3,6,7 However, data com-
paring the 2 operations in the same center are limited, and definitions
of remission are inconsistent between studies. The likely reasons for
this include strong surgeon, patient or cultural preference for one
procedure over another. This may explain the lack of published ran-
domized controlled studies comparing different types of operations.
The improved glycemic control after gastric banding depends
on weight loss, but after gastric bypass surgery this improvement
occurs before weight loss. Two mechanisms have been proposed to
explain this rapid normalization of glucose control after gastric by-
pass. The first suggests that exclusion of the duodenum and proximal
jejunum may reduce insulin resistance.8,9 The second involves ex-
aggerated responses from the distal small bowel to nutrients. In the
latter hypothesis, gut hormones produced in the distal small bowel
such as glucagon-like peptide 1 (GLP-1) may act as incretins stim-
ulating the beta cells in the pancreas to restore normal first phase
insulin responses.10
We aimed to investigate the improved glycemic control and rate
of remission of type 2 diabetes after gastric bypass and gastric banding
in a homogeneous population, using the same method for assessment
after each operation. Moreover, to explore potential mechanisms, we
measured changes in insulin resistance and insulin production in the
first week after surgery to test the hypothesis that GLP-1 contributes
to the improved glycemic control.
METHODS
All human studies were performed according to the principles
of the Declaration of Helsinki. The Somerset Research and Ethics
committee approved the study (LREC Protocol Number: 05/Q2202/
96). Exclusion criteria included pregnancy, substance abuse, more
than 2 alcoholic drinks per day. Written informed consent was ob-
tained from all participants.
Study 1: Glycemic Control After Gastric
Surgery Study
Selection criteria for study 1 included patients with type 2
diabetes who chose to have either gastric bypass or gastric banding
operations. This was not a randomized study, but data were collected
prospectively on 34 consecutive patients with type 2 diabetes who
had surgery by the same surgeon in 1 center over a 3-year period.
All patients were given unbiased information about both procedures
during the initial assessment by the surgeon. This was accompanied
by a patient information leaflet highlighting the advantages and dis-
advantages of banding and bypass. Also, patients were encouraged
to attend patient support groups and to review available information
on the internet with the objective of ensuring adequate information
about diabetes remission, complications, and long-term postoperative
diet. Patients’ own preferences, based on their under-under-standing
of what life would be like after the surgery, determined their opera-
tion. Fasting glucose, HbA1c, and dosage of antidiabetic medication
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were recorded preoperatively and during follow-up at 3, 6, 12, 18, 24,
and 36 months. In our study, we defined remission of type 2 diabetes
when all the following criteria were met:
1. Fasting plasma glucose below 7 mmol/L in the absence of medical
treatment for at least 3 days.
2. A 2-hour plasma glucose below 11.1 mmol/L following an oral
glucose tolerance test (OGTT) as specified by the World Health
Organisation.11
3. Glycated haemoglobin (HbA1c) below 6% after 3 months of last
hypoglycemic agent usage. This measurement was added as it is
often used in the surgical literature.3,6,7
All operations were performed laparoscopically by 1 surgeon
(R.W.) between January 2004 and January 2007. At submission, the
data from the latest follow-up which ranged from 24 to 36 months
were obtained. For the gastric bypass (n = 22), an isolated lesser
curve-based, 15 to 20 mL gastric pouch was created, and a retrocolic
antegastric Roux limbwasmade 100-cm long for patients with a body
mass index (BMI) equal to or less than 50 kg/m2 and 150-cm long
for patients with BMI of more than 50 kg/m2.12 The biliopancreatic
limb was 25 cm for all patients.12 For gastric banding (n = 12), the
Swedish Adjustable Gastric band (Ethicon Endo-Surgery) and the
LAP-BAND (Allergan) bands were used, and the pars flaccida dis-
section technique with gastro-gastric tunnelating sutures was used.6
No differences in outcomes such as weight loss, hospital stay, or
complications were observed between the 2 band types in our overall
series of 107 patients or in this series of 12 patients reported here.
Using an enhanced recovery protocol, postoperatively, patients were
allowed free fluids on return to the ward, and diet was recommenced
when tolerated for both operations. The recommended postoperative
diet for the first week was the same for the patients with banding
and bypass. These diets recommend approximately 700 to 1000 kcal
per day. Following gastric banding, patients were seen monthly and
adjustments were performed until optimal reduction in hunger or re-
striction was obtained. Patients were seen at least 6 times in the first
year and then yearly thereafter.
Study 2: Mechanism of Glycemic Control Study
The selection criteria for these study groups included patients
with (a) type 2 diabetes and obesity undergoing gastric bypass (n =
17), (b) type 2 diabetes and obesity undergoing gastric banding (n =
9), (c) type 2 diabetes and obesity undergoing very low calorie diet
for 1 week (n = 15), and (d) obesity without insulin resistance under-
going gastric bypass (n= 5). A 2-week preoperative diet of 1000 kcal
was used in all patients before surgery. For the patients with type 2
diabetes, the glycemic control was optimized with pharmacotherapy
and lifestyle changes for 6 months before surgery. None of the pa-
tients was on insulin during the study, and there was no difference in
the usage of hypoglycemic agents between the groups with diabetes.
Patients were studied immediately preoperatively and at 2, 4, 7, and
42 days after surgery, with the exception of the very low calorie diet
group. These patients were studied at day 0, 2, 4, and 7. Following a
12-hour fast, a venous catheter was placed and blood was obtained.
In patients who had bypass surgery, further collections of blood in
tubes containing Ethylenediaminetetraacetic acid (EDTA) and apro-
tinin were then taken at 15, 30, 60, 90, 120, 150, and 180minutes after
a 400 kcal standard meal. Samples were immediately centrifuged and
stored in a −80◦C freezer until analyzed with an established GLP-1
assay,13 automated glucose analyzer (Abbott laboratories, Chicago,
IL), and an automated insulin assay (Abbott laboratories, Chicago,
IL). Delta insulin was defined as the difference between a 0 minute
and 15 minute insulin measurement.14
Results were analyzed using SPSS statistical software (SPSS
Inc, Chicago, IL). Data are either expressed as mean (standard devi-
ation) or median (range). Fisher exact test was used for categorical
data. Time taken to diabetes remission was compared between opera-
tive groups by log-rank test. ANOVA with post hoc Dunnett test was
used for HOMA-IR, delta insulin, and GLP-1 responses. The Mann-
Whitney U test was used for nonparametric demographic data. The
unpaired t test was used for parametric demographic data. Results
were considered significant if P < 0.05.
RESULTS
Study 1: Glycemic Control After Gastric Surgery
At Musgrove Park Hospital, similar numbers of diabetic and
nondiabetic patients had gastric bypass (n= 109) and gastric banding
(n = 107) between January 2004 and January 2007, supporting the
premise that the surgeon did not have a preference. A total of 34
consecutive patients with type 2 diabetes requiring hypoglycemic
medication were identified preoperatively (16%). Of the 34 pa-
tients, 22 patients underwent gastric bypass and 12 underwent gastric
banding.
Surgery was performed between January 2004 and January
2007 and at submission, minimum follow-up was 24 months (range,
24–36 months), and no patient was lost to follow-up. There were
no significant differences in the demographic characteristics, dura-
tion of diabetes, or pre- and postoperative BMI between the groups
(Table 1). Patients remained obese postoperatively with BMIs of 33
(5.2) kg/m2 for gastric bypass and 32.6 (5.1) kg/m2 for gastric band-
ing patients. There were no significant differences in weight at any
time point during the 3-year period (Fig. 1). Twelve of the 22 gastric
bypass patients (54%) and 4 of the 12 gastric banding patients (33%)
required insulin therapy preoperatively (P = 0.04). There was one
early complication in a gastric bypass patient who recovered after
requiring a reoperation on postoperative day 1 for a small bowel en-
terotomy. The patient was discharged fully recovered after 114 days
and the case was described elsewhere.15 Diabetic gastric bypass and
gastric banding patients achieved less weight loss compared with the
nondiabetic patients in our overall series (data not shown). There
was no difference in median length of stay for gastric bypass be-
tween patients with diabetes (n= 22, 4 days range, 1–114) or without
diabetes (n= 87, 3 days range, 1–44) (P= 0.47). The nondiabetic pa-
tient that required hospital admission for 44 days was also described
TABLE 1. Study 1: Patient Characteristics Presented as
Mean (Standard Deviation) Except Where the Median
(Range) is Indicated
Bypass Banding P ∗
Age (yr) 46.0 (9.6) 47.4 (10.9) 0.71
Preoperative weight (kg) 137.4 (22.9) 137.7 (31.8) 0.97
Preoperative BMI 47.4 (7.2) 47.1 (7.1) 0.90
Preoperative HbA1c 9.1 (1.9) 8.4 (1.7) 0.29
Duration of diabetes (yr) 7.0 (1−18) 5.5 (1−14) 0.61
Proportion on insulin 12/22 (54%) 4/12 (33%) 0.04
preoperatively (%)
Follow-up (mo) 29.5 (8.0) 33.0 (7.5) 0.21
% Total weight loss 29.5 (8.4) 28.5 (10.0) 0.76
% Excess BMI loss 63.3 (30.8−103.2) 62.3 (45.1−105.9) 0.92
BMI at follow-up 33.0 (5.2) 32.6 (5.1) 0.80
HbA1c at follow-up 6.2 (1.2) 6.5 (1.2) 0.59
Fisher exact test was used for categorical data.
∗P < 0.05 by t test; or Mann - Whitney where median is erported.
BMI indicates body mass index. HbAlc indicates glycated haemoglobin.
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elsewhere and was discharged fully recovered following treatment for
an anastomotic leak.15 For gastric banding, there was no difference
in median length of stay between patients with diabetes (n = 12,
1 day range, 1–2) or without diabetes (n = 95, 1 day range, 1–3) (P=
0.68). Diabetic and nondiabetic patients after bypass stayed longer in
hospital than patients after banding (P < 0.001).
HbA1c improved by 2.9% after gastric bypass and 1.9% after
gastric banding (P < 0.001 compared with preoperatively for both
groups), reflecting weight loss, the additional effect of bypass, and the
hypoglycemic medication, respectively. The fasting plasma glucose
results were 6.6 (2.7) mmol/L (2 hour post-OGTT glucose 8.1 [5.8])
for the gastric bypass group and 7.3 (2.4) mmol/L (2 hour post-OGTT
glucose 11.8 [3.4]) for the gastric banding group (P= 0.43 for fasting
and 0.052 for post-OGTT glucose) at latest followup. The time to
diabetes remission was significantly shorter for gastric bypass than
gastric banding with a hazard ratio of 8.2 (P= 0.001, 95% confidence
interval, 1.8–36.7). At 1-year follow-up (Fig. 2), 15 of the 22 gastric
bypass patients (68%)were in a state indistinguishable from remission
compared with no gastric banding patients (P < 0.001), whereas
FIGURE 1. Weight loss over time for gastric bypass
(n = 22) and gastric banding (n = 12) patients over
a 3-year period. No differences were detected in
weight loss at 3, 6, 12, 24, and 36 months between
bypass and banding.
FIGURE 2. Kaplan-Meier curve for time to remission
of type-2 diabetes in patients who had gastric
bypass (solid line) or gastric banding (broken line)
over a 3-year period. Follow-up at each time point
was the same as in Figure 1.
the weight loss at 1 year was not significantly different between
bypass, 25.2% (8.2) and banding patients, 20.4% (9.1), (P= 0.14). At
latest follow up, 16 gastric bypass patients (72%) were in remission
compared with 2 gastric band patients (17%) (P = 0.01), whereas
the weight loss was not significantly different between bypass and
banding patients 29.5% (8.4) versus 28.5(10), P = 0.76.
Study 2: Mechanism of Glycemic Control Study
The demographic characteristics of the patients are shown in
Table 2. None of the bypass, banding, or diet patients required insulin
before or after the interventions. In patients with type 2 diabetes,
insulin resistance (measured by HOMA-IR) improved within 7 days
after gastric bypass, whereas after gastric banding or a 1000 kcal
diet HOMA-IR remained unchanged (Fig. 3). Although the insulin
resistance in the patients with diabetes and gastric bypass was reduced
by 44% over the first week, the HOMA-IR remained unchanged
at normal levels in those without diabetes who had gastric bypass
(Fig. 3). In contrast, delta insulin increased in both groups of gastric
bypass patients, with or without type 2 diabetes, as early as 2 days
Copyright © 2010 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
968 | www.annalsofsurgery.com C© 2010 Lippincott Williams & Wilkins
Annals of Surgery  Volume 252, Number 6, December 2010 Diabetes Remission After Gastric Bypass
TABLE 2. Study 2: Demographics of Patients Undergoing Standard Meal Tests
Preoperatively and at Day 2, 4, 7, and 42
Diet + DM Band + DM Bypass + DM Bypass Non DM P
Number 15 9 17 5
Age (yr) 43.7 (10) 48.1 (8.7) 48.3 (8.6) 42.4 (6.9) NS
Preoperative weight (kg) 139.0 (37.5) 129.5 (28.2) 138.9 (35.5) 143.8 (21.6) NS
Preoperative BMI 46.9 (8.1) 43.5 (11.7) 48.0 (5.7) 52.2 (3.3) NS
Preoperative glucose 5.9 (1.1) 6.1 (1.2) 7.1 (2) 5.9 (1.1) NS
Preoperative HOMA-IR 7.1 (3) 8.8 (9.6) 9.2 (7.8) 2.1 (0.4) <0.05
Comparisons are made between patients with diabetes (DM) who had very low calorie diet, gastric banding, gastric
bypass or patients who did not have diabetes but underwent gastric bypass.
BMI indicates bodymass index. NS indicates non-significant. HOMA-IR indicates homeostatic model assessment insulin
resistance.
FIGURE 3. Progression of insulin resistance in patients with
type 2 diabetes following a 1000 kcal diet with no surgery
over 7 days (n = 15) and gastric band (n = 9), gastric bypass
(n = 17) and nondiabetic patients following gastric bypass
(n = 5) over a period of 42 days. The solid line indicates the
level at which HOMA-IR is considered to indicate insulin
resistance. ∗P < 0.05 compared with preoperative state. #P <
0.05 compared with gastric banding at same time point. †P <
0.05 compared with very low calorie diet at same time point.
after surgery (Fig. 4). This increase is mirrored for GLP-1 in both
bypass groups (Fig. 5). Fasting levels of GLP-1 in the group with
type 2 diabetes who had gastric bypass did not change over the first
42 days (data not shown, P = 0.44).
DISCUSSION
This study is a direct comparison of the improved glycemic
control and “remission” rate for type 2 diabetes in the 2 commonest
metabolic operations performed in a single center serving a homo-
geneous population. In study 1, the bypass and banding groups had
similar age, sex, and BMIs pre- and postoperatively. The striking
finding was that at latest follow-up, the HbA1c improved by 1.9%
or more in both groups, whereas the proportion achieving fasting
plasma glucose concentrations below 7 mmol/L (off all hypoglyce-
mic medication) was much higher for gastric bypass (72%) than for
gastric banding (17%). In addition, the rate of “remission” over time
was markedly quicker for the gastric bypass. The latter 2 findings
FIGURE 4. Changes in delta insulin are shown after gastric
bypass in patients with type 2 diabetes (n = 17) and without
type 2 diabetes (n = 5), defined as the difference between
fasting and 15 minutes postprandial insulin. ∗P < 0.05
compared with preoperative state for both groups.
strongly suggest that the rapidly improved glycemic control cannot
be attributed to weight loss alone.
In addition to these findings, in study 2we found an unexpected
improvement in insulin resistance of 44% within 7 days after gastric
bypass. Insulin resistance after laparoscopic gastric banding or the
very low calorie diet did not change within 7 days. Furthermore,
patients without diabetes undergoing gastric bypass did not have any
change in their insulin resistance.
Insulin production as measured by delta insulin between 0
and 15 minutes also increased after gastric bypass in all patients
irrespective of whether they had type 2 diabetes. Both responses
of GLP-1 and delta insulin reached significance within 2 days after
surgery. Thus, it is possible that the changes in insulin production
are associated with the enhanced GLP-1 responses. However, fasting
GLP-1 levels remain unchanged within the first 42 days.
The patients participating in study 2, the mechanism of
glycemic control study, did not require insulin therapy before surgery.
The patients also had good glycemic control following a 6monthmed-
ical optimization program before the study and were thus less likely
to be glucotoxic. This may explain why changes in diet and calorie
consumption alone in the banding and very low calorie diet groups
did not change HOMA-IR.
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FIGURE 5. Area under the curve over a 3-hour period GLP-1
after gastric bypass in patients with type 2 diabetes (n = 17)
and without type 2 diabetes (n = 5) after a 400 kcal meal.
∗P < 0.05 compared with preoperative state for both groups.
Other direct comparisons of glycemic control between early
changes after gastric bypass and gastric banding also favored gas-
tric bypass, suggesting that there may be a different mechanism,
independent of weight loss, which explains diabetes remission after
bypass.16,17 Although in study 1, the glycemic control study, the remis-
sion rate for the gastric bypass group is comparable with other studies,
the remission rate for the gastric banding groupwas lower.4–7,16–20 The
differences in our results could be attributed to the way we defined re-
mission of type 2 diabetes as fasting plasma glucose below 7 mmol/L
and 2 hour post oral glucose tolerance test plasma glucose below
11.1 mmol/L with a HbA1c below 6% off all hypoglycemic agents,
which ismore stringent than previous studies.5,14,17–20 Moreover, study
1, the glycemic control study, only included patients with type 2 di-
abetes requiring medication of which a substantial portion required
insulin. In addition, the duration of diabetes before surgery ranged
up to 18 years with a median of 7 years in the bypass group and
5.5 years in the banding group. Prolonged duration of disease has
been associated with poorer remission rates of diabetes after bariatric
surgery.7 Also, the smaller proportion of gastric banding patients re-
quiring insulin in our study might be expected to favor the banding
group.
Schauer et al reported inferior weight loss after gastric bypass
in patients with diabetes compared with the overall cohort, for rea-
sons that are not known.3,7 This observation could explain the similar
weight loss between our gastric bypass and banding groups. Further-
more, intensive follow-up with regular band adjustments has been
shown to improve weight loss outcomes.21 This is a possible explana-
tion for the lack of difference in the weight loss between the 2 groups.
Kim et al also reported no difference in weight loss between banding
and bypass in nondiabetic obese subjects.18
Insulin resistance would usually be expected to increase after
major abdominal operations where bowel manipulation and duration
are similar to gastric bypass.22 Previous reports suggested that the
effect of gastric bypass on glucose metabolism may be partly because
of endocrine mechanisms.8,23 A recent study showed a reduction in
insulin resistance following both band and diet in addition to bypass.24
However, the earliest time point patients were studied was 4 weeks
postintervention, and therefore the insulin resistance changes were
attributed to weight loss.24
Data published from our unit has shown that delta insulin was
unchanged after 19 months following gastric banding.14 Changes in
responses of the incretin, GLP-1, are associated with the enhanced
delta insulin.25 However, the rapid improvement in insulin resistance
after gastric bypass surgery is observed even if patients are kept nil
by mouth9 and thus is unlikely related to GLP-1, as fasting levels of
GLP-1 did not change in our study.
A limitation of the glycemic control after gastric surgery study
(study 1) is the fact that it was not randomized. Another limitation
was the relatively small groups which may explain the nonsignificant
difference in 2 hour post-OGTT glucose results between the patients
with bands and bypasses. However, the groups were well-matched
and patients selected their own operation without any bias from the
surgeon. For the mechanisms of glycemic control study (study 2),
HOMA-IR was preferred over more invasive techniques, as it has
been used to track changes in insulin resistance over time.26,27 Thus,
our results can now be used to power new randomized controlled trials
using more invasive measurements of insulin resistance. Another
limitation is the number of calories consumed by the bypass and
banding group in the first week postoperatively. These were in the
same order as that of the very low calorie diet group, although it was
not practical to achieve an identical match.
In conclusion, gastric bypass and gastric banding lead to vastly
improved glycemic control, whereas type 2 diabetes is more likely to
go into a state indistinguishable from remission after gastric bypass
than gastric banding, irrespective of weight loss. Increased insulin
production in the first week after gastric bypass may be explained
by the enhanced postprandial GLP-1 responses. However, the mech-
anism of the rapidly improved insulin resistance after gastric bypass
remains unclear. Even despite our imperfect understanding, the data
suggest that sustained improvements in glycemic control and even
remission of type 2 diabetes can now be considered a realistic option
following metabolic surgery.
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Abstract
Background Bariatric surgery is the most effective treat-
ment option for obesity, and gut hormones are implicated in
the reduction of appetite and weight after Roux-en-Y
gastric bypass. Although there is increasing interest in the
gut hormone changes after gastric bypass, the long-term
changes have not been fully elucidated.
Methods Thirty-four participants were studied cross-
sectionally at four different time points, pre-operatively
(n=17) and 12 (n=6), 18 (n=5) and 24 months (n=6) after
laparoscopic Roux-en-Y gastric bypass. Another group of
patients (n=6) were studied prospectively (18–24 months).
All participants were given a standard 400 kcal meal after a
12-h fast, and plasma levels of peptide YY (PYY) and
glucagon-like peptide-1 (GLP-1) were correlated with
changes in appetite over 3 h using visual analogue scores.
Results The post-operative groups at 12, 18 and 24 months
had a higher post-prandial PYY response compared to pre-
operative (p<0.05). This finding was confirmed in the
prospective study at 18 and 24 months. There was a trend
for increasing GLP-1 response at 18 and 24 months, but
this did not reach statistical significance (p=0.189) in the
prospective study. Satiety was significantly reduced in the
post-operative groups at 12, 18 and 24 months compared to
pre-operative levels (p<0.05).
Conclusions Roux-en-Y gastric bypass causes an enhanced
gut hormone response and increased satiety following a
meal. This response is sustained over a 24-month period
and may partly explain why weight loss is maintained.
Keywords Roux-en-Y gastric bypass . RYGB . Gut
hormones . Peptide YY. Glucagon-like peptide-1 . GLP-1
Introduction
Surgical procedures are currently the only effective therapy
for long-term weight loss [1]. There are also profound
effects on obesity-related comorbidities, such as type 2
diabetes, hypertension and sleep apnoea, following bariatric
surgery [2].
Gut hormones cause hunger and satiety effects and thus
have an integral role in appetite regulation. The discovery
of these appetite-signalling peptides, the gut hormones, has
led to the establishment of the concept of the gut–brain
axis. They have been implicated to play an important role
in both weight loss and diabetes improvement after gastric
bypass surgery [3].
Roux-en-Y gastric bypass (RYGB) was designed to
promote weight loss due to a combination of reduced stomach
volume and malabsorption of nutrients. It is now known that
calorie malabsorption does not explain the weight loss;
however the effects of RYGB are not entirely due to the
reduced stomach volume. A number of studies have shown
that changes in gut hormone concentrations may partly
explain the weight loss following gastric bypass surgery.
We have recently demonstrated a causative link between
the exaggerated peptide YY (PYY) and glucagon-like
peptide-1 (GLP-1) response and the enhanced satiety after
RYGB [4]. In that study increased post-prandial PYY and
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GLP-1 responses were seen within days after RYGB, prior
to any significant weight loss. Furthermore in a comparison
of good versus poor responders to RYGB in terms of
weight loss, suboptimal PYY and GLP-1 post-prandial
responses were associated with the poor responders.
Finally, in a randomised double-blind saline controlled
study of patients after RYGB and laparoscopic adjustable
gastric banding (LAGB), inhibition of the gut hormone
response with octeotride (a somatostatin analogue) in-
creased food intake in the RYGB group, but not in the
LAGB group, suggesting that gut hormones might play a
role in the reduced food intake after RYGB [4].
Although there is increasing interest in the gut hormone
changes after gastric bypass, the long-term changes have
not been fully elucidated. The primary aim of this study
was to evaluate the changes in the PYY and GLP-1
response in the first 24 months after gastric bypass.
Materials and Methods
All human studies were performed according to the
principles of the Declaration of Helsinki. The Somerset
Research and Ethics committee approved the study
(LREC Protocol Number: 05/Q2202/96). Exclusion
criteria included pregnancy, substance abuse, more than
two alcoholic drinks per day and aerobic exercise for
more than 30 min three times per week. Written
informed consent was obtained from all participants.
Thirty-four participants were studied cross-sectionally at
four different time points, pre-operatively (n=17) and 12
(n=6), 18 (n=5) and 24 months (n=6) after RYGB. Another
group of patients (n=6) were studied prospectively. Follow-
ing a 12-h fast, a venous catheter was placed and blood was
obtained. Further collections of blood in tubes containing
EDTA and aprotinin were then taken at 15, 30, 60, 90, 120,
150 and 180 min after a 400 kcal standard meal. The 400-
kcal meal macromutrient content was 48.8% carbohydrate,
10.2% protein and 41% fat. Samples were immediately
centrifuged and stored in a −80°C freezer until analysis.
Plasma levels of the gut hormones PYY and GLP-1 were
compared at each time point. Visual analogue scales (VAS)
were used to measure hunger and satiety immediately before
consumption of the meal and at 60, 120 and 180 min later.
Surgical Technique
Laparoscopic Roux-en-Y gastric bypass was performed,
creating an isolated, lesser curve based, 15–20-mL gastric
pouch excluding the fundus [5]. A retrocolic antegastric
Roux limb was made 100 cm long for patients with a body
mass index (BMI) equal to or less than 50 kg/m2 and
150 cm long for patients with BMI of more than 50 kg/m2
[5]. The bilio-pancreatic limb was 25 cm for all patients.
The subjects included in the study had similar outcomes in
terms of excess weight loss compared with the rest of the
surgical cohort as a whole (data not shown).
Hormone Assays
All samples were assayed in duplicate. PYY-like
immunoreactivity was measured with a specific and
sensitive radioimmunoassay, which measures both the
full length (PYY1–36) and the fragment (PYY3–36) [6,
7]. Plasma GLP-1 was measured in duplicate by estab-
lished in-house radioimmunoassay [8, 9].
Statistical Analysis
Patient demographics, BMI and hormone levels are
expressed as means ± standard error of the mean. Values
Group Number (n) Age Sex (no. of women)
Pre-operative 17 47.8±2.0 11
12 months post-operative 6 45.2±4.0 5
18 months post-operative 5 49.6±3.3 3
24 months post-operative 6 43.3±4.1 6
Prospective study 6 47.8±2.0 5
Table 1 Demographic charac-
teristics of patients in cross-
sectional study and prospective
study
Fig. 1 BMI before and 12, 18 and 24 months after gastric bypass
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for the area under the curve were calculated with the use of
the trapezoidal rule. End points were compared with the use
of two-tailed, paired Student t tests or analysis of variance.
Results were analysed using SPSS statistical software
(SPSS Inc., Chicago, IL, USA).
Results
Cross-sectional Study
The characteristics of the four groups can be seen in
Table 1. The BMI in the post-operative groups is
significantly lower than the pre-operative group as expected
(Fig. 1). However there was no significant difference
between the three post-operative groups. The PYY post-
prandial response, measured as area under the curve, was
significantly enhanced in all the post-operative groups
compared to the pre-operative group (Fig. 2). There was a
trend for increased GLP-1 response in the post-operative
groups, but this did not reach statistical significance
(Fig. 3). Satiety as measured with the VAS was significant-
ly increased in all post-operative groups (Fig. 4).
Prospective Study
The characteristics of the patients participating in the
prospective study can be seen in Table 1. The PYY
response was enhanced post-operatively in this group
confirming the findings of the cross-sectional study
(Fig. 1). However the GLP-1 response was not increased
significantly post-operatively (p=0.189).
Fig. 2 The PYY response in the
cross-sectional (12, 18 and
24 months) and prospective
studies (18–24 months combined)
Fig. 3 The GLP-1 response in
the cross-sectional (12, 18 and
24 months) and prospective
studies (18–24 months
combined)
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Discussion
This study confirms that the enhanced PYY post-prandial
response and the associated enhanced satiety following
gastric bypass surgery are sustained for at least 24 months
post-operatively. The findings of the cross-sectional study
are further supported by the findings of the prospective
study. The fact that the above cannot be confirmed for the
GLP-1 response may be due to the small number of patients
included in the prospective study.
This study is one of the very few studies investigating
the PYY post-prandial response for longer than 6 months.
Limitations include the low number of patients and the
cross-sectional design. However the impact of the latter was
minimised with the prospective study. The majority of
participants were female, reflecting the higher number of
females undergoing bariatric surgery.
Korner et al. showed an exaggerated post-prandial
PYY response after RYGB in a study of 12 patients post-
RYGB with a mean post-operative period was 35 months
[10]. Chan et al. also showed an enhanced response in
another cross-sectional study of six patients 18 months
following RYGB [11]. Furthermore a recent study on eight
patients 9–48 months following RYGB confirmed the
above findings [12]. Two prospective studies showed an
increase in the basal (starving) PYY levels following
RYGB [13, 14].
Prospective studies measuring the post-prandial PYY
response in the long term are limited. Borg et al. showed an
increased post-prandial response in a prospective study with
6-month follow-up [15]. The same study suggested that gut
adaptation might play a role in long-term changes in the gut
hormone response. Three studies with 12-month follow-up
showed similar results [16–18]. Our results are in accor-
dance with the aforementioned studies with a minimum
follow-up of 6 months extending up to a year. These results
allow us to hypothesise that the enhanced PYY response is
sustained for at least 24 months and could explain the well-
described long-term weight loss after gastric bypass
surgery.
Similar studies investigated the changes in the GLP-1
response. Cross-sectional studies have indicated an en-
hanced post-prandial response following RYGB [10, 12,
19], while prospective studies with a follow-up extending
to 12 months confirmed this [15, 20–22]. Our findings
showed a trend for an enhanced GLP-1 response post-
operatively, but this did not reach significance.
In conclusion, RYGB leads to an enhanced PYY post-
prandial response and increased satiety. These changes are
sustained over a 24-month period. These findings suggest a
role for gut hormones in the maintenance of weight loss in
the long term.
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Effect of the definition of type II diabetes remission in the
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Background: The American Diabetes Association recently defined remission of type II diabetes as a
return to normal measures of glucose metabolism (haemoglobin (Hb) A1c below 6 per cent, fasting
glucose less than 5·6 mmol/l) at least 1 year after bariatric surgery without hypoglycaemic medication. A
previously used common definition was: being off diabetes medication with normal fasting blood glucose
level or HbA1c below 6 per cent. This study evaluated the proportion of patients achieving complete
remission of type II diabetes following bariatric surgery according to these definitions.
Methods: This was a retrospective review of data collected prospectively in three bariatric centres on
patients undergoing gastric bypass, sleeve gastrectomy and gastric banding.
Results: Some 1006 patients underwent surgery, of whom 209 had type II diabetes. Median follow-up was
23 (range 12–75) months. HbA1c was reduced after operation in all three surgical groups (P < 0·001).
A total of 72 (34·4 per cent) of 209 patients had complete remission of diabetes, according to the new
definition; the remission rates were 40·6 per cent (65 of 160) after gastric bypass, 26 per cent (5 of 19)
after sleeve gastrectomy and 7 per cent (2 of 30) after gastric banding (P < 0·001 between groups). The
remission rate for gastric bypass was significantly lower with the new definition than with the previously
used definition (40·6 versus 57·5 per cent; P = 0·003).
Conclusion: Expectations of patients and clinicians may have to be adjusted as regards remission of type
II diabetes after bariatric surgery. Focusing on improved glycaemic control rather than remission may
better reflect the benefit of this type of surgery and facilitate improved glycaemic control after surgery.
Presented to the Second Annual Scientiﬁc Meeting of the British Obesity and Metabolic Surgery Society, Wakeﬁeld,
UK, January 2011, and published in abstract form as Surg Obes Relat Dis 2011; 7: 247–248.
Paper accepted 4 August 2011
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Introduction
Although the concept of remission of type II diabetes
following gastric bypass and gastric banding surgery has
gained acceptance, the deﬁnitions of remission and cure of
diabetes have been controversial1. Recently a consensus
group comprising experts in endocrinology, diabetes
education, transplantation, metabolism, metabolic surgery
and haematology–oncology proposed new deﬁnitions of
partial and complete remission of type II diabetes1. There
are two important changes. First, a standard metric is
now proposed for reporting rates of diabetes remission,
which may facilitate comparison of future reports. Second,
the new deﬁnitions rely on more stringent criteria for
glycaemic control than previous criteria, so rates of diabetes
remission are likely to be lower2,3. This has implications for
treatment as it suggests that more patients are presumed
to beneﬁt from hypoglycaemic treatment after bariatric
surgery. This study evaluated diabetes remission rates
after gastric bypass, gastric banding and sleeve gastrectomy
according to the 2009 consensus deﬁnitions.
Methods
Data were collected prospectively in three bariatric surgery
centres, two in the UK and one in Norway4. For the UK
 2011 British Journal of Surgery Society Ltd British Journal of Surgery 2012; 99: 100–103
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centres, datawere also collected from theNational Bariatric
Surgery Registry, the result of a collaboration between the
Association of Laparoscopic Surgeons of Great Britain and
Ireland, Association of Upper Gastrointestinal Surgery
and British Obesity and Metabolic Surgery Society. The
analysis was retrospective. Permission was obtained from
the Imperial College Healthcare NHS Trust Clinical
Governance and Patient Safety Committee, and from the
Norwegian Data Protection Agency. The study included
patients with a preoperative diagnosis of type II diabetes
who underwent laparoscopic bariatric surgery between
August 2004 and July 2009. Patients were seen at 6 weeks,
6 months and 12 months after surgery.
Remission of type II diabetes was previously deﬁned
as being off diabetes medication with normal fasting
blood glucose (5·6 mmol/l) or a HbA1c level of less than
6 per cent2,3. This deﬁnition was used in recent meta-
analyses of the effect of bariatric surgery on type II
diabetes2,3. In the 2009 consensus document, partial remis-
sion of diabetes was deﬁned as hyperglycaemia (HbA1c less
than 6·5 per cent and fasting glucose 5·6–6·9 mmol/l) at
least 1 year after surgery in the absence of active hypogly-
caemic pharmacological therapy or ongoing procedures1.
Complete remission was deﬁned as a return to normal mea-
sures of glucose metabolism (HbA1c less than 6 per cent,
fasting glucose below 5·6 mmol/l) at least 1 year after
surgery without hypoglycaemic pharmacological therapy
or ongoing procedures1. Prolonged remission was deﬁned
as complete remission of at least 5 years’ duration and was
outside the remit of the study.
Statistical analysis
Continuous data, expressed as mean(s.d.), were compared
using one-way ANOVA. Fisher’s exact test and the
Freeman–Halton extension of Fisher’s exact test were used
for analysis of categorical data. P ≤ 0·050 was considered
statistically signiﬁcant. Data were analysed using SPSS
version 14 (SPSS, Chicago, Illinois, USA).
Results
A total of 1006 patients underwent bariatric surgery in
the three centres between August 2004 and July 2009.
The prevalence of type II diabetes before surgery was
26·5 per cent (36 of 136 patients) at Oslo University
Hospital, Aker, 16·9 per cent (93 of 551) at Musgrove
Park Hospital and 25·1 per cent (80 of 319) at Imperial
College Hospitals. The 209 patients with type II diabetes
before surgery were included in this study. Their mean
age was 48(10) years and two-thirds were women. The
preoperative body mass index (BMI) was 48(7) kg/m2 and
patients remained obese after surgery, with a postoperative
BMI of 35(7) kg/m2. Table 1 shows patient characteristics
and preoperative insulin use in relation to type of bariatric
procedure. Two patients in the bypass group, and one in
each of the sleeve gastrectomy and gastric banding groups
were taking glucagon-like peptide receptor agonists.
Median follow-up after surgery was 23 (range 12–75)
months. Based on the 2009 consensus criteria, the rate of
complete remission of type II diabetes after all bariatric
surgery procedures was signiﬁcantly lower than when the
previous deﬁnition was used: 34·4 per cent (72 of 209
Table 1 Patient characteristics and rates of remission of type II diabetes after bariatric surgery
All patients
(n = 209)
Gastric bypass
(n = 160)
Sleeve gastrectomy
(n = 19)
Gastric banding
(n = 30) P†
Age (years)* 48(10) 47(9) 53(14) 46(10) 0·041‡
Sex ratio (M : F) 137 (65·6) 105 (65·6) 11 (58) 21 (70) 0·695
Insulin use before surgery 63 (30·1) 51 (31·9) 6 (32) 6 (19) 0·457
BMI (kg/m2)*
Before surgery 48(7) 48(7) 50(8) 47(9) 0·390‡
After surgery 35(7) 34(6) 42(6) 36(8) 0·002‡
Fasting glucose (mmol/l)*
Before surgery 9·6(3·6) 9·8(3·6) 8·9(4·2) 7·4(0·7) 0·144‡
After surgery 6·3(2·6) 6·0(2·1) 8·0(5·3) 6·5(2·1) 0·004‡
HbA1c (%)*
Before surgery 8·0(1·9) 8·1(1·9) 7·5(1·5) 7·7(1·5) 0·388‡
After surgery 6·2(1·2) 6·2(1·2) 6·8(1·7) 6·3(0·7) 0·081‡
Complete remission based on 2009 criteria1 72 (34·4) 65 (40·6) 5 (26) 2 (7) <0·001
Partial remission based on 2009 criteria1 28 (13·4) 25 (15·6) 1 (5) 2 (7) 0·301
Remission based on previous definition2,3 103 (49·3) 92 (57·5) 6 (32) 5 (17) <0·001
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). Rates of remission of type II diabetes were determined a median
of 23 (range 12–75) months after bariatric surgery. BMI, body mass index; Hb, haemoglobin. †One-way ANOVA, ‡except Fisher’s exact test.
 2011 British Journal of Surgery Society Ltd www.bjs.co.uk British Journal of Surgery 2012; 99: 100–103
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Fig. 1 Remission of diabetes after gastric bypass, sleeve
gastrectomy and gastric banding based on the new (2009
consensus statement)1 and the previous2,3 deﬁnitions. P < 0·001
between groups. *P = 0·003 versus previous deﬁnition (one-way
ANOVA)
patients) versus 49·3 per cent (103 of 209) (P = 0·003)
(Table 1). Analysis by procedure showed no signiﬁcant
difference between remission rates based on new and
previous deﬁnitions for either sleeve gastrectomy or gastric
banding. However, for gastric bypass, the remission rate
was signiﬁcantly lower when the 2009 consensus criteria
were used (P = 0·003) (Fig. 1, Table 1). The remission rate
as deﬁned with the new criteria was 43·9 per cent (61 of
139 patients) at 12 months and 40·6 per cent (65 of 160)
at latest follow-up (median 23 months) after gastric bypass
surgery.
Oral hypoglycaemic medication was used by 47
(29·4 per cent) of 160 patients after gastric bypass, 12
(63 per cent) of 19 after sleeve gastrectomy, and 25
(83 per cent) of 30 after gastric banding (P < 0·001).
HbA1c was reduced after operation in all three surgical
groups (P < 0·001). Mean HbA1c levels after surgery
were 6·2(1·2), 6·8(1·7) and 6·3(0·7) per cent respectively
(P = 0·081 between groups).
Preoperative insulin use was associated with a signiﬁ-
cantly lower remission rate following gastric bypass. Of 51
patients in the gastric bypass group who were taking insulin
before operation, only eight achieved remission, compared
with 57 of 109 on oral hypoglycaemic agents (P < 0·001).
Discussion
This study evaluated the effect of the proposed 2009 criteria
on diabetes remission rates after bariatric surgery. At a
median follow-up of 23 months after surgery, rates of
complete remission of type II diabetes were 40·6 per cent
after gastric bypass, 26 per cent after sleeve gastrectomy
and 7 per cent after gastric banding. These rates are
substantially lower than previously reported remission
rates of approximately 83 per cent for gastric bypass,
81 per cent for sleeve gastrectomy and 44 per cent for
gastric banding2–8. Markers of glycaemic control such
as HbA1c were no different between the groups, but there
was a difference in additional hypoglycaemic agents used.
Although the antidiabetic effects of bariatric surgery
are increasingly being recognized, there is scepticism
regarding the role of surgical intervention in the treatment
algorithm of type II diabetes9,10. Establishing realistic
expectations among patients, clinicians and policy-makers
may lead to a more rationalized and equitable use of
bariatric surgery for the management of type II diabetes.
Strategies to achieve this include standardizing deﬁnitions
of the effect of surgery and avoiding the terms ‘cure’
and ‘remission’ unless they are deﬁned carefully. Thus,
the new criteria may emphasize bariatric surgery as the
superior tool for achieving glycaemic control rather than
as a tool for achieving remission from type II diabetes.
The principal beneﬁt of surgery, however, would not be
to improve glycaemic control per se but rather to reduce
microvascular and macrovascular complications associated
with diabetes11,12. The ﬁndings of this study emphasize
the need for intensive follow-up of patients with type II
diabetes following bariatric surgery, in order to review
pharmacological treatment, monitor for complications of
diabetes and ensure that adequate glycaemic control is
achieved.
Limitations of the study include the relatively small
numbers of patients with type II diabetes in the gastric
banding and sleeve gastrectomy groups. Another limitation
is the lack of data on duration of diabetes, which was not
part of the routine data collection in all of the centres.
However, the 20·8 per cent prevalence of diabetes is similar
to that in previously published series2,3. In addition, the
proportion of patients on insulin therapy was similar to
ﬁndings in the UK and Ireland National Bariatric Surgery
Registry13. Both of these observations suggest that the
results of this study could be applicable to other populations
undergoing bariatric surgery.
Signiﬁcant differences in age between the study groups
may have contributed to differences in diabetes remission
rates. Whether the results obtained after 23 months
will remain similar 5 years after surgery remains to be
determined. The remission rates in the present study using
both the old and new deﬁnitions were lower than those
in previous series2,3. The authors speculate that this could
reﬂect a longer duration or an increased severity of type
II diabetes among the participants in the present study.
 2011 British Journal of Surgery Society Ltd www.bjs.co.uk British Journal of Surgery 2012; 99: 100–103
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Measurement of β-cell function was not routine in this
population. Assessment of pancreatic function with c-
peptide may give additional insight into the effects of
bariatric surgical procedures on type II diabetes14,15.
Further studies with longer follow-up are needed to
determine the optimal management of patients with type
II diabetes following bariatric surgery. In addition, future
comparative studies of bariatric surgery for metabolic
disorders and particularly type II diabetes should include
hard endpoints such as changes in microvascular and
macrovascular complication rates.
The 2009 consensus criteria are associated with lower
type II diabetes remission rates after bariatric surgery
than previous deﬁnitions, but the reported glycaemic
control remains impressive. Using an agreed deﬁnition
of diabetes and focusing on complications of diabetes as
endpoints may remove some of the barriers to making
surgery a more widely accepted treatment option for type
II diabetes.
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Original article
Effect of bypassing the proximal gut on gut hormones involved with
glycemic control and weight loss
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Abstract Background: The reported remission of type 2 diabetes in patients undergoing Roux-en-Y gastric
bypass has brought the role of the gut in glucose metabolism into focus. Our objective was to
explore the differential effects on glucose homeostasis after oral versus gastrostomy glucose loading
in patients with Roux-en-Y gastric bypass at an academic health science center.
Methods: A comparative controlled investigation of oral versus gastrostomy glucose loading in 5
patients who had previously undergone gastric bypass and had a gastrostomy tube placed in the
gastric remnant for feeding. A standard glucose load was administered either orally (day 1) or by the
gastrostomy tube (day 2). The plasma levels of glucose, insulin, glucagon-like peptide 1 and peptide
YY were measured before and after glucose loading.
Results: Exclusion of the proximal small bowel from glucose passage induced greater plasma
insulin, glucagon-like peptide 1, and peptide YY responses compared with glucose loading by way
of the gastrostomy tube (P .05).
Conclusions: Exclusion of glucose passage through the proximal small bowel results in enhanced
insulin and gut hormone responses in patients after gastric bypass. The gut plays a central role in
glucose metabolism and represents a target for future antidiabetes therapies. (Surg Obes Relat Dis
2012;8:371–374.) © 2012 American Society for Metabolic and Bariatric Surgery. All rights
reserved.
Keywords: Gastric bypass; Bariatric surgery; Metabolic surgery; Diabetes remission; Gut hormones; Incretins; Glucagon-
Surgery for Obesity and Related Diseases 8 (2012) 371–374like peptide 1; GLP-1Roux-en-Y gastric bypass improves glycemic control
within days [1,2]. The initial increased insulin secretion and
reduced insulin resistance appears to be independent of weight
loss [3]. Increased glucagon-like peptide 1 (GLP-1) levels after
This study received support from the National Institutes of Health
Research Clinician Scientist Award (to C. le Roux) and the National
Institute for Health Research Biomedical Research Centre funding scheme
to Imperial College, London. There was no involvement in the design or
conduct of the study; collection, management, analysis, or interpretation of
the data; or preparation, review, or approval of the manuscript.
*Correspondence: Carel W. le Roux, M.R.C.P., Imperial Weight Cen-
tre, Imperial College London W6 8RF United Kingdom.E-mail: c.leroux@imperial.ac.uk
1550-7289/12/$ – see front matter © 2012 American Society for Metabolic and
doi:10.1016/j.soard.2012.01.021gastric bypass are associated with increased insulin secretion
but not reduced insulin resistance [1]. These findings, together
with experiments on animal models, have brought the gut’s
role in glucose homeostasis into focus and novel endoluminal
devices have been introduced in an attempt to mimic the
metabolic effects of gastric bypass [4–6]. A remaining conun-
drum is the rapid weight loss and weight loss maintenance after
gastric bypass, making it challenging to confirm the hypothesis
that the effects on glycemic control are indeed weight loss
independent. The aim of the present study was to investigate
the effect of glucose loading into different gut segments in
weight stable patients who have had their type 2 diabetes
placed into remission after gastric bypass.
Bariatric Surgery. All rights reserved.
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372 D. J. Pournaras et al. / Surgery for Obesity and Related Diseases 8 (2012) 371–374Methods
The study was approved by the Clinical Governance and
Patient Safety Committee of Imperial College Healthcare
National Health Service Trust (reference number 10/807)
and was performed according to the Declaration of Helsinki.
The 5 patients who had undergone gastric bypass provided
informed consent. Surgery was performed as previously
described [7]. All participants had had type 2 diabetes pre-
peratively and had had achieved normoglycemia without
equiring any hypoglycemic medication by the time of the
tudy. The mean body weight loss was 29.9%  4.6%
resulting in a body mass index reduction from 43.2 1.9 to
29.9  2.4 kg/m2 (P  .001). Because of surgical compli-
ations, the patients had been unable to maintain adequate
alorie intake. To allow for enteral feeding, all patients had
een provided with a functioning gastrostomy tube. The
atients were treated conservatively or surgically and had
ully recovered so that at the time of testing (14 4 months
ostoperatively, range 9–24), all patients had normal nutri-
ion status, tolerated oral liquids, and had a stable body
eight.
All examinations were performed at 8 AM after an over-
ight fast on 2 different days 3–6 days apart. A 410-mL
olution containing 75 g glucose, 287 kcal (Lucozade En-
rgy Original, GlaxoSmithKline, Middlesex, United King-
om) was given orally on day 1 (to verify the patients could
olerate the volume orally) and by gastrostomy on the sec-
nd occasion. The duration of the solution administration
as 10 minutes on both days. A schematic illustration of the
astrointestinal glucose route after oral and gastrostomy
oading is given in Figure 1. Blood was obtained by a
enous catheter using tubes containing ethylenediaminetet-
aacetic acid and aprotinin before and 15, 30, 60, 90, 120,
50, and 180 minutes after glucose loading. The samples
ere stored and peptide YY (PYY)-like immunoreactivity
full length, PYY1–36, and fragment, PYY3–36) and
lasma total GLP-1 were measured, as previously described
8–10]. Gastric inhibitory polypeptide (GIP) was measured
sing enzyme-linked immunosorbent assay (Millipore, Bil-
Fig. 1. Schematic illustration of gastrointestinal glucose route after oral
(black arrows) and after gastrostomy load (empty arrows).erica, MA). Glucagon was measured by an in-house radio-
mmunoassay [11]. Glucose was measured with an auto-
ated glucose analyzer (Abbott Laboratories, Chicago, IL),
nd insulin was measured with an automated chemilumi-
escent immunoassay (Abbott Laboratories, Chicago, IL).
The results were analyzed using GraphPad Prism, ver-
ion 5.00, for Windows (GraphPad Software, San Diego,
A). The data are presented as the mean  SEM. The
lasma levels of insulin, GLP-1, PYY, GIP, glucagon and
lucose after the 2 glucose loadings were analyzed with a
-way group (between subjects)  time (within subjects)
nalysis of variance, presented with the F test, and the
umbers in parentheses are the degrees of freedom. Post hoc
onferroni tests for each concentration were applied when
here was a significant group  time interaction. P .05
as considered significant.
esults
Figure 2 shows the plasma levels of glucose, insulin,
LP-1, PYY, GIP, and glucagon after oral and gastrostomy
lucose loading. Two-way analysis of variance revealed a
ignificant difference in plasma insulin, GLP-1, and PYY
all P .01) levels between the oral and gastrostomy glu-
cose loading. There was also a significant main effect of
time and a significant group  time interaction for insulin,
LP-1, and PYY (all P .001). The patients returned more
uickly to the baseline glucose levels after oral glucose
oading compared to patients who had received the glucose
oad by gastrostomy (P .001), with a significant group 
ime interaction (P .001) but no significant main group
ffect for glucose levels (P  .84).
No difference was found in the GIP postprandial re-
ponse between the 2 routes used. The glucagon postpran-
ial response was greater with the oral route (2-way
nalysis of variance, P .01); however, there was no
ignificant effect of time and group  time interaction.
The values of the 2-way analysis of variance for glucose,
insulin, GLP-1, PYY, GIP, and glucagon are summarized
in Table 1.
Discussion
The present study has demonstrated that an altered de-
livery of nutrients to the intestine, which excludes the prox-
imal gut, results in improved postprandial glucose handling.
In particular, excluding the distal stomach, duodenum, and
proximal jejunum from nutrient transit reduces the duration
of hyperglycemia and leads to enhanced insulin, incretin,
and satiety gut hormone responses after glucose loading. In
contrast, in weight stable patients, the restoration of the
duodenal passage after gastric bypass by gastrostomy
increases the duration of hyperglycemia and attenuates
the incretin and insulin responses to glucose. Our obser-
vations support the hypothesis that endocrine changes
t P .00
T
T
t
373Proximal Small Bowel and Glycemic Control / Surgery for Obesity and Related Diseases 8 (2012) 371–374play an important role in the improvement of diabetes
after gastrointestinal bypass surgery [3,4,12–18]. How-
ever, differentiating between the relative contribution of
proximal versus distal small gut signals to glycemic con-
trol was outside the purpose of the present study.
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able 1
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Variable Time
Glucose F(7,57)  5.81; P .001
Insulin F(7,57)  7.64; P .001
GLP-1 F(7,58)  10.51; P .001
PYY F(7,58)  8.79; P .001
GIP F(6,43)  3.98; P  .003
Glucagon F(4,30)  1.98; P  .12GLP-1  glucagon-like peptide 1; PYY  peptide YY; GIP  gastric inhibitExclusion of the duodenum and jejunum in Goto-Kak-
izaki, spontaneously nonobese type 2 diabetic rats, can have
a weight loss-independent effect on type 2 diabetes, sug-
gesting that the proximal gut might be implicated in the
pathogenesis of the disease [4,19]. Glucose tolerance was
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other study of the same type of rats, duodenojejunal bypass
led to the improvement of oral glucose tolerance in contrast
to gastrojejunostomy, which had no effect [4]. Exclusion of
the duodenum by reoperation of the rats with gastrojejunos-
tomy improved glucose tolerance, and restoration of the
duodenal passage in rats that had undergone duodenojejunal
bypass caused the recurrence of impaired glucose tolerance
[4]. The available human data supporting the weight loss-
independent effect of Roux-en-Y gastric bypass on glucose
homeostasis and the “foregut hypothesis” are limited.
GIP responses after gastric bypass remain controversial,
with most investigators showing a decrease [16], but others
showing an increase [15]. We did not find a significant
difference in our study, but our experiment was not powered
to detect a difference in GIP.
A single case has been reported in which nutrient stim-
ulation by oral feeding was compared with gastric tube
feeding in a patient after gastric bypass [20]. However, by
repeating the experiments in a series of weight stable pa-
tients in whom diabetes had gone into remission, we have
shown a consistent threefold elevation of insulin, GLP-1,
and PYY after oral glucose loading. Dirksen et al. [20] have
also demonstrated no overall difference in GIP or glucagon,
consistent with the result of our study.
One limitation of our study was the nonrandom alloca-
tion of oral and gastrostomy days; however, we had to
ensure that the patients could tolerate the volume orally,
before administering it through the gastrostomy tube. More-
over, each patient served as their own control, and all tests
were performed within a 3–6-day period.
Conclusions
Exclusion of the proximal small gut by gastric bypass
surgery resulted in weight-independent modifications of gut
hormones and glucose homeostasis. Understanding the
mechanisms by which gastric bypass alters the metabolism
might lead to novel devices or therapeutic approaches for
the treatment of type 2 diabetes.
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The Role of Bile After Roux-en-Y Gastric Bypass in
Promoting Weight Loss and Improving Glycaemic
Control
Dimitri J. Pournaras, Clare Glicksman, Royce P. Vincent, Shophia Kuganolipava,
Jamie Alaghband-Zadeh, David Mahon, Jan H.R. Bekker, Mohammad A. Ghatei,
Stephen R. Bloom, Julian R.F. Walters, Richard Welbourn, and Carel W. le Roux
Department of Investigative Medicine (D.J.P., R.P.V., M.A.G., S.R.B., C.W.l.R.), Imperial Weight Centre,
Imperial College London, London W6 8RF, United Kingdom; Department of Bariatric Surgery (D.J.P.,
D.M., R.W.), Musgrove Park Hospital, Taunton TA1 5DA, United Kingdom; Department of Clinical
Biochemistry (C.G., R.P.V., J.A.-Z.), King’s College Hospital, London SE5 9RS, United Kingdom;
Department of Gastroenterology (S.K., J.R.F.W.), Imperial College London, London HA7 4FG, United
Kingdom; Department of Surgery (J.H.R.B.), University of Pretoria, Pretoria 5100, South Africa; and
Experimental Pathology (C.W.l.R.), Conway Institute, School of Medicine and Medical Sciences,
University College Dublin, Dublin 4, Ireland
Gastric bypass leads to the remission of type 2 diabetes independently of weight loss. Our hypoth-
esis is that changes in bile flow due to the altered anatomy may partly explain the metabolic
outcomes of the operation. We prospectively studied 12 patients undergoing gastric bypass and
six patients undergoing gastric banding over a 6-wk period. Plasma fibroblast growth factor
(FGF)19, stimulated by bile acid absorption in the terminal ileum, and plasma bile acids were
measured. In canine and rodent models, we investigated changes in the gut hormone response
after altered bile flow. FGF19 and total plasma bile acids levels increased after gastric bypass
comparedwith no change after gastric banding. In the caninemodel, both food and bile, on their
own, stimulated satiety gut hormone responses. However, when combined, the response was
doubled. In rats, drainage of endogenous bile into the terminal ileum was associated with an
enhanced satiety gut hormone response, reduced food intake, and lower body weight. In conclu-
sion, aftergastric bypass, bile flow is altered, leading to increasedplasmabile acids, FGF19, incretin.
and satiety gut hormone concentrations. Elucidating the mechanism of action of gastric bypass
surgery may lead to novel treatments for type 2 diabetes. (Endocrinology 153: 0000–0000, 2012)
A link betweenbile acids and glycemic control has beensuggested by studies showing improved blood glu-
cose in patients with type 2 diabetes when receiving the
bile acid sequestrants cholestyramine and colesevelam (1–
5). Several possible mechanisms have been proposed, in-
cluding the disruption of enterohepatic circulation of bile
acids and a number of different effects through the farne-
soid X receptor (FXR) pathway, which is the intracellular
signaling pathway for bile acids (4, 6). Bile acids also ac-
tivate the cell-membrane G protein-coupled receptor,
TGR5, which has been shown to stimulate the incretin,
glucagon-like peptide-1 (GLP-1) in vitro in an FXR-inde-
pendentmanner (7).GLP-1 in turn stimulates-cells in the
pancreas to release insulin (8).
Gastric bypass surgery is being used as a treatment for
type2diabetes, although themechanismof action remains
largely unclear (9–11). The improved glycemic control in
the immediate postoperative period is weight loss inde-
pendent, because simultaneous improved insulin secretion
and reduced insulin resistance have been observed be-
tween d 2 and 7 after gastric bypass (9). The early increase
in insulin secretion was associated with an enhanced
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GLP-1 response (9), which may partly be explained by
L-cell stimulation from bile acids (12–14). Moreover, the
decrease in insulin resistance may also be the result of
increased fasting plasma bile acid levels after gastric by-
pass surgery (15, 16), because firstly, bile acids inhibit
gluconeogenesis in an FXR dependent and independent
manner (17–20) and bind to TGR5, leading to cAMP gen-
eration and activation of the intracellular type 2 thyroid
hormone deiodinase (21). Secondly, bile acids also act via
the phosphatidylinositol 3 kinase/serine-threonine kinase
pathway directly promoting insulin signaling and glyco-
gen synthase activation, thus aiding insulin-dependent
control of glucose metabolism in the liver (22). Thirdly,
possible effects of bile acids on fibroblast growth factor
(FGF)19 could lead to enhanced mitochondrial activity,
which improves insulin resistance (23). Recently FGF19
has been shown to regulate glycogen metabolism in an
insulin-independent manner (24). Furthermore, FGF19
has been shown to correlate with nutritional status (25).
Finally, tauroursodeoxycholic acidhas alsobeen shown to
protect against the onset of insulin resistance in obese and
diabetic mice by alleviating stress in the endoplasmic re-
ticulum (26).
The prolonged improvements in glycemic control after
gastric bypass are further aided by the substantial and
maintained weight loss. The attenuated appetite may be
partly explained by enhanced satiety gut hormones from
the endocrine L cell, such as peptide YY (PYY), GLP-1,
andoxyntomodulin (27, 28). Bile acids are also implicated
in the release of these L-cell hormones.
We hypothesized that the altered anatomy after gastric
bypass affects bile delivery to the terminal ileum and lead
to elevated plasma bile acids. We postulated that changes
in bile flow result in increased satiety gut hormone re-
sponses, reduced food intake, and weight loss. Our aim
was to test this hypothesis in humans after gastric bypass
surgery and to explore further the potential mechanisms
involved in two animal models of altered bile flow.
Materials and Methods
Thehuman studieswereperformedaccording to theprinciples of
the Declaration of Helsinki. The Somerset Research and Ethics
committee approved the study (LREC protocol no. 05/Q2202/
96). The canine studies were approved by the ethics committee
of Onderstepoort Vetinary School (University of Pretoria). The
rat studies were approved by the Home Office United Kingdom
(PL 70-6669).
Human studies
Written informed consentwas obtained fromall participants.
Exclusion criteria included pregnancy, substance abuse, and
more than two alcoholic drinks per day. Twelve gastric bypass
patients (seven females and five males) with mean age of 45.2
2.7 yr and body mass index 49.8  1.5 as well as six gastric
banding patients (four females and two males), with mean age
45.4  2.6 yr and body mass index 44  2.0 kg/m2 were re-
cruited. All patients were prescribed a 2-wk preoperative diet of
1000 kcal before surgery. Operations were performed laparo-
scopically by one surgeon. The technique for the gastric bypass
has been described previously (29). For gastric banding, the
Swedish Adjustable Gastric band (Ethicon Endo-Surgery, Lon-
don, UK) and the LAP-BAND (Allergan, Marlow, UK) bands
were usedwith the pars flaccida dissection technique and gastro-
gastric tunnelating sutures (30).Usinganenhanced recoverypro-
tocol postoperatively, all patients were allowed free fluids on
return to the ward, and diet was recommenced when tolerated.
The recommended postoperative diet for the first week was the
same for the patients with banding and bypass. After a 12-h fast,
blood was obtained in tubes containing EDTA and aprotinin.
Samples were immediately centrifuged and stored in a 80 C
freezer until analysis.
Canine studies
Four male and four female Beagles were fasted overnight and
then given a standard 400 g of test meal of dog chow (Husky,
Purina, South Africa). The composition was 7.5% protein, 2%
fat, 1% fiber, 7.5%crude ash, and82%moisture. Fivemilliliters
of blood were collected (in tubes containing EDTA and apro-
tinin) every 30 min from 30 min before the meal up to 150 min
postprandially.
The next day, the dogs were prepared for theater by placing
an overnight fentanyl patch and withholding food overnight.
The common bile duct was transected. An 8 French Foley cath-
eter was placed into the gall bladder. An 8 French feeding tube
was advanced through the pylorus to the duodenumwith themost
distal point being 5–8 cm distal to the pylorus, close to the level of
the ampulla of Vater (Fig. 1A). For the first 12 h after the surgery,
the dogs were given ad libitum access to water but no food.
Only one dog was terminated after showing signs of jaundice
and infection. The dogs received a standard meal of 400 g of
normal chow at the start of the light phase. At this time, as much
bile as possible was aspirated from the Foley catheter and in-
jected through the gastrostomy tube, followed by a 5-ml flush of
saline. This prevented the dogs from becoming jaundiced and
allowed normal digestion.
On d 4–6, the dogs were randomized to a 180-min crossover
designed protocol of venous blood collection every 30 min after
1) a standardmeal of 400 g of dog food only without bile; 2) bile
only, without food; or 3) 400 g of dog food and bile in
combination.
Rodent studies
Sixteen male Wistar obese rats were randomized to a sham
operation, which maintained the normal bile delivery to the du-
odenum or to an operation that would deliver bile to the ileum.
The bile-in-duodenumgroupunderwent transections 1 cmprox-
imal anddistal to the drainage point of the commonbile duct and
reanastomosis to maintain the normal anatomy but allow for a
similar surgical insult. The bile-in-ileum group had the same
transection of the duodenum, but the proximal anddistal ends of
the transected duodenumwere anastomosed end to end and con-
2 Pournaras et al. Bile Acids After Gastric Bypass Endocrinology, August 2012, 153(8):0000–0000
tinuity restored (Fig. 1B). The segment of the duodenum con-
taining the commonbile ductwas anastomosed side to side to the
distal jejunum, 10 cm proximally to the terminal ileum. This
allowed bile and pancreatic juices to bypass the duodenum and
most of the jejunum.
Bodyweight and foodconsumptionwasmeasureddaily at the
beginning of the light phase for 28 d. Feces were collected over
a 24-h period on d 25. The rats were then fasted for 12 h before
they were terminated, and blood samples were collected.
FGF19 assay
Plasma FGF19 concentration was measured using a quanti-
tative sandwich ELISA technique (FGF19Quantikine ELISAkit,
catalog no. DF1900; R&D Systems, Minneapolis, MN).
Bile acids assay
The measurement of fractionated
plasmabile acidswasperformedwith liq-
uid chromatography tandem mass spec-
trometry (31). The method allowed 12
different bile acids [cholic acid (CA), che-
nodeoxycholic acid (CDC), deoxycholic
acid (DC), glycocholic acid (GCA), gly-
codeoxycholic acid (GCD), glycocheno-
deoxycholic acid (GCDC), glycolitho-
cholic acid (GLC), glycoursodeoxycholic
acid (GUDC), lithocholic acid (LC), tau-
rocholic acid (TCA), taurochenodeoxy-
cholic acid (TCDC), and taurodeoxy-
cholic acid (TDC)] to bemeasuredwithin
the range of 0.1–10 M.
GLP-1 and PYY assay
All sampleswere assayed in duplicate.
Analysis was performed with an estab-
lished GLP-1 RIA (7). PYY-like immu-
noreactivitywasmeasuredwitha specific
and sensitive RIA, which measures both
the full length (PYY1-36) and the frag-
ment (PYY3-36) (32).
Bomb calorimetry
To evaluate nutrient absorption, feces
were collectedover24honpostoperatived25 fromall rats. Feces
weredried inanovenandweighed; calorie contentwasmeasured
using an established ballistic bomb calorimeter technique (33).
Rodent C-reactive protein (CRP) assay
Toassess inflammation serumCRP levelsweremeasured (Rat
Serum CRP ELISA kit catalog no. 1010; Alpha Diagnostics In-
ternational, San Antonio, TX).
Statistical analysis
Resultswere analyzed usingGraphPadPrismversion 5.00 for
Windows (GraphPad Software, San Diego, CA). Data are ex-
pressed as means  SEM when the data follow a Gaussian dis-
tribution.When the data did not follow aGaussian distribution,
the median (range) is used. Values for the area under the curve
(AUC) were calculated with the use of the trapezoidal rule. End
points were compared with the use of two-tailed, paired Stu-
dent’s t tests for parametric data and Mann-Whitney U test for
nonparametric data. Results were considered significant if P 
0.05.
Results
Human study FGF19
Preoperative fasted plasma FGF19 levels did not differ
between gastric banding and gastric bypass patients [me-
dian 140 ng/liter range (26–466) vs. 123 (41–406), re-
spectively; P  0.37]. However, these values were lower
than those found in nonobese controls (34). In the gastric
FIG. 1. A, Schematic illustration of the anatomy and canulation of the canine model. A
gastrostomy tube was placed into the duodenum close to the ampulla of Vater. The common
bile duct was ligated and the gallbladder canulated to allow drainage of bile. B, Schematic
illustration of the functional anatomy of the bile in ileum group. Transections 1 cm proximal and
distal to the drainage point of the common bile duct were performed. The proximal and distal
ends of the transected duodenum were anastomosed end to end and continuity restored. The
segment of the duodenum containing the common bile duct was anastomosed side to side to
the distal jejunum, 10 cm proximally to the terminal ileum.
FIG. 2. Fasting plasma FGF19 concentrations (median and
interquartile ranges) at d 0, 4, and 42 in six gastric banding patients
(white bars) and 12 gastric bypass patients (black bars). *, P  0.05
Mann-Whitney U test. Preop, Preoperatively.
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banding group, there was no significant change from pre-
operative values for fasting FGF19 at d 4 or 42 after sur-
gery. In the gastric bypass group, fasting levels of plasma
FGF19 were significantly increased as early as 4 d after
gastric bypass compared with preoperative values (P 
0.01) (Fig. 2). The enhanced FGF19 level were sustained
at 42 d postoperatively (P  0.05).
Human study plasma bile acids
Fasting concentrations of total plasma bile acids mea-
sured in banding and bypass patients preoperatively were
not different (Fig. 3). On d 4, fasting bile acids were in-
creased after gastric bypass, and there was a significant
difference comparedwith the banding group. Byd42after
gastric bypass fasting, total bile acid concentrations were
higher compared with preoperative levels. There was no
difference in the banding group.
A similar pattern of results (increase in the gastric by-
pass group but not in the banding group) was previously
shown for GLP-1 and PYY in these same patients (9).
Canine studies
The responses of GLP-1 and PYY were studied in this
model after stimulation with food or bile alone or a com-
bination of both. Unfortunately, at the time of these ex-
periments, therewas no available assay for canine FGF19.
Baseline GLP-1 and PYY levels were the same before and
after the operation (6936 vs. 7290 forGLP-1 and 6386 vs.
5856 for PYY). Figure 4 shows the AUC and the time
course over 150min for the postprandial GLP-1 and PYY
response after the standard meal of 400 g of dog food. In
the operated dogs, both food alone and bile alone lead to
a significant GLP-1 and PYY response from baseline, al-
though the responses were attenuated. The response to
bile and or food alone was inferior to the combination of
food and bile either pre- or postoperatively.
Rodent studies
In this model, rats had bile draining into their ileum or
duodenum. Both the fasting plasma GLP-1 levels (Fig. 5A)
and the plasma PYY levels (Fig. 5B) were higher in the bile-in-
ileum group than in the bile-in-duodenum group (P 0.05).
Figure 6A demonstrates that both the bile-in-ileum and
bile-in-duodenum groups lost a similar initial amount of
weightduringthefirst4dwhilerecoveringfromsurgery.The
bile-in-duodenum group, however, reached their preopera-
tive weight within 8 d. The bile-in-ileum groupweighed sig-
nificantly less than the bile-in-duodenum group on d 6 (P
0.05) and continued to have a lower bodyweight for the du-
ration of the study (P 0.05). Figure 6B shows that the rats
in the bile-in-ileum group ate significantly less than the bile-
in-duodenum group (P 0.05).
Fecal parameters at 25 d after the operation did not
reveal differences between the bile-in-ileum and the bile-
in-duodenumgroupsat the endof the
experiment in dry weight (4.12 
0.20 vs. 4.28 0.18 g, P 0.55) or
in calorific content (3.58  0.4 vs.
3.58 0.4 fecal kcal/24 h,P 0.91).
There was no evidence of increased
inflammation in the bile-in-ileum
compared with the bile-in-duode-
num group either by white cell count
(11.5 0.32 1000/l vs. 11.64
0.42  1000/l, P  0.79) or CRP
(370.88  26.03 vs. 378.5  21.71
g, P  0.83).
Discussion
We showed in obese patients that
FGF19 and plasma total bile acids
FIG. 3. Fasting total plasma bile acid concentrations at d 0, 4, and 42
in six gastric banding patients (white bars) and 12 gastric bypass
patients (black bars). *, P  0.05 Mann-Whitney U test. Preop,
Preoperatively.
FIG. 4. A, AUC for the postprandial GLP-1. B, AUC for postprandial PYY response after 400 g of
food in dogs pre- or postoperatively either receiving food alone without bile (food), bile alone
without food (bile), or food and bile in combination (food  bile).*, P  0.05. The time course
of the postprandial response for GLP-1 (C) and PYY (D).
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were increased after gastric bypass but not after gastric
banding.We have shown previously that GLP-1 and PYY
are affected in the samewayas FGF19 in these patients (9).
How could the alterations in gastro-intestinal physiology
produce these changes?
Both food and bile on their own can release GLP-1 and
PYY as shown in the canine model, but the combination
of food and bile (before surgery or after surgery) resulted
in greater PYY responses compared with food alone,
whereas GLP-1 also showed a trend to be higher after the
combination of food and bile. Endogenous bile acids and
pancreatic juices delivered in the rat model 10 cm proxi-
mally to the terminal ileum were also associated with el-
evated plasma GLP-1 and PYY, reduced food intake, and
lower body weight. Taken together, these data suggest
that oneof themechanismsbywhich a gastric bypass leads
to beneficial elevations ofGLP-1 andPYYmaybe through
the undiluted flow of bile through the biliopancreatric
limb and the altered delivery of bile to the terminal ileum.
Well-matched patients undergoing gastric banding
were used as a control group, because they have a similar
laparoscopic surgical insult and identical preoperative and
immediate postoperative diets comparedwith bypass, but
in the gastric banding operation, there is no change in the
anatomy of the gut that would affect
bile flow. Exogenous bile salts have
been shown to be the most potent
stimulus of gut hormones from the
endocrineL cells, such as PYY in rab-
bit colon explants (12), in vivo in
conscious dogs (13), and in humans
(14). GLP-1, PYY, and bile are re-
leased postprandially and in propor-
tion to the amount of calories con-
sumed. Although early arrival of
nutrients at the terminal ileum still
remains a possibility, the reduced gut
motility and early peak GLP-1 and
PYY responses postprandially sug-
gest other mechanisms, which may involve bile in the re-
lease of L-cell hormones.
The gallbladder is not usually removed during Roux-
en-Y gastric bypass, and there is no indication that gall-
bladder contraction is adversely affected after gastric
bypass. Previous studies suggested an increase in chole-
cystokinin after jejunoileal bypass, which may result in
enhancedbile flow from the gallbladder or liver (34).After
gastric bypass, the length of small bowel from the ampulla
of Vater to the terminal ileum is reduced by 100–150 cm,
and bile may thus reach the terminal ileum before the in-
gested food, which triggers the release of bile. We postu-
late that due to the anatomical changes after gastric by-
pass, bile progresses down the biliopancreatic limb to the
distal L cells in an undiluted state. This could lead to in-
creased availability of bile acids in the distal intestine with
the potential to engage TGR5 on L cells. Bile acid activa-
tionofTGR5hasbeen found tostimulateGLP-1production
in vitro andmay explain the early and exaggerated release of
incretin gut hormones, such as GLP-1 and subsequently in-
sulin (8). Bile acids would normally be more bound up in
micelles due to the presence of nutrients and therefore less
likely to stimulate L cells for peptide secretion.
Although the canine studies
should be interpreted with caution,
especially because the anatomical
changes are dissimilar to gastric by-
pass, wewould suggest that both bile
and food contribute to the postpran-
dial gut hormone response. The role
of bile can be attributed to the fact
that bile conjugated with food facil-
itates better digestion of complex in-
gested fats by intestinal lipases into
smaller lipid subunits, therefore lead-
ing to a more effective stimulation of
L cells (35). Inhibition of intestinal
FIG. 5. Plasma GLP-1 (A) and PYY (B) levels in rats that had bile draining into their duodenum or
bile draining into their ileum.
FIG. 6. A, Weight of rats in bile-in-duodenum (solid line) and bile-in-ileum (broken line) groups
before and up to 28 d after surgery. B, Food intake of bile-in-duodenum (solid line) and bile-in-
ileum (broken line) rats before and up to 28 d after surgery. *, P  0.05.
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lipases leads to attenuated postprandial GLP-1 and PYY
associated with increased appetite (35). However, the re-
sults of the rodent studies do not support this hypothesis,
because the distal intestinal delivery of bile should inter-
fere with the intestinal digestion of fats and hence lead to
reduced L-cell responses. As the opposite was demon-
strated, the effect of bile on digestion of ingested fats can-
not explain the enhanced gut hormone response, suggest-
ing that bile acids may play a role as signaling molecules.
Bile acids may also influence glucose metabolism by
altering body weight. Weight loss may result from en-
hanced satiety, which may be facilitated via L cell-derived
gut hormones (9, 25). In addition, bile acids increase en-
ergy expenditure in brown adipose tissue, thus preventing
obesity and insulin resistance via induction of the cAMP-
dependent thyroid hormone-activating enzyme type 2 io-
dothyronine deiodinase (21). This is achieved via the
TGR5 and is consistent with recent findings that in rat
models, gastric bypass prevented the decrease in energy
expenditure after weight loss (36, 37).
Activation of the FXR may also mediate the effects of
bile acids on energy homeostasis via FGF19 released from
ileal enterocytes, leading to improvedmetabolic rate and de-
creased adiposity (38, 39). FGF19 has recently been shown
to inhibit hepatic gluconeogenesis (40). FGF19was only as-
sayed in humans, because unfortunately there are no reliable
assays foruse indogsorrats.FGF19andtheFGF15ortholog
in rodents are thought to provide feedback inhibition of bile
acid synthesis in the liver.Why the increased levels of FGF19
after gastric bypass are associated with an increase in total
bile acids is not immediately apparent, unless the changes in
ileal bile acid absorptionandFXR-mediatedFGF19produc-
tion are much greater than the effects on the liver.
Some of the beneficial metabolic effect of Roux-en-Y
gastric bypass on glycemic control may be attributed to
changes in bile acids (15). Our prospective study confirms
the previous cross sectional observation that total plasma
bile acids are elevated after gastric bypass. We went on to
show that this happens as early as 42 d after surgery. We
propose an additional mechanism for the observed im-
provements in glycemic control involving altered bile flow
after gastric bypass. The changes facilitated by bile may
increase satiety and improved glycemic control via gut
hormones as well as a direct effect on insulin resistance.
Therefore, bile may be one of the key products of the
proximal gut, which transfers a message to the distal gut
and to other metabolically active tissues.
Limitations of our study include the lack of random-
ization in the human studies. However, the groups were
wellmatched for preoperative patient characteristics. Por-
tal vein levels of FGF19 and bile acids were not measured,
and the relationshipbetweenportal veins and systemic levels
after gastric bypass is not currently known. Furthermore
only fasting levels of FGF19 and bile acids were measured.
Postprandial changes may also occur and are the subject of
future studies. In the canine experiment, a dislodgement of
either the feeding tube or the Foley catheter could have lead
to chemical peritonitis affecting the results. However, the
postmortem examination confirming the position of the
tubes makes this unlikely. In the rat experiment, the differ-
ence in the severity of the operative procedures may have
caused different inflammatory response, but the lack of dif-
ference in the biochemical and histological markers of in-
flammation mitigates against this.
In conclusion, Roux-en-Y gastric bypass causes
changes in bile flow resulting in increased total plasmabile
acids concentrations, FGF19, GLP-1, and PYY. Altering
the flow of endogenous bile leads to an increase in gut
hormone responses, which can be further enhanced by the
synergistic delivery of food. Bile may partly explain the
pleotrophicmetabolic effects seen after gastric bypass sur-
gery and could be a therapeutic target for novel surgical
devices or pharmaceuticals.
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